US6310211B1 - 8-hydroxy-7-substituted quinolines as anti-viral agents - Google Patents

8-hydroxy-7-substituted quinolines as anti-viral agents Download PDF

Info

Publication number
US6310211B1
US6310211B1 US08/924,683 US92468397A US6310211B1 US 6310211 B1 US6310211 B1 US 6310211B1 US 92468397 A US92468397 A US 92468397A US 6310211 B1 US6310211 B1 US 6310211B1
Authority
US
United States
Prior art keywords
hydroxy
quinolinecarboxamide
methyl
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/924,683
Inventor
Valerie Ann Vaillancourt
Karen Rene Romines
Arthur Glenn Romero
John Alan Tucker
Joseph Walter Strohbach
Olivier Bezencon
Suvit Thaisrivongs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to US08/924,683 priority Critical patent/US6310211B1/en
Priority to US09/425,564 priority patent/US6252080B1/en
Priority to US09/425,789 priority patent/US6211376B1/en
Assigned to PHARMACIA & UPJOHN COMPANY reassignment PHARMACIA & UPJOHN COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEZENCON, OLIVIER, ROMERO, ARTHUR G., ROMINES, KAREN R., STROHBACH, JOSEPH A., THAISRIVONGS, SUVIT, TUCKER, JOHN A., VAILLANCOURT, VALERIE A.
Priority to US10/014,780 priority patent/US6500842B1/en
Application granted granted Critical
Publication of US6310211B1 publication Critical patent/US6310211B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • the present invention provides for 8-hydroxy-7-substituted quinoline compounds and pharmaceutically acceptable salts thereof which are useful as antiviral agents.
  • the invention also relates to a pharmaceutical composition containing such compound in combination with a suitable excipient, the composition being useful in combating viral infections.
  • the invention also relates to a method for selectively combating viral infections in animals, including man. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus, and the human herpes virus type 8 (HHV-8).
  • CMV cytomegalovirus
  • the herpesviruses comprise a large family of double stranded DNA viruses.
  • the herpesvirus family can be divided into three subfamilies ( ⁇ , ⁇ , ⁇ ) based upon a number of biological properties such as host range and tropism, viral life cycle, and viral persistence and latency.
  • Eight of the herpesviruses herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), have been shown to infect humans.
  • HSV-1 and HSV-2 are the prototypic ⁇ -herpesviruses. These two serotypes share approximately 50% nucleotide homology. Both are neurotropic viruses, but their primary sites of replication are different. HSV-1 typically infects the oral mucosa resulting in ulcerations commonly referred to as cold sores. HSV-2 infects and causes ulcerations of the genital mucosa. HSV infection can also result in disseminated disease and encephalitis, especially in immunocompromised patients. D. O. White and F. J. Fenner, In Medical Virology, D. O. White and F. J. Fenner, eds., Academic Press, p. 318-347 (1994).
  • VZV is also an ⁇ -herpesvirus and is the causitive agent of chicken pox.
  • VZV establishes a latent infection in the dorsal root ganglia of the peripheral nervous system. From its latent site, VZV can cause recurrent disease commonly referred to as shingles or zoster. The probability of shingles increases with age and frequently occurs in immunocompromised patients.
  • HCMV Human cytomegalovirus
  • HCMV ulcerative colitis .
  • HCMV also establishes lifelong latency in the host.
  • HCMV DNA polymerase (HCMV pol) is an enzyme essential for viral replication.
  • the current therapies for HCMV; Ganciclovir, Foscarnet and Vistide act by inhibition of HCMV pol.
  • EBV is a ⁇ -herpesvirus which replicates in the epithelial cells of the nasopharynx and salivary glands and resides latently in B-cells. Childhood infections of EBV are normally asymptomatic. However, EBV infection is associated with several diseases in adults such as infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkins disease.
  • A. B. Rickinson and E. Kieff In Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, eds., Lippincott-Raven Press, New York, p. 2397-2446 (1996).
  • HHV-6 is a ⁇ -herpesvirus which causes roseola (exanthem subitum) in children. P. Lusso, Antivir. Res. 31:1-21 (1996). HHV-7 shares 50-60% nucleotide sequence homology with HHV-6. It's disease association is unclear, but it may be involved in some cases of roseola. N. Frenkel and E. Roffman, In Virology, B. N. Fields, D. M. Knipe, P. M. Howley, eds., Lippincott-Raven Press, New York, p. 2609-2622 (1996).
  • HHV-8 also known as Kaposi's sarcoma associated herpesvirus (KSHV)
  • KSHV Kaposi's sarcoma associated herpesvirus
  • U.S. Pat. No. 4,959,363 discloses 1-(N-substituted)-1,4-dihydro-4-oxo-6- and/or -7-substituted-3-quinolinecarboxamides as antiviral agents.
  • the compounds of the present invention are 1-(N-unsubstituted)-8-hydroxy-7-quinolinecarboxamides.
  • U.S. Pat. Nos. 5,459,146 and 5,506,236 disclose 4-substituted-3-alkyl-pyrazolo[3,4-b]quinoline compounds as antiviral agents. Basically, these compounds are the tricyclic version of compounds such as those disclosed in the '363 patent above, and are structurally very different from the compounds of the present invention.
  • U.S. Pat. No. 5,378,694 discloses compounds such as 1-(N-substituted)-3-substituted-4-hydroxy-2-quinolinones, and generically, 3-substituted-4-hydroxycoumarin compounds as antiviral agents.
  • U.S. Pat. No. 5,412,104 discloses compounds similar to those disclosed in the '694 patent for anti-viral or anti-hypertensive use; however, these 1-(N-substituted) reference compounds are disclosed as having substituents other than hydroxy at the 4-position of the quinolinone ring.
  • the compounds of the present invention are 1-(N-unsubstituted)-8-hydroxy-7-quinolinecarboxamides.
  • German patent DE 1 908 548 discloses a variety of compounds including 4-hydroxy-quinoline compounds which may be substituted at the 3-position by carboxamide groups, and which are useful against cold viruses.
  • Published German patent application DE 44 25 647 A1 discloses heterocyclic-1-phenyl substituted quinolone and naphthyridone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 648 A1 discloses 6 and 6,8-substituted 1-[4-(1H-1,2,4-triazol-1-yl-methyl)phenyl] quinolone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 650 A1 discloses substituted triazolylmethylphenylnaphthyridone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 659 A1 discloses N1-diverse 6-fluoro-8-difluoromethoxy substituted quinolone carboxylic acids for treating retroviral infections.
  • the compounds of these references are structurally very different from the compounds of the present invention.
  • JP 8099957-A discloses optionally heterocyclyl substituted 4-oxo-quinoline and naphthyridine derivatives which are useful for treating herpes, particularly herpes simplex virus, herpex zoster virus and cytomegalovirus.
  • JP 7165748-A discloses compounds having heterocyclic ketones which are used in antiviral agents for treating cytomegalovirus infectious disease.
  • U.S. Pat. No. 5,463,072 discloses a process for the preparation of naphtholic 2-equivalent cyan couplers which are useful in color photography. It discloses an 8-hydroxy-quinoline compound having a substituted thiazole moiety at the 6-position and a carbamoyl moiety at the 7-position.
  • Derwent Abstract 91-232424/32 discloses the use of 5HT-3 antagonists for the prevention or reduction of dependence on alcohol, psycho-stimulants, nicotine or opiates.
  • a variety of compounds is disclosed including quinoline compounds having unsubstituted phenyl rings.
  • Derwent Abstract 90-343755/46 discloses serotonin 5HT3 antagonists used for treating stress related psychiatric disorders, rhinitis, nasal disorders and lung embolism. It discloses a variety of compounds, including quinoline compounds substituted by bridged piperidine groups.
  • U.S. Pat. No. 5,240,940 discloses fungicidal compositions comprising a combination of two fungicides, one of which is a quinoline or cinnoline compound.
  • U.S. Pat. No. 4,881,969 discloses sulfonamides as herbicidal agents.
  • JP 63307451 discloses a silver halide color photographic photosensitive material with improved granularity containing a water-soluble coupler capable of a coupling reaction with an oxidant main ingredient in color developing, which coupler may include specific 8-hydroxy-quinoline compounds.
  • JPO7033729-A discloses the production of N-cyano-N-substituted-arylcarboxyimidamide compounds in which aryl may be 8-quinolyl groups.
  • WO 9632015 discloses synergistic fungicidal compositions made of quinoline derivatives and cytochrome complex III inhibitors.
  • the present invention particularly provides:
  • -het is a 5-, 6 or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic;
  • -cycloalkyl is a saturated or unsaturated hydrocarbon ring including any bicyclic group in which the above ring is connected to a benzene, heterocyclic or other hydrocarbon ring;
  • n is zero (0) to six (6), inclusive;
  • p is one (1), two (2) or three (3);
  • the present invention furer provides:
  • R 4 is other than t-pentyl.
  • the present invention also provides:
  • n is zero (0) to six (6) inclusive; or a pharmaceutically acceptable salt or a Nexide thereof.
  • the present invention further provides compounds of formula II
  • the present invention provides
  • -het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic;
  • -cycloalkyl is a saturated or unsaturated hydrocarbon ring including any bicyclic group in which the above ring is connected to a benzene, heterocyclic or other hydrocarbon ring;
  • n is zero (0) to six (6), inclusive;
  • p is one (1), two (2) or three (3);
  • cytomegalovirus or a pharmaceutically acceptable salt or N-oxide thereof; as well as a method of treating a cytomegalovirus comprising the administration of an effective amount of a compound of the formula IA.
  • the present invention also provides:
  • An antiviral pharmaceutical composition which comprises a pharmaceutically acceptable excipient and an effective amount of a compound of formula I.
  • the present invention provides:
  • n is zero (0) to four (4) inclusive
  • het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocyclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and if chemically feasible, the nitrogen atom may be in the protected form;
  • the present invention also provides:
  • R 2 , R 3 and R 4 may be the same or different and are
  • EWG is an electron withdrawing group
  • R 1 , R 2 and R 3 are as defined in claim 1 ;
  • R 5 is pyrrolidin-1-yl optionally substituted with EWG or R 6 ;
  • n is zero (0) to three (3)
  • m is zero (0) to one (1)
  • -het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic;
  • R 7 is t-butyl
  • “Pharmaceutically acceptable salts” refers to those salts which possess the biological effectiveness and properties of the parent compound and which are not biologically or otherwise undesirable.
  • Noide refers to the oxidized form of the nitrogen in the ring of the 8-hydroxy-quinoline compounds of the present invention.
  • the preparation of such compounds is well known to one of ordinary skill in organic chemistry, including methods such as oxidation with metachloro-peroxy-benzoic acid.
  • Electrode-withdrawing group means any substituent on the ring which tends to draw electron density from the ring. Examples of such groups include halogen, nitro, cyano, carboxylic acids, carboxylic esters, sulfoxides, sulfones, sulfonamides, ketones and aldehydes.
  • Halogen means fluroine, chlorine, or bromine.
  • Het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocyclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and if chemically feasible, the nitrogen atom may be in the protected form; and substituted or unsubstituted.
  • hetero examples include the following: thiadiazolyl, thiazolyl, benzothiazolyl, pyridinyl (or pyridyl), morpholinyl, imidazolyl, indolyl, and piperazinyl.
  • the compounds of the present invention are named according to the IUPAC or CAS nomenclature system.
  • the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C i -C j indicates a moiety of the integer “i” to the integer “j” carbon atoms, inclusive.
  • (C 1 -C 3 )alkyl refers to alkyl of one to three carbon atoms, inclusive, or methyl, ethyl, propyl and isopropyl, straight and branched forms thereof.
  • Charts A-I describe the preparation of the compounds of the present invention. All of the starting materials are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the final compounds of the present invention are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the variables used in the charts are as defined below or as in the claims.
  • the compound of formula A-2 wherein R 1 is —H and R 2 is —H is the intermediate compound of Preparation 1 below.
  • the compound of formula A-2 wherein R 1 is —F and R 2 is —H is the intermediate compound of Preparation 4 below.
  • the compound of formula A-2 wherein R 1 is —Cl and R 2 is —H is the intermediate compound of Preparation 3 below.
  • the compound of formula A-2 wherein R 1 is —H and R 2 is —CH 3 is the intermediate compound of Preparation 5 below.
  • the acid of formula C-1 is condensed with the amine of formula C-2, which is commercially available (e.g, p-chloro or p-nitrobenzylamine), under appropriate conditions (EDC is used as the coupling agent, HOBt, DMF, rt, 18 hr) to yield the compound of formula C-3.
  • R 1 and R 2 in formula C-1 are the same as R 1 and R 2 in formula C-3.
  • X in formula C-2 is the same as X in formula C-3.
  • the compound of formula C-3 wherein R 1 is —Br, R 2 is —H and X is —Cl is the final compound of Example 9 below.
  • the compound of formula C-3 wherein R 3 is —H, R 2 is —CH 3 and X is —Cl is the final compound of Example 10 below.
  • the compound of formula C-3 wherein R 1 is —Cl, R 2 is —H and X is —Cl is the final compound of Example 11 below.
  • the compound of formula C-3 wherein R 1 is —H, R 2 is —H and X is —NO 2 is the final compound of Example 12 below.
  • the compound of formula C-3 wherein R 1 is —F, R 2 is —H and X is —Cl is the final compound of Example 16 below.
  • Chart C is the preferred coupling method for benzylamines.
  • Chart E discloses a more efficient method of coupling the 8-hydroxyquinoline-7-carboxylic acids with anilines and heterocyclic amines utilizing PCl 3 as the condensing agent.
  • the compound of formula E-1 is coupled with the compound of formula E-2 (using PCl 3 , xylenes, at reflux, for 18 hr) to yield the compound of formula E-3 wherein X is —H (which is the final compound of Example 5 below) or X is —Br (which is the final compound of Example 6 below).
  • X in formula E-1 is the same as X in formula E-3.
  • Chart E is the preferred coupling method for heterocyclic amines.
  • the required thiazolones of formula F-3 are prepared in three steps from commercially available acids of formula F-1 as follows: the compound of formula F-1 is first treated with P (red) in Br and is then treated with AcCl in methanol to yield the compound of formula F-2. This compound is then reacted with thiourea at ethanol at reflux to yield the compound of formula F-3. T. Sohda et al., Chem. Pharm. Bull., Vol. 30, No. 10, pages 3601-3616 (1982).
  • Chart H discloses another method of coupling which is used in the condensation of benzylamines, although the yields are lower than found for the EDC couplings.
  • the compound of formula H-1 is coupled with the compound of formula H-2 (using PCl 3 , xylenes, at reflux for 18 hr) to yield the compound of formula H-3, which is the final compound of Example 1 below.
  • the preparation of the starting materials is accomplished by O-methylation of commercially-available 5,7-dihalo-8-hydroxyquinolines according to the procedure of R. A. W. Johnstone and M. E. Rose in Tetrahedron, vol. 35, page 21169 (1979).
  • the compound of formula J-1 is treated with t-butyllithium or n-butyllithium at low temperature in ether/toluene, then exposed to sulfur dioxide gas to prepare the compound of formula J-2.
  • Conversion of the compound of formula J-2 to the sulfonyl chloride of formula J-3 is accomplished by treatment with N-chlorosuccinimide (CH 4 Cl 2 , 3 hr).
  • the sulfonamide of formula J-4 is then prepared by reaction of the sulfonyl chloride of formula J-3 with 1 equivalent of a primary amine of the formula R 2 NH 2 and 2 equivalents of pyridine in CH 2 Cl 2 (15 hr). Finally, the compound of formula J-5 is prepared using either excess pyridinium hydrochloride (220° C., 10 min) or excess boron tribromide (CH 2 Cl 2 , 1.5 hr).
  • K-3 Compounds of the structure K-3 are prepared from commercially-available 5,7-dihalo-8-hydroxyquolines (K-1) in two steps. Formation of the silylether intermediates K-2 is accomplished by reaction of the 8-hydroxyquinolines K-1 with chlorotrialkylsilanes in the presence of imidazole and DMF at room temperature for 18-20 hours. The intermediates are then treated with t-butyllithium or n-butyllithium at low temperature in THF to give the compound of formula K-3.
  • the compound of M-1 is chlorinated with phosphorus oxychloride in CH 2 Cl 2 /DMF at room temperature.
  • the resulting chloride of M-2 is reductively cleaved by hydrogenation in EtOH, Et 3 N to give M-3.
  • Methyl ether deprotection with pyridine hydrochloride at 220° C. gives 2-trifluoromethyl-8-hydroxyquinoline of M-4.
  • This material is carboxylated to M-5 under Kolbe-Schmidt conditions. Standard amide couplings gives the desired products of M-6.
  • N-1 4,8-dihydroxyquinoline of N-2, which again is carboxylated under Kolbe-Schmidt conditions to give N-3.
  • Standard amide couplings give the desired products of N-4.
  • Aryl aldehydes of O-2 are condensed with 8-hydroxyquinaldine of O-1 at 180° C. to form the 2-styryl-8-hydroxyquinolines of O-3. These are carboxylated under Kolbe-Schmidt conditions to give O-4. Standard couplings of the resulting acid with amines gives the desired amides O-5.
  • the preparation of the starting material of formula P-1 is accomplished by chlorination of commercially-available 8-hydroxyquinaldine according to the procedure described in DE 1770065.
  • the compound of formula P-1 is then treated with neat flourosulfonic acid at 120° C. to form the compound of formula P-2.
  • the sulfonamides of formula P-3 are prepared by heating to 140° C. a mixture of 1 eq of the sulfonyl flouride of formula P-2, 2 eq of the primary amine of formula RNH 2 and 3 eq of N,N-diisopropylethylamine in chlorobenzene.
  • the preparation of the starting material of formula Q-1 is accomplished by O-methylation of commercially-available 5,7-dibromo-2-methyl-8-quinolinol according to the procedure of R. A. W. Johnstone and M. E. Rose in Tetrahedron, vol. 35, page 21169 (1979).
  • the styrene derivative of formula Q-2 is obtained by heating the 2-methylquinoline of formula Q-1 with benzaldehyde for 18 h.
  • the preparation of the starting material of formula R-1 is accomplished by chlorination of commercially-available 8-hydroxyquinaldine according to the procedure described in DE 1770065.
  • the 7-iodo derivative of formula R-2 is their prepared by reaction of the quinoline of formula R-1 with iodine monochloride in methanol.
  • the compound of formula R-2 is treated successively with methyl magnesium bromide and n-butyllithium at ⁇ 78° C. in THF, then exposed to sulfur dioxide gas to prepare the compound of formula R-3.
  • Conversion of the compound of formula R-3 to the sulfonyl chloride of formula R-4 is accomplished by treatment with N-chlorosuccinimide in methylene chloride at room temperature for 2 h.
  • the sulfonamide of formula R-5 is then prepared by reaction of the sulfonyl chloride of formula R4 with 2-(4-aminophenyl)ethylamine and pyridine in methylene chloride. Finally, the compound of formula R-6 is prepared by reaction of the compound of formula R-5 with excess sulfonyl chloride of the formula RSO 2 Cl in pyridine.
  • the commercially-available 5-flouro-8-hydroxyquinoline of formula S-1 is treated with neat chlorosulfonic acid at 90-105° C. to form the sulfonyl chloride of formula S-2.
  • the sulfonamide of formula S-3 is then prepared by reaction of 1 eq of the sulfonyl chloride of formula S-2 with 3 eq of benzylamine in THF.
  • T-1 8-hydroxyquinoline
  • T-2 7-carboxylic acid
  • T-2 7-carboxylic acid
  • the acid is then condensed with various aliphatic amines after activation with either 1,1′-carbonyldiimidazole, or alternatively 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenzotriazole to afford the desired amides of the formula T-3.
  • the above amides are prepared either as discrete analogues or as part of a parallel synthesis block.
  • Anhydride U-1 is prepared from 8-hydroxy-7-quinoline carboxylic acid using 2,2,2-trichloroethyl chloroformate and diisopropylethylamine.
  • the purity of the starting materials is crucial for this reaction to succeed; particularly, any trace of any metalic cations but alkali cations, or Lewis acids, has to be avoided, as they lead to an inhibition of the reaction as well as to decarboxylation of anhydride U-1, probably through a chelation of both starting material and product; during the whole course of the reaction, strictly basic conditions have to be maintained, acidic conditions favoring a decarboxylation of the product as well.
  • Ester U-3 is prepared from 8-hydroxy-7-quinoline carboxylic acid as well, the 8-hydroxy substituent being first protected to ester U-2 according to a literature procedure (German Patent No. 540842, Dec. 10, 1931) and subsequent activation of the 7-carboxylic acid as its fluoride, using cyanuric fluoride and diisopropylethylamine.
  • N-Aryl-8-hydroxy-7-quinolinecarboxamides V-4-14 are prepared as single compounds from anhydride U-1 (Chart U) following GP II described below. Both amide coupling and deprotection of the 8-hydroxy substituent can be realized in a single step with primary amines, provided some traces of water are present in the reaction mixture. (No water needs to be added; water coming from glassware and used solvents is enough to ensure a complete deprotectino, at least on small scale.) Probably, the amide function of the still protected intermediate is nucleophic enough to attack the carbonate at the 7-position via a six-membered ring, subsequent hydrolysis, catalyzed by pyridinium chloride, leads to the desired amides.
  • N-Aryl-8-hydroxy-7-quinolinecarboxamides V-21-36 are prepared by parallel synthesis from anhydride U-1, following GP III described below.
  • N-Aryl-8-hydroxy-7-quinolinecarboxamides V-15-20 are prepared as single compounds following GP IV described below from ester U-3 (Chart U). After the coupling step is achieved (6 h to 5 days depending on the amine), methanol is added, which leads to the deprotection of the 8-hydroxy substituent within 6 to 24 h.
  • N-aryl-8-hydroxyquinoline-7-carboxamidies V-17-20 as well as V-37-94 are also prepared by parallel synthesis from ester U-3, following GP V described below.
  • 2-amino5-alkyl-1,3,4-thiadiazoles W-95-98, W-100-102, W-105, W-108 and X-109-117 which are to be coupled with the activated 8-hydroxy-7-quinoline carboxylic acid derivatives U-1 or U-3 (refer to Chart U) to afford the corresponding 8-hydroxy-N-(1,3,4-thiadiazol-2-yl)-7-quinolinecarboxamides X-118-136, required one to four steps.
  • 2-Amino5-bromo-1,3,4-thiadiazole W-95 is prepared through bromination of commercially available 2-amino-1,3,4-thiadiazole.
  • Thiadiazole derivatives W-96-98 are prepared through direct bromide displacement of thiadiazole W-95 with the corresponding amines. Using the same strategy, nitrile W-100 is prepared from aminonitrile W-99, itself prepared from piperonal through a Strecker synthesis. Displacement of the bromide of thiadiazole W-95 with L- and D-phenylalanine methyl esters leads to esters W-101 and W-102, though in low yields.
  • tert-butyl esters are hydrolyzed in selected examples to yield acids Z137-139. These acids are isolated as their corresponding hydrotrifluoroacetates.
  • N-(5-alkylamino-1,3,4-thiadiazol-2-yl)-8-hydroxy-7-quinolinesulfonamides are prepared from the corresponding thiadiazoles and 8-hydroxy-7-quinolinesulfonyl chloride AA-C, prepared in two steps from a 8-hydroxy-7-halogenoquinoline AA-A.
  • the compounds of the present invention and pharmaceutically acceptable salts thereof are usefull as antiviral agents.
  • these compounds are useful to combat viral infections in animals, including man.
  • these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV).
  • CMV cytomegalovirus
  • Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus, and the human herpes virus type 8 (HHV-8).
  • the compounds of the present invention have shown activity in one or more of the assays described below. All of these assays are indicative of a compound's activity and thus of its use as an anti-viral agent.
  • the HCMV polymerase assay is performed using a scintillation proximity assay (SPA) as described in several references, such as N. D. Cook, et al., Pharmaceutical Manufacturing International, pages 49-53 (1992); K. Takeuchi, Laboratory Practice, September issue (1992); U.S. Pat. No. 4,568,649 (1986); which are incorporated by reference herein. Reactions are performed in 96-well plates. The assay is conducted in 100 ⁇ l volume with 5.4 mM HEPES (pH 7.5), 11.7 mM KCl, 4.5 mM MgCl 2 , 0.36 mg/ml BSA, and 90 nM 3 H-dTTP.
  • SPA scintillation proximity assay
  • HCMV is diluted in enzyme dilution buffer containing 50% glycerol, 250 mM NaCl, 10 mM HEPES (pH 7.5), 100 ⁇ g/ml BSA, and 0.01% sodium azide.
  • the HCMV polymerase which is expressed in recombinant baculovirus infected SF-9 cells and purified according to literature procedures, is added at 10% (or 10 ⁇ l) of the final reaction volume, i.e., 100 ⁇ l.
  • a modified version of the above HCMV polymerase assay is performed as described above, but with the following changes: Compounds are diluted in 100% DMSO until final dilution into assay buffer. In the previous assay, compounds are diluted in 50% DMSO. 4.5 mM dithiotherotol (DTT) is added to the polymerase buffer. Also, a different lot of CMV polymerase is used, which appears to be more active resulting in a more rapid polymerase reaction. Results of the testing of compounds of the present invention in this assay are shown in Tables 3, 6 and 7 below.
  • HCMV cell culture based assay
  • An ELISA (enzyme linked immunosorbant assay) format is used as described in W. A. Tatarowicz, N. S. Lurain and K. D. Thompson, J. Virol. Meth., 35:207-215 (1991).
  • Human foreskin fibroblast cells are infected with HCMV at a multiplicity of 0.025 plaque forming units per microtiter plate well for a period of 90 minutes.
  • the virus inocula is removed and a suspension of test compound prepared in tissue culture media is added for a period of 4 days.
  • the growth media is aspirated and replaced with 95% ethanol to allow fixation of virus infected cultures.
  • the ethanol is removed and the wells are washed twice with saline.
  • a solution of 2% dry fat milk, 1% bovine sera albumin prepared in saline is added to wells to allow for non-specific binding of protein material to plastic surfaces for 1 hr.
  • Murine monoclonal antibody prepared in saline directed against the late (65 KD) matrix protein of HCMV is added to test wells for 1 hr.
  • the wells are washed twice and antibody, conjugated with the enzyme horse radish peroxidase, with specificity against murine IgG is added to test wells for 1 hr.
  • Test wells are washed three times with saline.
  • compositions containing the compound in combination with a suitable excipient are prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E. W. Martin (Mark Publ. Co., 15th Ed., 1975), which is hereby incorporated by reference herein.
  • the compounds of the present invention are administered parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically, orally, or rectally, depending on whether the preparation is used to treat internal or external viral infections.
  • compositions are administered orally or parenterally at dose levels, calculated as the free base, of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight, and are used in man in a unit dosage form, administered one to four times daily in the amount of 1 to 1000 mg per unit dose.
  • the compounds are presented in aqueous solution in a concentration of from about 0.1 to 10%, more preferably about 0.1 to 7%.
  • the solution may contain other ingredients, such as emulsifiers, antioxidants or buffers.
  • 5Chloro-8-hydroxyquinoline (5.00 g) and potassium carbonate (11.54 g) are mixed together in a stainless steel bomb and heated to 170° C. under 800 p.s.i. CO 2 for 7 days.
  • the reaction is cooled and the resulting solid is dissolved in 800 mL water.
  • the insoluble material is filtered and partitioned between 800 mL water and 400 mL EtOAc in a separatory funnel.
  • the aqueous layer is washed with EtOAc (3 ⁇ 400 mL).
  • the aqueous layer is then acidified to pH 4.5 with conc. HCl.
  • the resulting solid is collected, washed with water and dried.
  • the crude product is triturated with i-PrOH and dried to yield 1.481 g of the title product as a brown solid.
  • 5-Fluoro-8-hydroxyquinoline (3.00 g) and potassium carbonate (7.62 g) are mixed together in a stainless steel bomb and heated to 170° C. under 800 p.s.i. CO 2 for 7 days.
  • the reaction is cooled and the resulting solid is partitioned between 800 mL water and 400 mL EtOAc in a separatory funnel.
  • the aqueous layer is washed with EtOAc (3 ⁇ 400 mL).
  • the aqueous layer is then acidified to pH 4.5 with conc. HCl and cooled.
  • the resulting solid is collected, washed with water and dried.
  • the crude product is triturated with i-PrOH and dried to yield 1.67 g of the title product as a brown solid.
  • the title compound is prepared from 5-Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-methoxy-7-quinolinesulfonamide, which is the second title compound of Preparation 9, and 6 equivalents of BBr 3 according to the procedure described in Example 18. Crystallization from Et 2 O/hexane affords 0.035 g of tie title compound as a dark tan solid.
  • the title compound is prepared from 5-chloro-N-(4-chlorophenyl)-8-methoxy-7-quinolinesulfonamide, which is the fist title compound of Preparation 9, and 6 equivalents of BBr 3 according to the procedure described in Example 18. Crystallization from Et 2 O/hexane/CH 2 Cl 2 affords 0.015 g of the title compound as a red-brown solid.
  • the title compound is prepared from 5-chloro-8-methoxy-N-(3-phenylpropyl)-7-quinolinesulfonamide, which is the title compound of Preparation 11, and 6 equivalents of BBr 3 according to the procedure described in Example 18. Crystallization from CHCl 3 /acetone/EtOH affords 0.063 g of the title compound as a red-brown solid.
  • the title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 17, substituting benzylamine for 4-chlorobenzylamine. Crystallization from CH 2 Cl 2 /Et 2 O gives 0.104 g of the title compound as a pale orange solid.
  • the title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 17, substituting 2-(4-chlorophenyl)ethylamine for 4-chlorobenzylamine. Crystallization from CH 2 Cl 2 gives 0.100 g of the title compound as a pale yellow solid.
  • the title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 18, substituting benzylamine for 4-chlorobenzylamine. Crystallization from CH 2 Cl 2 gives 0.150 g of the title compound as a light peach solid.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 2,4-dichlorophenethylamine for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 1-2% MeOH/CHCl 3 ) followed by crystallization from CH 2 Cl 2 /hexane gives 0.35 g of the title compound as a yellow solid.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 2-aminoethyl phenyl sulfide for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 1-2% MeOH/CHCl 3 ) followed by crystallization from CH 2 Cl 2 /hexane gives 0.40 g of the title compound as a yellow solid.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting benzylamine for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 0.5-1% MeOH/CH 2 Cl 2 ) followed by crystallization from EtOAc/hexanes gives 0.197 g of the title compound as orange crystals.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 4-chloroanline for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 1% MeOH/CHCl 3 ) followed by crystallization from EtOAc/hexane and rinsing with additional EtOAc gives 0.056 g of the title compound as a beige solid.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting n-octylamine for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 1-2% MeOH/CHCl 3 ) followed by crystallization from EtOAc/hexane gives 0.045 g of the title compound as an orange solid.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 4-fluorobenzylamine for 4-chlorobenzylamine in the former procedure.
  • Column chromatography (elution with 0.5-1% MeOH/CH 2 Cl 2 ) gives 0.135 g of the title compound as an orange foam.
  • the title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 1-naphthalenemethylamine for 4-chlorobenzylamine in the former procedure. Crystallization from CH 2 Cl 2 /hexanes gives 0.127 g of the title compound as light brown crystals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides for 8-hydroxy-7-substituted quinoline compounds such as formula IA
Figure US06310211-20011030-C00001
These compounds are useful as anti-viral agents. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Ser. No. 60/025,870, filed Sep. 10, 1996, and U.S. Ser. No. 60/050,720, filed Jun. 25, 1997.
FIELD OF THE INVENTION
The present invention provides for 8-hydroxy-7-substituted quinoline compounds and pharmaceutically acceptable salts thereof which are useful as antiviral agents. The invention also relates to a pharmaceutical composition containing such compound in combination with a suitable excipient, the composition being useful in combating viral infections. The invention also relates to a method for selectively combating viral infections in animals, including man. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus, and the human herpes virus type 8 (HHV-8).
BACKGROUND OF THE INVENTION
The herpesviruses comprise a large family of double stranded DNA viruses. The herpesvirus family can be divided into three subfamilies (α, β, γ) based upon a number of biological properties such as host range and tropism, viral life cycle, and viral persistence and latency. Eight of the herpesviruses, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), have been shown to infect humans.
HSV-1 and HSV-2 are the prototypic α-herpesviruses. These two serotypes share approximately 50% nucleotide homology. Both are neurotropic viruses, but their primary sites of replication are different. HSV-1 typically infects the oral mucosa resulting in ulcerations commonly referred to as cold sores. HSV-2 infects and causes ulcerations of the genital mucosa. HSV infection can also result in disseminated disease and encephalitis, especially in immunocompromised patients. D. O. White and F. J. Fenner, In Medical Virology, D. O. White and F. J. Fenner, eds., Academic Press, p. 318-347 (1994).
VZV is also an α-herpesvirus and is the causitive agent of chicken pox. VZV establishes a latent infection in the dorsal root ganglia of the peripheral nervous system. From its latent site, VZV can cause recurrent disease commonly referred to as shingles or zoster. The probability of shingles increases with age and frequently occurs in immunocompromised patients. A. M. Arvin, In Virology, B. N. Field, D. M. Knipe, and P. M. Howley, ed., Lippincott-Raven Press, New York, p. 2547-2586 (1996).
Human cytomegalovirus (HCMV), a β-herpesvirus, is an ubiquitous agent producing infection in individuals of all age groups. Infection rates of 60-100%, depending on geographic area and socioeconomic status have been reported. R. J. Whitley, S. Goldsmith and J. Gnann, In Society for General Microbiology. 45th Symposium: Control of Virus Diseases, Mimmock, N.J.; P. D. Griffiths and C. R. Madely, eds., Cambridge University Press, Cambridge, p. 315 (1990). The majority of infections are asymptomatic. However infections occuring in the immunocompromised patient, including organ transplant recipients and individuals with AIDS may be severe and include HCMV induced pneumonia, colitis, and retinitis. L. W. Drew, Clin. Infect. Dis. 14:608-615 (1992). HCMV is the leading cause of blindness in AIDS patients. T. C. Merigan and S. Resta, Rev. Infect. Dis.12: S693 (1990). HCMV also establishes lifelong latency in the host.
HCMV DNA polymerase (HCMV pol) is an enzyme essential for viral replication. D. H. Spector, K. M. Klucher, D. K. Rabert and D. A. Wright, In Herpesvirus Transcription and Its Regulation, E. K. Wagner, ed., CRC Press, Boca Raton, Fla., p. 261 (1991). The current therapies for HCMV; Ganciclovir, Foscarnet and Vistide act by inhibition of HCMV pol. A. K. Field and K. K. Biron, Clin. Micro. Reviews 7:(1) 1-13 (1994). See also U.S. Pat. Nos. 4,199,574; 4,215,113; 4,355,032; and E. DeClercq et al., Antiviral Research, Vol 8, pages 261-272 (1987). Ganciclovir and Foscarnet display significant toxicity and induction therapy is restricted to an intravenous route of administration. D. Faulds and R. C. Heel, Drugs, 39:597 (1990). Maintenance therapy with Ganciclovir and Foscarnet will likely contribute to drug resistant virus. A. K. Field and K. K. Biron, Clin. Micro. Reviews 7:(1) 1-13 (1994). Clearly less toxic, orally bioavailable alternatives are needed.
EBV is a γ-herpesvirus which replicates in the epithelial cells of the nasopharynx and salivary glands and resides latently in B-cells. Childhood infections of EBV are normally asymptomatic. However, EBV infection is associated with several diseases in adults such as infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkins disease. A. B. Rickinson and E. Kieff, In Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, eds., Lippincott-Raven Press, New York, p. 2397-2446 (1996).
HHV-6 is a β-herpesvirus which causes roseola (exanthem subitum) in children. P. Lusso, Antivir. Res. 31:1-21 (1996). HHV-7 shares 50-60% nucleotide sequence homology with HHV-6. It's disease association is unclear, but it may be involved in some cases of roseola. N. Frenkel and E. Roffman, In Virology, B. N. Fields, D. M. Knipe, P. M. Howley, eds., Lippincott-Raven Press, New York, p. 2609-2622 (1996). HHV-8, also known as Kaposi's sarcoma associated herpesvirus (KSHV), is a γ-herpesvirus which has recently been associated with Kaposi's sarcoma in AIDS patients and multiple myeloma. M. B. Rettig et al., Science, 276:1851-1854 (1997).
INFORMATION DISCLOSURE
Published Japanese patent application H1-136152 published May 29, 1989 discloses a silver halide photographic light-sensitive material comprising a support, and thereon, at least 1 silver halide emulsion layer containing a cyan dye-forming coupler represented by a broad generic formula. This broad generic formula includes 8-hydroxy-quinoline derivatives substituted by a wide variety of substituents, e.g., substituted carboxamide groups at the 7-position. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention. Also, the compounds of the present invention are useful as pharmaceutical agents, specifically HCMV inhibitors, whereas the reference compounds are useful in color photography.
Published Japanese patent application HEI 3-73949 published Mar. 28, 1991 discloses a thermally developable color light-sensitive material comprising at least a light-sensitive silver halide, a reducing agent, a binder, and a coupler represented by a first generic formula and/or a second generic formula on a support. These broad generic formulas include 8-hydroxy-quinoline derivatives substituted by a wide variety of substituents, e.g., substituted carboxamide groups at the 7-position. As noted for the previous Japanese reference, none of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention. Also, the compounds of the present invention are useful as pharmaceutical agents, specifically HCMV inhibitors, whereas the reference compounds are useful in color photography.
Published Japanese patent application 02152966 A2 discloses 4-hydroxy-carbostyryl derivatives as anti-allergy and antiinflammatory agents. The compounds of the present invention are 1-(N-unsubstituted)-8-hydroxy-7-quinolinecarboxamides.
U.S. Pat. No. 4,959,363 discloses 1-(N-substituted)-1,4-dihydro-4-oxo-6- and/or -7-substituted-3-quinolinecarboxamides as antiviral agents. The compounds of the present invention are 1-(N-unsubstituted)-8-hydroxy-7-quinolinecarboxamides.
U.S. Pat. Nos. 5,459,146 and 5,506,236 disclose 4-substituted-3-alkyl-pyrazolo[3,4-b]quinoline compounds as antiviral agents. Basically, these compounds are the tricyclic version of compounds such as those disclosed in the '363 patent above, and are structurally very different from the compounds of the present invention.
U.S. Pat. No. 5,378,694 discloses compounds such as 1-(N-substituted)-3-substituted-4-hydroxy-2-quinolinones, and generically, 3-substituted-4-hydroxycoumarin compounds as antiviral agents. U.S. Pat. No. 5,412,104 discloses compounds similar to those disclosed in the '694 patent for anti-viral or anti-hypertensive use; however, these 1-(N-substituted) reference compounds are disclosed as having substituents other than hydroxy at the 4-position of the quinolinone ring. The compounds of the present invention are 1-(N-unsubstituted)-8-hydroxy-7-quinolinecarboxamides.
German patent DE 1 908 548 discloses a variety of compounds including 4-hydroxy-quinoline compounds which may be substituted at the 3-position by carboxamide groups, and which are useful against cold viruses.
Published German patent application DE 44 25 647 A1 discloses heterocyclic-1-phenyl substituted quinolone and naphthyridone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 648 A1 discloses 6 and 6,8-substituted 1-[4-(1H-1,2,4-triazol-1-yl-methyl)phenyl] quinolone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 650 A1 discloses substituted triazolylmethylphenylnaphthyridone carboxylic acids for treating retroviral infections; Published German patent application DE 44 25 659 A1 discloses N1-diverse 6-fluoro-8-difluoromethoxy substituted quinolone carboxylic acids for treating retroviral infections. The compounds of these references are structurally very different from the compounds of the present invention.
Derwent Abstract 96-246942/25 of JP 8099957-A discloses optionally heterocyclyl substituted 4-oxo-quinoline and naphthyridine derivatives which are useful for treating herpes, particularly herpes simplex virus, herpex zoster virus and cytomegalovirus.
Derwent Abstract 95-271358/36 of JP 7165748-A discloses compounds having heterocyclic ketones which are used in antiviral agents for treating cytomegalovirus infectious disease.
Nowhere do these references teach or suggest the specific 8-hydroxyquinoline-7-carboxamide compounds of the present invention which are useful as anti-HCMV agents.
U.S. Pat. No. 5,463,072 discloses a process for the preparation of naphtholic 2-equivalent cyan couplers which are useful in color photography. It discloses an 8-hydroxy-quinoline compound having a substituted thiazole moiety at the 6-position and a carbamoyl moiety at the 7-position.
International Publication WO 95/11592, published May 4, 1995, discloses a marine structure carrying a coating comprising a layer which contains a quinoline compound, or an N-oxide or a salt thereof, having antifouling activity. It generically discloses such compounds with a variety of substituents, such as hydroxy, (optionally substituted C1-12-alkyl)sulphonyl, (optionally substituted aryl)sulphonyl, mono or di (optionally substituted C1-12alkyl)aminosulphonyl.
Derwent Abstract 91-232424/32 (Sandoz A G) discloses the use of 5HT-3 antagonists for the prevention or reduction of dependence on alcohol, psycho-stimulants, nicotine or opiates. A variety of compounds is disclosed including quinoline compounds having unsubstituted phenyl rings.
Derwent Abstract 90-343755/46 (Sandoz Ltd.) discloses serotonin 5HT3 antagonists used for treating stress related psychiatric disorders, rhinitis, nasal disorders and lung embolism. It discloses a variety of compounds, including quinoline compounds substituted by bridged piperidine groups.
Derwent Abstract 90-290145/38 (DuPont DeNemours Co.) discloses n-substituted naphthalene or quinoline sulphonamides which are radio and chemo-sensitising agents in tumour treatment. Other than the sulfonamide bonds, the quinoline compounds are not further substituted on their phenyl rings.
Derwent Abstract 90-264471/35 (Yoshitomi Pharm. Ind. KK.) discloses (iso)quinoline-sulphonamide compounds and their acid addition salts as vasodilators and cerebral circulation improving agents.
Derwent Abstract 85-063337/11 (Sandoz-Patent-Gmbh) discloses a variety of new fused heterocyclic sulphonic amide and ester derivatives with analgesic, antiarrythmic and antipsychotic activities.
Derwent Abstract 22,706 (Pfizer & Co.) discloses quinoline derivatives and their acid addition salts as bronchodilators, but no sulfonamide substituents are disclosed for these compounds.
U.S. Pat. No. 5,240,940 discloses fungicidal compositions comprising a combination of two fungicides, one of which is a quinoline or cinnoline compound. U.S. Pat. No. 4,881,969 discloses sulfonamides as herbicidal agents.
European Published applications 0326330 and 0326328 discloses quinoline, quinazoline and cinnoline fungicides.
JP 63307451 discloses a silver halide color photographic photosensitive material with improved granularity containing a water-soluble coupler capable of a coupling reaction with an oxidant main ingredient in color developing, which coupler may include specific 8-hydroxy-quinoline compounds.
JPO7033729-A discloses the production of N-cyano-N-substituted-arylcarboxyimidamide compounds in which aryl may be 8-quinolyl groups.
International Publication Number WO 96/25399, published Aug. 22, 1996, discloses aroylaniline derivatives which exhibit anti-retroviral activity.
International Publication Number WO 97/03069, published Jan. 30, 1997, discloses substituted heteroaromatic compounds which are protein tyrosine kinase inhibitors, in particular to substituted quinolines and quinazolines.
International Publication Number WO 96/06084, published Feb. 29, 1996, discloses quinolylamine derivatives which are usefull for the treatment of arrhythmia
European Patent Application No. 0206751, published Dec. 30, 1996, discloses 2-substituted-phenylalkenyl-quinoline derivatives which are useful as selective antagonists of leukotrienes of D4.
International Application No. WO 9632015 discloses synergistic fungicidal compositions made of quinoline derivatives and cytochrome complex III inhibitors.
European Patent Application No. 0399818 discloses diarylstyrylquinoline diacids which are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
SUMMARY OF THE INVENTION
The present invention particularly provides:
A compound of formula IA
wherein R0 is
a) —(CH2)n—X1,
b) —(CH2)n—C3-C8 cycloalkyl substituted by zero (0) or one (1) R8,
c) —(CH2)p W1X2,
d) —(CH2)p W1CH2X1, or
e) —(CH2)n—CHR9—(CH2)n—X1;
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl,
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
i) —NHV1,
j) —CH2NHV1, or
k) —CH2Z1;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein R4 is
a) —H
b) —F,
c) —Cl,
d) —Br,
e) —NO2,
f) —CF3,
g) —W1—R10,
h) —C1-C6 alkyl,
i) —C3-C8 cycloalkyl,
j) —[CH2]n-aryl,
k) —[CH2]n-het,
l) —C2C3-C8 cycoalkyl,
m) —SO2NH-het
n) —CN,
o) —I, or
p) —CH2—OH;
wherein R5 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —W1—R10,
f) —CF3,
g) —C1-C6 alkyl,
h) —C3-C8 cycloalkyl,
i) —(CH2)n-aryl substituted by R6,
j) —(CH2)n-het substituted by R7, or
k) —CH2—C3-C8 cycloalkyl;
wherein R6 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein R7 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein R8 is
a) —C1-C4 alkyl,
b) —W1—H, or
c) —CH2W1H;
wherein R9 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11,
e) —CH(OH)R11,
f) —CH2OH,
g) —CO2R11, or
h) -aryl;
wherein R10 is
a) —H,
b) —C1-C6 alkyl,
c) —C3-C8 cycloalkyl,
d) —(CH2)n-aryl optionally substituted with F, Cl, CH2OH or —NO2,
e) —(CH2)n-het, or
f) —CH2—C3-C8 cycloalkyl;
wherein R11 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —(CH2)n X1, or
d) —CH2—C3-C8 cycloalkyl;
wherein X1 is
a) -aryl substituted by zero (0), one (1), two (2), or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R6,
c) —C1-C8 alkyl,
d) —CH(OH)-phenyl,
e) —S-phenyl,
f) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4,
g) —CN,
h) —OH,
i) —C8-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8, or
j) 4-eyano2,3,5,6tetrafluoro-phenyl;
wherein X2 is
a) -aryl substituted by zero (0), one (1), two (2) or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R5,
c) —C1-C8 alkyl,
d) —CH(OH)-phenyl, or
e) —C3-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8;
wherein W1 is
a) —NH,
b) -oxygen, or
wherein V1 is
a) —R11,
b) —C(O)R11,
c) —SO2R11, or
d) —C(O)NHR11;
wherein Z1 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11, or
e) —CO2R11;
wherein -aryl is
a) -phenyl,
b) -naphthyl,
c) -biphenyl,
d) -tetrahydro-naphthyl, or
e) fluorenyl;
wherein -het is a 5-, 6 or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic; wherein -cycloalkyl is a saturated or unsaturated hydrocarbon ring including any bicyclic group in which the above ring is connected to a benzene, heterocyclic or other hydrocarbon ring;
wherein n is zero (0) to six (6), inclusive;
wherein p is one (1), two (2) or three (3);
or a pharmaceutically acceptable salt or N-oxide thereof.
The present invention furer provides:
The compound of formula IA provided that:
a) when R0 is —(CH2)nX1 and X1 is —OH, then n is one or greater; and
b) when R0 is CH2)p W1X2, W1 is -oxygen or -sulfur and X2 is phenyl then R4 is other than t-pentyl.
The present invention also provides:
A compound of formula I
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl, or
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein X1 is
a) -phenyl substituted by zero (0) or one (1) R4,
b) -het substituted by zero (0) or one (1) R5,
c) —C1-C12 alkyl,
d) —CH(OH)-phenyl,
e) —S-phenyl,
f) -naphthyl,
g) —NHSO2-phenyl substituted by one (1) R4, or
h) —CN;
wherein het is
a) -1,3,4-thiadiazol-2-yl,
b) -4,5-dihydro-4-oxo-2-thiazolyl,
c) -thiazolyl,
d) -benzothiazolyl,
e) -pyridinyl,
f) -morpholinyl, or
g) -imidazolyl;
wherein R4 is
a) —H
b) —F,
c) —Cl,
d) —Br,
e) —NO2,
f) —OCH2,
g) —CF3, or
h) —C1-C4 alkyl;
wherein R5 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —(CH)n-phenyl substituted by R6),
f) -thienyl substituted by R7, or
g) —OH;
wherein R6 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein R7 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein n is zero (0) to six (6) inclusive; or a pharmaceutically acceptable salt or a Nexide thereof.
The present invention further provides compounds of formula II
wherein R1 is
a) —H,
b) —Cl,
c) —Br, or
d) —NO2;
wherein R2 is
a) —H,
b) —CH3,
c) —CF3,
d) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
e) —CH═CH-furanyl, or
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4;
wherein X1 is
a) -phenyl substituted by one (1) R4,
b) -het substituted by one (1) R5,
c) —CH(OH)-phenyl,
d) —S-phenyl,
e) -naphthyl,
f) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4, or
g) —CN;
wherein het is
a) -1,3,4-thiadiazol-2-yl,
b) 4,5-dihydro-4-oxo-2-thiazolyl,
c) -2-thiazolyl, or
d) -2-benzothiazolyl;
wherein R4 is
a) —H,
b) —Cl,
c) —Br,
d) —NO2, or
e) —OCHS;
wherein R5 is
a) —H,
b) —Cl,
c) —(CH2)n-(phenyl substituted by R6),
d) -2-thienyl substituted by R7, or
e) OH;
wherein R6 is
a) —H,
b) —Cl, or
c) —Br,
wherein R7 is
a) —H,
b) —Cl, or
c) —Br.
In another aspect, the present invention provides
A use of a compound of formula IA to prepare a medicament for treating a susceptible cytomegaloviral infection in a mammal
wherein R0 is
a) —CH2)n—X1,
b) —(CH2)nC3-C8 cycloalkyl substituted by zero (0) or one (1) R8,
c) —(CH2)pW1X2,
d) —(CH2)pW1CH2X1, or
e) —(CH2)n—CHR9—(CH2)n—X1;
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl,
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
i) —NHV1,
j) —CH2NHV1, or
k) —CH2Z1;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein R4 is
a) —H
b) —F,
c) —Cl,
d) —Br,
e) —NO2,
f) —CF3,
g) —W1—R10,
h) —C1-C6 alkyl,
i) —C3-C8 cycloalkyl,
j) —[CH2]n-aryl,
k) —[CH2]n-het,
l) —CH2—C3-C8 cycloalkyl,
m) —SO2NH-het
n) —CN,
o) —I, or
p) —CH2—OH;
wherein R5 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —W1—R10,
f) —CF3,
g) —C1-C6 alkyl,
h) —C3-C8 cycloalkyl,
i) —(CH2)n-aryl substituted by R6,
j) —(CH2)n-het substituted by R7, or
k) —CH2—C3-C8 cycloalkyl;
wherein R6 is
a) —H,
b) —F,
c) —Cl, or
d) —Br,
wherein R7 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein R8 is
a) —C1-C4 alkyl,
b) —W1—H, or
c) —CH2W1H;
wherein R9 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11,
e) —CH(OH)R11,
f) —CH2OH,
g) —CO2R11, or
h) -aryl;
wherein R10 is
a) —H,
b) —C1-C6 alkyl,
c) —C3-C8 cycloalkyl,
d) —(CH2)n-aryl optionally substituted with F, Cl, CH2OH or —NO2,
e) —(CH2)n-het, or
f) —CH2—C3-C8 cycloalkyl;
wherein R11 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —(CH2)nX1, or
d) —CH2—C3-C8 cycloalkyl;
wherein X1 is
a) -aryl substituted by zero (0), one (1), two (2), or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R5,
c) —C1-C8 alkyl,
d) —CH(OH)-phenyl,
e) —S-phenyl,
f) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4,
g) —CN,
h) —OH,
i) —C3-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8, or
j) -4-cyano-2,3,5,6-tetrafluoro-phenyl;
wherein X2 is
a) -aryl substituted by zero (0), one (1), two (2) or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R5,
c) —C1-C8 alkyl,
d) —CH(OH)-phenyl, or
e) —C3-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8;
wherein W1 is
a) —NH,
b) -oxygen, or
c) -sulfur;
wherein V1 is
a) —R11,
b) —C(O)R11,
c) SO2R11, or
d) —C(O)NHR11;
wherein Z1 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11, or
e) —CO2R11;
wherein -aryl is
a) -phenyl,
b) -naphthyl,
c) -biphenyl,
d) -tetrahydronaphthyl, or
e) fluorenyl;
wherein -het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic;
wherein -cycloalkyl is a saturated or unsaturated hydrocarbon ring including any bicyclic group in which the above ring is connected to a benzene, heterocyclic or other hydrocarbon ring;
wherein n is zero (0) to six (6), inclusive;
wherein p is one (1), two (2) or three (3);
or a pharmaceutically acceptable salt or N-oxide thereof; as well as a method of treating a cytomegalovirus comprising the administration of an effective amount of a compound of the formula IA.
The present invention also provides:
An antiviral pharmaceutical composition which comprises a pharmaceutically acceptable excipient and an effective amount of a compound of formula I.
Further, the present invention provides:
A compound of the formula III
wherein R1 is
a) —H,
b) —C1-C5 alkyl, or
c) —CH═CH-aryl;
wherein R2 is
a) —C1-C10 allyl,
b) —(CH2)nR3,
c) —CH(R4)R3, or
d) —(CH2)n—X2R3;
wherein R3 is
a) -aryl,
b) -het substituted by zero (0) to two (2) R5, or
c) —C3-C6 cycloalkyl;
wherein R4 is
a) —C1-C5 alkyl, or
b) -aryl;
wherein X1 is
a) —H,
b) —F,
c) —Cl,
d) —Br, or
e) —I;
wherein X2 is
a) —O—,
b) —S—, or
c) —NH—;
wherein n is zero (0) to four (4) inclusive;
wherein aryl is
a) phenyl substituted by zero (0) to two (2) R5, or
b) naphthyl substituted by zero (0) to two (2) R5;
wherein het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocyclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and if chemically feasible, the nitrogen atom may be in the protected form;
wherein R5 is
a) —H,
b) —C1-C5 alkyl,
c) —F,
d) —Cl,
e) —OCH3,
f) —CF3,
g) —NHSO2-het substituted by zero (0) to two (2) —C1-C5 alkyl, or
h) —NHSO2-phenyl;
or a pharmaceutically acceptable salt thereof;
A compound of formula III
wherein R1 is
a) —H,
b) —CH3, or
c) —CH═CH-phenyl;
wherein R2 is
a) —(CH2)nR3,
b) —(CH2)n—X2—R3, or
c) —CH(R4)R3;
wherein R3 is
a) -phenyl substituted by zero (0) to two (2) R5,
b) -het,
c) -naphthyl, or
d) —C3-6 cycloalkyl;
wherein R4 is
a) —CH3, or
b) -phenyl;
wherein R5 is
a) —F,
b) —Cl,
c) —NHSO2-phenyl;
wherein X1 is
a) —Cl, or
b) —Br;
wherein X2 is
a) —O—, or
b) —S—;
wherein het is
a) -imidazolyl, or
b) -indolyl.
The present invention also provides:
A compound of the formula IV
where X1 is
a) —H,
b) —F,
d) —Br, or
e) —I;
wherein R2, R3 and R4 may be the same or different and are
a) —C1-C5 alkyl, or
b) -phenyl.
Also provided is:
A compound of formula V
wherein X1 is
a) phenyl substituted by zero (0) to three (3) R4,
b) naphthyl substituted by zero (0) to three (3) R4,
c) fluorenyl substituted by zero (0) to three (3) R4,
d) het substituted by zero (0) to one (1) R5, or
e) 4-cyano-2,3,5,6-tetrafluorophenyl;
wherein R4 is
a) —F,
b) —Cl,
c) —Br,
d) —I,
e) —NO2,
f) —CN,
g) —CF3,
h) —C1-C6 alkyl,
i) phenyl,
j) cyclohexyl,
k) hydroxymethyl,
l) —OR10,
m) —SR10, or
n) —SO2NH-het;
wherein het is
a) 1,3-benzodioxol-4-yl,
b) 1,3-benzodioxo-5-yl,
c) coumarinyl,
d) indazoyl,
e) indolyl,
f) benzothiazolyl,
g) benzothiadiazolyl,
h) quinolinyl,
i) pyridinyl,
j) 1,3,4-thiadiazol-2-yl, or
k) isoxazolyl substituted with one or two C1-C4 alkyl;
wherein R5 is
a) —F,
b) —Cl,
c) —Br,
d) —I,
e) —CF3,
f) —C1-C4-alkyl, or
g) —C1-C2-alkylsubstituted with an aryl;
wherein R10 is
a) hydrogen,
b) —C1-C4 alkyl,
c) phenyl,
d) benzyl, or
e) 4-nitrophenyl; as well as
A compound of formula V
wherein het is
a) indazoyl,
b) indoyl, or
c) isoxazolyl substituted with one (1) or two (2) C1-C4 alkyl
Finally, the present invention provides:
A compound of formula VI or VII
wherein X is
a) —C, or
b) —SO;
wherein Y is
a) —NH,
b) —O, or
c) —S;
wherein EWG is an electron withdrawing group;
wherein R1, R2 and R3 are as defined in claim 1;
wherein R4 is
a) —H,
b) —(CH2)n—CO2—C1-C6 alkyl,
c) —(CH2)m-phenyl optionally substituted with one (1) or two (2) R7,
d) —(CH)m-het,
e) —C1-C6 alkyl optionally substituted by one R6,
f) —C1-C4 alkyl-NH—COOCH2-benzyl, or
g) —C1-C4 alyl-S—CH3;
wherein R5 is pyrrolidin-1-yl optionally substituted with EWG or R6;
wherein n is zero (0) to three (3);
wherein m is zero (0) to one (1);
wherein -het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic;
wherein R6 is
a) hydroxy,
b) —C1-C6 alkyloxy,
c) mercapto, or
d) —C1-C6 alkylmercapto;
wherein R7 is
a) hydroxy, or
b) —C1-C6 alkyloxy; as well as
A compound of formula VI or VII
wherein R7 is t-butyl;
wherein EWG is
a) —NH—CO2C(CH3)3,
b) —CN,
c) —COX2—C1-C6 alkyl, or
d) —COOH;
wherein X2 is
a) —O—, or
b) —NH; and
wherein het is
a) 1,3-benzodioxol-4-yl,
b) 1,3-benzodioxol-5-yl, or
c) indolyl.
“Pharmaceutically acceptable salts” refers to those salts which possess the biological effectiveness and properties of the parent compound and which are not biologically or otherwise undesirable.
“Noide” refers to the oxidized form of the nitrogen in the ring of the 8-hydroxy-quinoline compounds of the present invention. The preparation of such compounds is well known to one of ordinary skill in organic chemistry, including methods such as oxidation with metachloro-peroxy-benzoic acid.
“Electron-withdrawing group” means any substituent on the ring which tends to draw electron density from the ring. Examples of such groups include halogen, nitro, cyano, carboxylic acids, carboxylic esters, sulfoxides, sulfones, sulfonamides, ketones and aldehydes.
“Halogen” means fluroine, chlorine, or bromine.
“Het” is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocyclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and if chemically feasible, the nitrogen atom may be in the protected form; and substituted or unsubstituted. Examples of “het” include the following: thiadiazolyl, thiazolyl, benzothiazolyl, pyridinyl (or pyridyl), morpholinyl, imidazolyl, indolyl, and piperazinyl.
The compounds of the present invention are named according to the IUPAC or CAS nomenclature system.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-Cj indicates a moiety of the integer “i” to the integer “j” carbon atoms, inclusive. Thus, for example, (C1-C3)alkyl refers to alkyl of one to three carbon atoms, inclusive, or methyl, ethyl, propyl and isopropyl, straight and branched forms thereof.
Throughout this application, abbreviations which are well known to one of ordinary skill in the art may be used, such as “Ph” for phenyl, “Me” for methyl, and “Et” for ethyl.
The following Charts A-I describe the preparation of the compounds of the present invention. All of the starting materials are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the final compounds of the present invention are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the variables used in the charts are as defined below or as in the claims.
CHART A
The preparation of the starting materials, 8-hydroxyquinoline-7-carboxylic acids, is accomplished in low to moderate yields by the carboxylation of 8-hydroxyquinolines, which are either commercially available or which are prepared by literature methods: G. S. Bawa, K. E. Hartman, and M. N. Jouillie, Journal of Medicinal Chemistry, Vol.16, No. 2, pages 134-138 (1973); L. C. March, W. A. Romanchick, G. S. Bawa, and M. M. Jouillie, Journal of Medicinal Chemistry, Vol. 16, No. 4, pages 337-342 (1973). The compound of formula A-1 is reacted with K2CO3 (3 eq.), CO2(800 p.s.i) at 170° for 7 days, to yield the compound of formula A-2. J. Hannah et al., Journal of Medicinal Chemistry, Vol. 21, No. 11, pages 1093-1100 (1978). (R1 and R2 in formula A-1 are the same as R1 and R2 in formula A-2.)
The compound of formula A-2 wherein R1 is —H and R2 is —H is the intermediate compound of Preparation 1 below. The compound of formula A-2 wherein R1 is —F and R2 is —H is the intermediate compound of Preparation 4 below. The compound of formula A-2 wherein R1 is —Cl and R2 is —H is the intermediate compound of Preparation 3 below. The compound of formula A-2 wherein R1 is —H and R2 is —CH3 is the intermediate compound of Preparation 5 below.
Figure US06310211-20011030-C00002
CHART B
Bromination of 8-hydroxyquinoline-7-carboxylic acid of formula B-1 with one equivalent of bromine (HOAc, reflux, 1 hr) yields 5-bromo-8-hydroxy-7-quinolinecarboxylic acid of formula B-2 in quantitative yield, which is prepared in Preparation 2 below. R. Schmitt and F. Engelmann, Chem. Ber., 20; 1887; 2694.
Figure US06310211-20011030-C00003
CHART C
The acid of formula C-1, prepared as described in Charts A and B above, is condensed with the amine of formula C-2, which is commercially available (e.g, p-chloro or p-nitrobenzylamine), under appropriate conditions (EDC is used as the coupling agent, HOBt, DMF, rt, 18 hr) to yield the compound of formula C-3. (R1 and R2 in formula C-1 are the same as R1 and R2 in formula C-3. X in formula C-2 is the same as X in formula C-3.) The compound of formula C-3 wherein R1 is —Br, R2 is —H and X is —Cl is the final compound of Example 9 below. The compound of formula C-3 wherein R3 is —H, R2 is —CH3 and X is —Cl is the final compound of Example 10 below. The compound of formula C-3 wherein R1 is —Cl, R2 is —H and X is —Cl is the final compound of Example 11 below. The compound of formula C-3 wherein R1 is —H, R2 is —H and X is —NO2 is the final compound of Example 12 below. The compound of formula C-3 wherein R1 is —F, R2 is —H and X is —Cl is the final compound of Example 16 below. Chart C is the preferred coupling method for benzylamines.
Figure US06310211-20011030-C00004
CHART D
Under the same conditions as in Chart C above (i.e., EDC, HOBt, DMF, rt, 7 days), the acid of formula D-1 is condensed with the heterocyclic amine of formula D-2 to give the final compound of formula D-3, which is prepared in Example 8 below.
Figure US06310211-20011030-C00005
CHART E
Chart E discloses a more efficient method of coupling the 8-hydroxyquinoline-7-carboxylic acids with anilines and heterocyclic amines utilizing PCl3 as the condensing agent. H. Singh, A. K. Singh, S. Sharma, R. N. Iyer, J. Med. Chem., 20:826 (1977); H. Singh, S. Sharma, R. N. Iyer, Ind. J. Chem., 15B:73 (1977); S. K. Dubey, A. K. Singh, H. Singh, S. Sharma, R. N. Iyer, J. Med. Chem., 37:999 (1994). The compound of formula E-1 is coupled with the compound of formula E-2 (using PCl3, xylenes, at reflux, for 18 hr) to yield the compound of formula E-3 wherein X is —H (which is the final compound of Example 5 below) or X is —Br (which is the final compound of Example 6 below). (X in formula E-1 is the same as X in formula E-3.) Chart E is the preferred coupling method for heterocyclic amines.
Figure US06310211-20011030-C00006
CHART F
The required thiazolones of formula F-3 are prepared in three steps from commercially available acids of formula F-1 as follows: the compound of formula F-1 is first treated with P(red) in Br and is then treated with AcCl in methanol to yield the compound of formula F-2. This compound is then reacted with thiourea at ethanol at reflux to yield the compound of formula F-3. T. Sohda et al., Chem. Pharm. Bull., Vol. 30, No. 10, pages 3601-3616 (1982).
Figure US06310211-20011030-C00007
CHART G
Anilines are also coupled in low to moderate yields under the conditions of Chart E. Thus, the compound of formula G-1 is coupled with the compound of formula G-2 (using PCl3, xylenes, at reflux, for 18 hours) to yield the compound of formula G-3. (R1 in formula G-1 is the same as R1 in formula G-3.) The compound of formula C-3 wherein R1 is —H is the final compound of Example 3 below; the compound of formula G-3 wherein R1 is —Br is the final compound of Example 4 below; and the compound of formula G-3 wherein R1 is —Cl is the final compound of Example 15 below. The coupling conditions of this reaction are preferred when anilines are used.
Figure US06310211-20011030-C00008
CHART H
Chart H discloses another method of coupling which is used in the condensation of benzylamines, although the yields are lower than found for the EDC couplings. The compound of formula H-1 is coupled with the compound of formula H-2 (using PCl3, xylenes, at reflux for 18 hr) to yield the compound of formula H-3, which is the final compound of Example 1 below.
Figure US06310211-20011030-C00009
CHART I
Other heterocyclic amines are also condensed with quinoline carboxylic acids under these conditions. The quinoline carboxylic acid of formula I-1 (which was prepared in Chart A above) is coupled with the appropriate heterocyclic amine of formula I-2, I-4, I-6 or I-8 (using PCl3, xylenes, at reflux, for 18 hours) to yield the compound of formula I-3, I-5, I-7 or I-9, respectively. The compound of formula I-3 is the final compound of Example 2 below; the compound of formula I-5 is the final compound of Example 7 below; the compound of formula I-7 is the compound of Example 13 below which is useful as an intermediate; and the compound of formula I-9 is the final compound of Example 14 below.
Figure US06310211-20011030-C00010
Figure US06310211-20011030-C00011
CHART J
The preparation of the starting materials is accomplished by O-methylation of commercially-available 5,7-dihalo-8-hydroxyquinolines according to the procedure of R. A. W. Johnstone and M. E. Rose in Tetrahedron, vol. 35, page 21169 (1979). The compound of formula J-1 is treated with t-butyllithium or n-butyllithium at low temperature in ether/toluene, then exposed to sulfur dioxide gas to prepare the compound of formula J-2. Conversion of the compound of formula J-2 to the sulfonyl chloride of formula J-3 is accomplished by treatment with N-chlorosuccinimide (CH4Cl2, 3 hr). The sulfonamide of formula J-4 is then prepared by reaction of the sulfonyl chloride of formula J-3 with 1 equivalent of a primary amine of the formula R2NH2 and 2 equivalents of pyridine in CH2Cl2 (15 hr). Finally, the compound of formula J-5 is prepared using either excess pyridinium hydrochloride (220° C., 10 min) or excess boron tribromide (CH2Cl2, 1.5 hr).
Figure US06310211-20011030-C00012
CHART K
Compounds of the structure K-3 are prepared from commercially-available 5,7-dihalo-8-hydroxyquolines (K-1) in two steps. Formation of the silylether intermediates K-2 is accomplished by reaction of the 8-hydroxyquinolines K-1 with chlorotrialkylsilanes in the presence of imidazole and DMF at room temperature for 18-20 hours. The intermediates are then treated with t-butyllithium or n-butyllithium at low temperature in THF to give the compound of formula K-3.
Figure US06310211-20011030-C00013
CHART L
To a mixture of o-anidisine of L-1 and ethyl-4,4,4-trifluoroacetoacetate of L-2 is added 6N HCl. The resulting enamine is heated in diphenylether at 250° C. to produce 4-hydroxy-8-methoxy-2-trifluoromethylquioline of L-3.
Figure US06310211-20011030-C00014
CHART M
The compound of M-1 is chlorinated with phosphorus oxychloride in CH2Cl2/DMF at room temperature. The resulting chloride of M-2 is reductively cleaved by hydrogenation in EtOH, Et3N to give M-3. Methyl ether deprotection with pyridine hydrochloride at 220° C. gives 2-trifluoromethyl-8-hydroxyquinoline of M-4. This material is carboxylated to M-5 under Kolbe-Schmidt conditions. Standard amide couplings gives the desired products of M-6.
Figure US06310211-20011030-C00015
CHART N
Alternatively, pyridine hydrochloride deprotection of N-1 gives the 4,8-dihydroxyquinoline of N-2, which again is carboxylated under Kolbe-Schmidt conditions to give N-3. Standard amide couplings give the desired products of N-4.
Figure US06310211-20011030-C00016
CHART O
Aryl aldehydes of O-2 are condensed with 8-hydroxyquinaldine of O-1 at 180° C. to form the 2-styryl-8-hydroxyquinolines of O-3. These are carboxylated under Kolbe-Schmidt conditions to give O-4. Standard couplings of the resulting acid with amines gives the desired amides O-5.
Figure US06310211-20011030-C00017
CHART P
The preparation of the starting material of formula P-1 is accomplished by chlorination of commercially-available 8-hydroxyquinaldine according to the procedure described in DE 1770065. The compound of formula P-1 is then treated with neat flourosulfonic acid at 120° C. to form the compound of formula P-2. Finally, the sulfonamides of formula P-3 are prepared by heating to 140° C. a mixture of 1 eq of the sulfonyl flouride of formula P-2, 2 eq of the primary amine of formula RNH2 and 3 eq of N,N-diisopropylethylamine in chlorobenzene.
Figure US06310211-20011030-C00018
CHART Q
The preparation of the starting material of formula Q-1 is accomplished by O-methylation of commercially-available 5,7-dibromo-2-methyl-8-quinolinol according to the procedure of R. A. W. Johnstone and M. E. Rose in Tetrahedron, vol. 35, page 21169 (1979). The styrene derivative of formula Q-2 is obtained by heating the 2-methylquinoline of formula Q-1 with benzaldehyde for 18 h. The intermediate of formula Q-2 (which corresponds to J-1, R1=CH═CHPh, X1=X2=Br) is then advanced in four steps to the sulfonamides of formula Q-3 (which corresponds to J-5, R1=CH═CHPh, X1=Cl; R2=R) following the route previously described in Chart J.
Figure US06310211-20011030-C00019
CHART R
The preparation of the starting material of formula R-1 is accomplished by chlorination of commercially-available 8-hydroxyquinaldine according to the procedure described in DE 1770065. The 7-iodo derivative of formula R-2 is their prepared by reaction of the quinoline of formula R-1 with iodine monochloride in methanol. The compound of formula R-2 is treated successively with methyl magnesium bromide and n-butyllithium at −78° C. in THF, then exposed to sulfur dioxide gas to prepare the compound of formula R-3. Conversion of the compound of formula R-3 to the sulfonyl chloride of formula R-4 is accomplished by treatment with N-chlorosuccinimide in methylene chloride at room temperature for 2 h. The sulfonamide of formula R-5 is then prepared by reaction of the sulfonyl chloride of formula R4 with 2-(4-aminophenyl)ethylamine and pyridine in methylene chloride. Finally, the compound of formula R-6 is prepared by reaction of the compound of formula R-5 with excess sulfonyl chloride of the formula RSO2Cl in pyridine.
Figure US06310211-20011030-C00020
CHART S
The commercially-available 5-flouro-8-hydroxyquinoline of formula S-1 is treated with neat chlorosulfonic acid at 90-105° C. to form the sulfonyl chloride of formula S-2. The sulfonamide of formula S-3 is then prepared by reaction of 1 eq of the sulfonyl chloride of formula S-2 with 3 eq of benzylamine in THF.
Figure US06310211-20011030-C00021
CHART T
Commercially available 8-hydroxyquinoline (T-1) is converted to the 7-carboxylic acid (T-2) by heating at 175° C. in the presence of potassium carbonate under 800 psi carbon dioxide gas for 7 days. The acid is then condensed with various aliphatic amines after activation with either 1,1′-carbonyldiimidazole, or alternatively 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenzotriazole to afford the desired amides of the formula T-3. The above amides are prepared either as discrete analogues or as part of a parallel synthesis block.
Figure US06310211-20011030-C00022
CHART U
Anhydride U-1 is prepared from 8-hydroxy-7-quinoline carboxylic acid using 2,2,2-trichloroethyl chloroformate and diisopropylethylamine. The purity of the starting materials is crucial for this reaction to succeed; particularly, any trace of any metalic cations but alkali cations, or Lewis acids, has to be avoided, as they lead to an inhibition of the reaction as well as to decarboxylation of anhydride U-1, probably through a chelation of both starting material and product; during the whole course of the reaction, strictly basic conditions have to be maintained, acidic conditions favoring a decarboxylation of the product as well. Ester U-3 is prepared from 8-hydroxy-7-quinoline carboxylic acid as well, the 8-hydroxy substituent being first protected to ester U-2 according to a literature procedure (German Patent No. 540842, Dec. 10, 1931) and subsequent activation of the 7-carboxylic acid as its fluoride, using cyanuric fluoride and diisopropylethylamine.
Figure US06310211-20011030-C00023
CHART V
N-Aryl-8-hydroxy-7-quinolinecarboxamides V-4-14 are prepared as single compounds from anhydride U-1 (Chart U) following GP II described below. Both amide coupling and deprotection of the 8-hydroxy substituent can be realized in a single step with primary amines, provided some traces of water are present in the reaction mixture. (No water needs to be added; water coming from glassware and used solvents is enough to ensure a complete deprotectino, at least on small scale.) Probably, the amide function of the still protected intermediate is nucleophic enough to attack the carbonate at the 7-position via a six-membered ring, subsequent hydrolysis, catalyzed by pyridinium chloride, leads to the desired amides. Similarly, N-Aryl-8-hydroxy-7-quinolinecarboxamides V-21-36 are prepared by parallel synthesis from anhydride U-1, following GP III described below. N-Aryl-8-hydroxy-7-quinolinecarboxamides V-15-20 are prepared as single compounds following GP IV described below from ester U-3 (Chart U). After the coupling step is achieved (6 h to 5 days depending on the amine), methanol is added, which leads to the deprotection of the 8-hydroxy substituent within 6 to 24 h. N-aryl-8-hydroxyquinoline-7-carboxamidies V-17-20 as well as V-37-94 are also prepared by parallel synthesis from ester U-3, following GP V described below.
When parallel synthesis is used, some impurities appear occasionally besides the desired product, mainly the carbamate resulting from an attack of the amine at the carbonate positions when anhydride U-1 is involved, or methyl 8-hydroxy-7-quinoline carboxylate after methanolic treatment of the reaction mite from ester
Figure US06310211-20011030-C00024
CHART W
The synthesis of 2-amino5-alkyl-1,3,4-thiadiazoles W-95-98, W-100-102, W-105, W-108 and X-109-117, which are to be coupled with the activated 8-hydroxy-7-quinoline carboxylic acid derivatives U-1 or U-3 (refer to Chart U) to afford the corresponding 8-hydroxy-N-(1,3,4-thiadiazol-2-yl)-7-quinolinecarboxamides X-118-136, required one to four steps. 2-Amino5-bromo-1,3,4-thiadiazole W-95 is prepared through bromination of commercially available 2-amino-1,3,4-thiadiazole. Thiadiazole derivatives W-96-98 are prepared through direct bromide displacement of thiadiazole W-95 with the corresponding amines. Using the same strategy, nitrile W-100 is prepared from aminonitrile W-99, itself prepared from piperonal through a Strecker synthesis. Displacement of the bromide of thiadiazole W-95 with L- and D-phenylalanine methyl esters leads to esters W-101 and W-102, though in low yields. Known literature procedures are used to prepare amino acids W-103 and W-106, of which acid groups are converted into the corresponding tert-butyl esters (compounds W-104 and W-107) by standard procedures; subsequent bromide displacement as last step affords esters W-105 and W-108.
Figure US06310211-20011030-C00025
Figure US06310211-20011030-C00026
CHART X
Bromide displacement with commercially available piperonyl amine leads to thiadiazole W-109; similarly, using some amino acid tert-butyl esters leads to esters X-110 to X-117.
Figure US06310211-20011030-C00027
CHART Y
These thiadiazoles, as well as commercially available 2-amino-5-(trifluoromethyl)-1,3,4-thiadiazole, are then coupled using the same methodology as described for the amides V-4-20 from anhydride U-1 or ester U-3 to give amides Y-118-125 or y-126-136, respectively. Depending on the applied work-up procedure, these compounds are isolated as the free compounds, as the hydrochloride salt or as a hydrate.
Figure US06310211-20011030-C00028
Figure US06310211-20011030-C00029
CHART Z
The tert-butyl esters are hydrolyzed in selected examples to yield acids Z137-139. These acids are isolated as their corresponding hydrotrifluoroacetates.
Figure US06310211-20011030-C00030
CHART AA
N-(5-alkylamino-1,3,4-thiadiazol-2-yl)-8-hydroxy-7-quinolinesulfonamides are prepared from the corresponding thiadiazoles and 8-hydroxy-7-quinolinesulfonyl chloride AA-C, prepared in two steps from a 8-hydroxy-7-halogenoquinoline AA-A.
Figure US06310211-20011030-C00031
It will be apparent to those skilled in the art that the described synthetic procedures are merely representative in nature and that alternative synthetic processes are known to one of ordinary skill in organic chemistry.
The compounds of the present invention and pharmaceutically acceptable salts thereof are usefull as antiviral agents. Thus, these compounds are useful to combat viral infections in animals, including man. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus, and the human herpes virus type 8 (HHV-8).
Also, while many of the compounds of the present invention have shown activity against the CMV polymerase, these compounds may be active against the cytomegalovirus by this or other mechanisms of action. Thus, the description below of these compounds' activity against the CMV polymerase is not meant to limit the present invention to a specific mechanism of action.
The compounds of the present invention have shown activity in one or more of the assays described below. All of these assays are indicative of a compound's activity and thus of its use as an anti-viral agent.
The HCMV polymerase assay is performed using a scintillation proximity assay (SPA) as described in several references, such as N. D. Cook, et al., Pharmaceutical Manufacturing International, pages 49-53 (1992); K. Takeuchi, Laboratory Practice, September issue (1992); U.S. Pat. No. 4,568,649 (1986); which are incorporated by reference herein. Reactions are performed in 96-well plates. The assay is conducted in 100 μl volume with 5.4 mM HEPES (pH 7.5), 11.7 mM KCl, 4.5 mM MgCl2, 0.36 mg/ml BSA, and 90 nM 3H-dTTP. Assays are run with and without CHAPS, (3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane-sulfonate), at a final concentration of 2 mM. HCMV is diluted in enzyme dilution buffer containing 50% glycerol, 250 mM NaCl, 10 mM HEPES (pH 7.5), 100 μg/ml BSA, and 0.01% sodium azide. The HCMV polymerase, which is expressed in recombinant baculovirus infected SF-9 cells and purified according to literature procedures, is added at 10% (or 10 μl) of the final reaction volume, i.e., 100 μl. Compounds are diluted in 50% DMSO and 10 μl are added to each well. Control wells contain an equivalent concentration of DMSO. Unless noted otherwise, reactions are initiated via the addition of 6 nM biotinylated poly(dA)-oligo(dT) template/primer to reaction mixtures containing the enzyme, substrate, and compounds of interest. Plates are incubated in a 25° C. or 37° C. H2O bath and terminated via the addition of 40 μl/reaction of 0.5 M EDTA (pH 8) per well. Reactions are terminated within the time-frame during which substrate incorporation is linear and varied depending upon the enzyme and conditions used, i.e., 30 min. for HCMV polymerase. Ten μl of streptavidin-SPA beads (20 mg/ml in PBS/10% glycerol) are added following termination of the reaction. Plates are incubated 10 min. at 37° C., then equilibrated to room temperature, and counted on a Packard Topcount. Linear regressions are performed and IC50's are calculated using computer software. Results of the testing of compounds of the present invention in this assay are shown in Tables 1, 2, 5, 9, 10, 11, 13 (except for the last compound which was tested under modified conditions) and 14 below.
A modified version of the above HCMV polymerase assay is performed as described above, but with the following changes: Compounds are diluted in 100% DMSO until final dilution into assay buffer. In the previous assay, compounds are diluted in 50% DMSO. 4.5 mM dithiotherotol (DTT) is added to the polymerase buffer. Also, a different lot of CMV polymerase is used, which appears to be more active resulting in a more rapid polymerase reaction. Results of the testing of compounds of the present invention in this assay are shown in Tables 3, 6 and 7 below.
Compounds are tested for direct antiviral activity against HCMV using a cell culture based assay. An ELISA (enzyme linked immunosorbant assay) format is used as described in W. A. Tatarowicz, N. S. Lurain and K. D. Thompson, J. Virol. Meth., 35:207-215 (1991). Human foreskin fibroblast cells are infected with HCMV at a multiplicity of 0.025 plaque forming units per microtiter plate well for a period of 90 minutes. The virus inocula is removed and a suspension of test compound prepared in tissue culture media is added for a period of 4 days. The growth media is aspirated and replaced with 95% ethanol to allow fixation of virus infected cultures. The ethanol is removed and the wells are washed twice with saline. A solution of 2% dry fat milk, 1% bovine sera albumin prepared in saline is added to wells to allow for non-specific binding of protein material to plastic surfaces for 1 hr. Murine monoclonal antibody prepared in saline directed against the late (65 KD) matrix protein of HCMV is added to test wells for 1 hr. The wells are washed twice and antibody, conjugated with the enzyme horse radish peroxidase, with specificity against murine IgG is added to test wells for 1 hr. Test wells are washed three times with saline. A solution of o-phenylene diamine, a substrate for horse radish peroxidase is added for 15 minutes at which time enzymatic conversion occurs indicating reactivity of the enzyme with its substrate. This conversion is evident as a color reaction which was spectrophoretically monitored at 490 nm. The intensity of the color indirectly reflects the presence of antibody directed against the viral 65 KD matrix antigen. The presence of the viral matrix antigen reflects the amount of HCMV replication. Thus, test wells, in which little viral replication has occurred, would have little or no antibody binding and are present with low levels of color. Non-infected wells serve as the assay background control. Results of the testing of compounds of the present invention in this assay are shown in Tables 4, 7 and 12 below.
These compounds of the present invention are administered in a pharmaceutical composition containing the compound in combination with a suitable excipient, the composition being useful in combating viral infections. Pharmaceutical compositions containing a compound appropriate for antiviral use are prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E. W. Martin (Mark Publ. Co., 15th Ed., 1975), which is hereby incorporated by reference herein.
The compounds of the present invention are administered parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically, orally, or rectally, depending on whether the preparation is used to treat internal or external viral infections.
For internal infections, the compositions are administered orally or parenterally at dose levels, calculated as the free base, of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight, and are used in man in a unit dosage form, administered one to four times daily in the amount of 1 to 1000 mg per unit dose.
For parenteral administration or for administration as drops, as for eye infections, the compounds are presented in aqueous solution in a concentration of from about 0.1 to 10%, more preferably about 0.1 to 7%. The solution may contain other ingredients, such as emulsifiers, antioxidants or buffers.
The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment and, of course, the judgment of the attending practitioner.
The following compounds of the present invention are preferred:
N-[5-[(4-Chlorophenyl)methyl]-1,3,4-thiadiazol-2-yl-8-hydroxy-7-quinolinecarboxamide;
5-Bromo-N-(4-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
5-Chloro-N-(4-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide;
8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-(2-phenylethenyl)-7-quinolinecarboxamide;
N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide;
8-Hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide;
N-[(4-Chlorophenyl)methyl]-2-[2-(2-furyl)ethenyl]-8-hydroxy-7-quinolinecarboxamide;
5-chloro-8-hydroxy-2-methyl-N-(3-phenylpropyl)-7-quinolinecarboxamide;
5-chloro-8-hydroxy-2-methyl-N-[(2-phenylthio)ethyl]-7-quinolinecarboxamide;
8-hydroxy-N-[5-[4-[(1-methylethyl)phenylsulfonyl]amino]pentyl]-7-quinolinecarboxamide;
8-hydroxy-N-(cyanomethyl)-7-quinolinecarboxamide;
8-hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethyl]-7-quinolinecarboxamide;
N-(2,2-Diphenylethyl)-8-hydroxy-7-quinolinecarboxamide;
N-(3,3-Diphenylpropyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(cis-myrtanyl)-7-quinolinecarboxamide;
8-Hydroxy-N-(diphenylmethyl)-7-quinolinecarboxamide;
8-Hydroxy-N-(2-octyl)-7-quinolinecarboxamide;
N-[2-((1R,2S)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-nonyl-7-quinolinecarboxamide;
N-(4-tert-Butylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
R-8-Hydroxy-N-[1-(1-naphthyl)ethyl]-7-quinolinecarboxamide;
S-N-[1-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[2-((1S,2R)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
S-8-Hydroxy-N-[1-(1-naphthyl)ethyl]-7-quinolinecarboxamide;
N-[(2-Chloro-6-phenoxy-phenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
S-8-Hydroxy-N-[2-(1-hydroxy-3-[4-hydroxyphenyl])propyl]-7-quinolinecarboxamide;
8-Hydroxy-N-undecyl-7-quinolinecarboxamide;
8-Hydroxy-N-(2-methylcyclohexyl)-7-quinolinecarboxamide;
N-[1-(2-Ethyl)hexyl]-8-hydroxy-7-quiolinecarboxamide;
8-Hydroxy-N-(1-naphthalenylmethyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[2-(2-[4-phenoxy]phenyl)ethyl]-7-quiolinecarboxamide;
R-N-[1-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
S-O-Benzyl-N-[7-(7-Carboxy-8-hydroxy)quinolyl]-tyrosine, methyl ester;
N-[2-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-(4-Cyanophenyl)-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
N-(3-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
N-Fluoren-2-yl-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
8-Hydroxy-N-{4-[(indazo-6-ylamino)sulfonyl]phenyl}-7-quinolinecarboxamide monohydrochloride;
N-(3-Benzoxyphenyl)-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
N-(4-Benzoxyphenyl)-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
8-Hydroxy-N-[4-(4-nitrophenoxy)phenyl]-7-quinolinecarboxamide monohydrochloride;
8-Hydroxy-N-naphth-1-yl-7-quinolinecarboxamide;
N-(2-Chloro-4-nitrophenyl)-8-hydroxy-7-quinolinecarboxamide;
N-Biphen-2-yl-8-hydroxy-7-quinolinecarboxamide;
N-(4-Chloro-2-methylphenyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(4-propylphenyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[4-(hydroxymethyl)phenyl]-7-quinolinecarboxamide;
8-Hydroxy-N-indazol-5-yl-7-quinolinecarboxamide;
8-Hydroxy-N-(5-iodo-2-methylphenyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[5-(2-phenylethyl)amino-1,3,4-thiadiazol-2-yl]-7-quinolinecarboxamide monohydrochloride;
N-[5-(Butylamino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
5-Bromo-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-Heptyl-8-hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide;
N-Heptyl-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide;
8-Hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinecarboxamide;
N-[(4-Chlorophenyl)methyl]-8-hydroxy-5-nitro-7-quinolinecarboxamide;
N-[5-[3-(4-Chlorophenyl)methyl]-4,5-dihydro-4-oxo-2-thiazolyl]-8-hydroxy-7-quinolinecarboxamide;
(E)-8-Hydroxy-2-(2-phenylethenyl)-N-(3-phenylpropyl)-7-quinolinecarboxamide;
N-{5-[(1,3-Benzodioxol-5-ylcyanomethyl)amino]-1,3,4-thiadiazol-2-yl}-8-hydroxy-7-quinolinecarboxamide monohydrochloride;
N-[5-({1,3-Benzodioxol-5-yl-[(tert-butoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide semihydrate;
N-[5-({1,3-Benzodioxol-4-yl-[(tert-butoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide semihydrate;
(S)-N-[5-({[(tert-Butoxy)carbonyl]-[4-hydroxybenzyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide;
(S)-N-[5-({5-[Benzoxy]amido-1-[(tert-butoxy)carbonyl]pentyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide;
(S)-N-[5-({1-[(tert-Butoxy)carbonyl]-2-indol-3-ylethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide monohydrate; and
(S)-N-[5-({1-[(tert-Butoxy)carbonyl]-2-[4-(tert-butoxy)phenyl]ethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide monohydrate.
The following sulfonamide compounds of the present invention are preferred:
5-Chloro-8-hydroxy-2-methyl-N-[2-(phenylthio)ethyl]-7-quinolinesulfonamide;
5-Chloro-N-(4-chlorophenyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide;
5-Chloro-N-[4-fluorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide;
5-Chloro-8-hydroxy-2-methyl-N-(1-naphthalenylmethyl)-7-quinolinesulfonamide;
5-Chloro-N-(cyclohexylmethyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide;
5-Chloro-8-hydroxy-2-methyl-N-(3-phenylpropyl)-7-quinolinesulfonamide;
5-Chloro-8-hydroxy-2-methyl-N-(2-phenoxyethyl)-7-quinolinesulfonamide;
5-Chloro-N-(diphenylmethyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide;
(R)-5-Chloro-8-hydroxy-2-methyl-N-(1-phenylethyl)-7-quinolinesulfonamide;
(S)-5-Chloro-8-hydroxy-2-methyl-N-(1-phenylethyl)-7-quinolinesulfonamide;
5-Chloro-N-[2-(4-chlorophenyl)ethyl]-8-hydroxy-7-quinolinesulfonamide;
5-Bromo-8-hydroxy-N-(phenylmethyl)-7-quinolinesulfonamide;
5-Chloro-N-[2-(2,4-dichlorophenyl)ethyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide;
(E)-5-Chloro-8-hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinesulfonamide; and
5-Chloro-8-hydroxy-2-methyl-N-[2-[4[(phenylsulfonyl)amino]phenyl]ethyl]-7-quinolinesulfonamide.
DESCRIPTION OF PREFERRED EMBODIMENTS PREPARATION 1 8-Hydroxyquinoline-7-carboxylic Acid (Formula A-2 wherein R1 is —H and R2 is —H) Refer to Chart A
Figure US06310211-20011030-C00032
8-Hydroxyquinoline (50.0 g) and potassium carbonate (142.8 g) are mixed together in a stainless steel bomb and heated at 170° C. under 1200 p.s.i. CO2 for 7 days. The reaction is then cooled and the resulting solid is partitioned between water (6 L) and EtOAc (1 L). The organic layer is extracted with water (2×300 mL). The combined aqueous layers are extracted with EtOAc (3×500 mL). The aqueous layer is then acidified to pH 4.5 with conc. HCl. The resulting solid is collected, dried and triturated with i-PrOH to yield 51.97 g of the title compound as a tan solid.
Physical characteristics are as follows:
1H NMR (300 MHz, DMSO) δ 8.89, 8.58, 7.89, 7.78, 7.28.
EXAMPLE 1 N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide (Formula H-3) Refer to Chart H
Figure US06310211-20011030-C00033
A solution of 8-hydroxyquinoline-7-carboxylic acid (0.250 g) of Preparation 1 and 4-chlorobenzylamine (0.187 g) in 25 mL xylenes is heated to reflux. To this is added dropwise PCl3 (0.073 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected and recrystallized from EtOAc/hexanes to yield 0.088 g of the title product as a yellow solid.
Physical characteristics are as follows:
MP 162-165° C.; 1H NMR (300 MHz, DMSO) δ 9.46, 8.93, 8.43, 8.03, 7.70, 7.46, 7.39, 4.56. 13C NMR (75 MHz, DMSO) δ 168.5, 156.8, 149.2, 138.6, 137.5, 132.0, 129.7, 128.8, 125.8, 124.1, 117.5, 113.2, 42.5. IR (mull) 3081, 1964, 1932, 1635, 1610, 1601, 1577, 1558, 1500, 1492, 1325, 1295, 846, 836, 800 cm−1. MS (FAB) m/z 313 (M+H), 315, 314, 313, 312, 173, 172, 69, 57, 55, 43. HRMS (EI) found 312.0669.
EXAMPLE 2 N-[5-[(4-Chlorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide (Formula I-3) Refer to Chart I
Figure US06310211-20011030-C00034
A solution of 8-hydroxyquinoline-7-carboxylic acid (0.236 g) of Preparation 1 and 2-amino5-(4chlorobenzyl)thiadiazole (0.282 g) in 25 mL xylenes is heated to reflux. To this is added dropwise PCl3 (0.069 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, dried and recrystallized HOAc to yield 0.079 g of the title product as a gold solid.
Physical characteristics are as follows:
MP 276-278° C.; 1H NMR (300 MHz, DMSO) δ 8.87, 8.75, 8.04, 7.88, 7.39, 7.17, 4.37. IR (mull) 1661, 1608, 1567, 1537, 1489, 1422, 1292, 1218, 1212, 819, 810, 789, 740, 652, 613 cm−1. MS (EI) m/z 396 (M+), 398, 397, 396, 173, 172, 171, 125, 116, 89, 63 (4). HRMS (EI) found 396.0471.
EXAMPLE 3 N-(4-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide (Formula G-3 wherein R1 is —H) Refer to Chart G
Figure US06310211-20011030-C00035
A solution of 8-hydroxyquinoline-7-carboxylic acid (3.78 g) of Preparation 1 and 4-chloroaniline (2.55 g) in 250 mL xylenes is heated to reflux. To this is added dropwise PCl3 (1.37 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, washed with water and dried. The crude product is recrystallized from EtOAc/hexanes to yield 1.96 g of the title product as an orange solid.
Physical characteristics are as follows:
MP 207-209° C.; 1H NMR (300 MHz, DMSO) δ 11.15, 8.91, 8.47, 8.00, 7.77, 7.71, 7.40, 7.39. 13C NMR (75 MHz, DMSO) δ 165.8, 156.0, 147.9, 138.5, 138.4, 138.2, 131.3, 129.2, 127.7, 127.6, 123.9, 122.1, 116.1, 115.9. IR (mull) 3048, 1996, 1939, 1659, 1588, 1539, 1531, 1485, 1397, 1288, 1253, 1235, 1215, 809, 745 cm−1. MS (EI) m/z 298 (M+), 300, 299, 298, 173, 172, 127, 117, 116, 89, 63. HRMS (EI) found 298.0518. Anal. found: C, 64.39; H, 3.68; N, 9.32; Cl, 11.82.
EXAMPLE 4 5-Bromo-N-(4-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide (Formula G3 wherein R1 is —Br) Refer to Chart G
Figure US06310211-20011030-C00036
A solution of 5-bromo-8-hydroxyquinoline-7-carboxylic acid (2.68 g) of Preparation 2 and 4-chloroaniline (1.28 g) in 250 mL xylenes is heated to reflux. To this is added dropwise PCl3 (0.69 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, washed with water and dried. The crude product is recrystallized from EtOAc/hexanes to yield 1.97 g of the title product as an orange solid.
Physical characteristics are as follows:
MP 213-215° C.; 1H NMR (300 MHz, DMSO) δ 10.99, 9.00, 8.55, 8.25, 7.87, 7.75, 7.42. 13C NMR (75 MHz, DMSO) δ 164.5, 155.6, 149.1, 139.7, 137.9, 136.9, 130.5, 129.6, 129.3, 128.0, 125.4, 122.2, 117.2, 107.4. IR (mull) 2043, 1957, 1926, 1658, 1594, 1558, 1552, 1521, 1493, 1480, 1400, 1395, 1291, 807, 634 cm−1. MS (EI) m/z 376 (M+), 378, 376, 252, 251, 250, 196, 194, 129, 127, 115; HRMS (EI) found 375.9618. Anal. found: C, 50.15; H, 2.60; N, 7.27; Br, 20.85; Cl, 9.23.
PREPARATION 2 5-Bromo-8-hydroxyquinoline-7-carboxylic Acid (Formula B-2) Refer to Chart B
Figure US06310211-20011030-C00037
8-Hydroxyquinoline-7-carboxylic acid (1.00 g) is suspended in 25 mL acetic acid. To this is added bromine (0.845 g) dropwise. The mixture is heated to reflux for 1 h, then poured into cold water. The resulting solid is collected, washed with water and dried to yield 1.43 g of the title product as a yellow solid.
Physical characteristics are as follows:
MP 244-246° C.; IR (mull) 3093, 2138, 1995, 1590, 1553, 1396, 1312, 1233, 1108, 911, 820, 779, 67, 730, 671 cm−1. MS (EI) m/z 267 (M+), 269, 267, 251, 249, 225, 223, 195, 193, 115, 114. HRMS (EI) found 266.9507. Anal. found: C, 41.84; H, 2.83; N, 4.98; Br, 28.00.
EXAMPLE 5 N-[5-(4-Chlorophenyl)-4,5-dihydro-4-oxo-2-thiazolyl]-8-hydroxy-7-quinolinecarboxamide (Formula E-3 wherein X is —Cl) Refer to Chart E
Figure US06310211-20011030-C00038
A solution of 8-hydroxyquinoline-7-carboxylic acid (0.280 g) of Preparation 1 and 2-amino-5-(4-chlorophenyl)-4-hydroxy-1,3-thiazole (0.340 g) in 50 mL xylenes is heated to reflux. To this is added dropwise PCl3 (0.103 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, washed with water and dried. The crude product is triturated with HOAc to yield 0.236 g of the title product as a gold solid.
Physical characteristics are as follows:
MP 272-276° C. (dec). 1H NMR (300 MHz, DMSO) δ 13.75, 8.87, 8.72, 8.09, 7.86, 7.63, 7.37, 7.23. IR (mull) 2042, 1954, 1702, 1685, 1535, 1482, 1424, 1338, 1300, 1262, 1223, 1186, 1181, 1093, 833 cm−1. MS (EI) m/z 397 (M+), 397, 241, 226, 173, 172, 171, 155, 145, 116, 89. HRMS (EI) found 397.0278.
EXAMPLE 6 5-Bromo-N-[5-(4-chlorophenyl)-4,5-dihydro-4-oxo-2-thiazolyl]-8-hydroxy-7-quinolinecarboxamide (Formula E-3 wherein X is —Br) Refer to Chart E
Figure US06310211-20011030-C00039
A solution of 5-bromo-8-hydroxyquinoline-7-carboxylic acid (0.268 g) of Preparation 2 and 2-amino-5-(4-chlorophenyl)-4-hydroxy-1,3-thiazole (0.227 g) in 50 mL xylenes is heated to reflux. To this is added dropwise PCl3 (0.069 g). Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, washed with water and dried. The crude product is recrystallized from HOAc to yield 0.055 g of the title product as an orange solid.
Physical characteristics are as follows:
MP 254-556° C. (dec). 1H NMR (300 MHz, DMSO) δ 13.25, 8.98 8.72, 8.28, 7.99, 7.63, 7.45, 7.37. IR (mull) 3077, 1996, 1705, 1698, 1676, 1652, 1594, 1531, 1492, 1319, 1306, 1262, 1218, 1170, 1093 cm−1. MS (EI) m/z 475 (M+), 252, 251, 250, 226, 157, 156, 155, 115, 114, 89. HRMS (EI) found 474.9391.
EXAMPLE 7 N-[5-(5-Bromo-2-thienyl)-2-thiazolyl]-8-hydroxy-7-quinolinecaraoxidede (Formula I-5) Refer to Chart I
Figure US06310211-20011030-C00040
A solution of 8-hydroxyquinoline-7-carboxylic acid (0.43 g) of Preparation 1 in 80 mL xylenes is heated to reflux. PCl3 (0.12 mL) is added dropwise and the mixture stirred for 20 minutes. 2-Amino-5-(5-bromothien-2-yl)thiazole (0.62 g) is added in one portion and the reaction refluxed overnight. The reaction is cooled to room temperature and H2O is added to quench excess PCl3. The solvents are removed and the residue is dissolved in acetic acid. A dark orange solid precipitates upon addition of hexanes (0.28 g) to yield the title product.
Physical characteristics are as follows:
MP 279-281° C. dec. 1H NMR (300 MHz, DMSO-d6) δ 8.89, 8.71, 8.09, 7.86, 7.55, 7.38, 7.25, 7.21. 13C NMR (75 MHz, TFA-d) δ 167.26, 161.84, 153.55, 148.16, 144.66, 135.44, 132.94, 131.36, 128.99, 128.85, 128.71, 127.06, 125.24, 119.44, 117.29, 113.07, 109.38. IR (mull) 3082, 1996, 1925, 1664, 1608, 1539, 1490, 1428, 1343, 1299, 1273, 1230, 1212, 1034, 7376. MS (EI) m/z 431 (M+), 433, 431, 262, 260, 180, 173, 172, 117, 116, 89. HRMS (EI) found 430.9401.
EXAMPLE 8 N-[5-(3-Chlorophenyl)-4,5-dihydro-4-oxo-2-thiazolyl]-8-hydroxy-7-quinolinecarboxamide (Formula D-3) Refer to Chart D
Figure US06310211-20011030-C00041
To a solution of 8-hydroxyquinoline-7-carboxylic acid (0.284 g,) of Preparation 1 and 2-amino-5-(3-chlorophenyl)-4-hydroxy-1,3-thiazole (0.340 g) in 20 mL DMF is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g). The mixture is stirred at room temperature for 7 days. The solution is then poured into 30 mL ice-water. The resulting solid is collected and dried. The crude product is triturated with hot EtOAc, then with hot i-PrOH to yield 0.182 g of the title product as a yellow solid.
Physical characteristics are as follows:
MP 268-272° C. (dec). 1H NMR (300 MHz, DMSO) δ 13.88, 8.87, 8.72, 8.08, 7.86, 7.73, 7.47, 7.34, 7.22. 7.14. 13C NMR (75 MHz, DMSO) δ 164.6, 160.2, 155.6, 153.8, 144.4. 142.4, 136.7, 135.6,133.9, 132.8, 131.0, 129.3, 124.7, 124.6, 124.3, 123.7, 113.6, 111.8, 97.9. IR (mull) 2047, 1996, 1945, 1703, 1684, 1571, 1536, 1423, 1300, 1261, 1222, 1185, 1113, 1085, 833 cm−1. MS (EI) m/z 397 (M+), 397, 241, 213, 173, 172, 171, 145, 116, 115, 89. HRMS (EI) found 397.0290. Anal. found: C, 56.78; H, 3.08; N, 10.31; Cl, 8.43; S, 7.66.
EXAMPLE 9 5-Bromo-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide (Formula C-3 wherein R1 is —Br, R2 is —H, and X is —Cl) Refer to Chart C
Figure US06310211-20011030-C00042
To a solution of 5-bromo-8-hydroxyquinoline-7-carboxylic acid (0.402 g) of Preparation 2 and 4-chlorobenzylamine (0.219 g) in 20 mL DMF is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g). The mixture is stirred overnight. The solution is then poured into 30 mL ice-water. The resulting solid is collected and dried to yield 0.157 g of the title product as an off-white solid.
Physical characteristics are as follows:
MP 148-151° C.; 1H NMR (300 MHz, DMSO) δ 9.38, 8.97, 8.44, 8.32, 7.80, 7.38, 4.55. 13C NMR (75 MHz, DMSO) δ 167.1, 156.9, 150.3, 140.5, 138.4, 135.6, 132.0, 129.8, 129.6, 129.0, 128.8, 125.5, 114.2, 108.9, 42.6. IR (mull) 3372, 3291, 2427, 1996, 1960, 1926, 1637, 1535, 1492, 1433, 1414, 1337, 931, 798, 681 cm−1. MS (EI) m/z 390 (M+), 392, 252, 251, 250, 225, 223, 142, 140, 125, 115. HRMS (EI) found 389.9777. Anal. found: C, 52.48; H, 3.05; N, 7.27; Br, 19.70; Cl, 9.09.
EXAMPLE 10 N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinecarboxamide (Formula C-3 wherein R1 is —H, R2 is —CH3, and X is —Cl) Refer to Chart C
Figure US06310211-20011030-C00043
To a solution of 8-hydroxy-2-methylquinoline-7-carboxylic acid (0.305 g) of Preparation 5 and 4-chlorobenzylamine (0.219 g) in 20 mL DMF is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g). The mixture is stirred overnight. The solution is then poured into 30 mL ice-water. The resulting solid is collected and dried to yield 0.337 g of the title product as an off-white solid.
Physical characteristics are as follows:
MP 95-98° C.; 1H NMR (300 MHz, DMSO) δ 9.40, 8.21, 7.90, 7.51, 7.39, 7.35, 4.54, 2.67. 13C NMR (75 MHz, DMSO) δ 169.0, 158.1, 157.2, 139.0, 138.6, 136.6, 132.0, 129.7, 129.5, 128.8, 124.8, 124.3, 117.1, 112.6, 21.4, 25.1. IR (mull) 1950, 1905, 1645, 1635, 1607, 1561, 1539, 1507, 1491, 1423, 1410, 1338, 1286, 1245, 846 cm−1. MS (EI) m/z 326 (M+), 326, 187, 186, 160, 159, 131, 130, 125, 103, 77. HRMS (EI) found 326.0829. Anal. found: C, 65.52; H, 4.74; N, 8.57; Cl, 10.79.
EXAMPLE 11 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide (Formula C-3 wherein R1 is —Cl, R2 is —H, and X is —Cl) Refer to Chart C
Figure US06310211-20011030-C00044
To a solution of 5-chloro-8-hydroxyquinoline-7-carboxylic acid (0.335 g) of Preparation 3 and 4-chlorobenzylamine (0.219 g) in 20 mL DMF is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g). The mixture is stirred overnight. The solution is then poured into 30 mL ice-water. The resulting solid is collected and dried to yield 0.167 g of the title product as an off-white solid.
Physical characteristics are as follows:
MP 163-166° C.; 1H NMR (300 MHz, DMSO) δ 9.37, 9.00, 8.50, 8.15, 7.80, 7.38, 4.55. 13C NMR (75 MHz, DMSO) δ 167.2, 156.3, 150.3, 140.3, 138.4, 133.1, 132.0, 129.8, 128.8, 128.4, 125.5, 125.1, 119.1, 113.5, 42.6. IR (mull) 3362, 3292, 2429, 2280, 1962, 1929, 1636, 1619, 1537, 1493, 1433, 1338, 953, 799, 680 cm−1. Ms (EI) m/z 346 (M+), 346, 207, 206, 181, 179, 150, 142, 140, 127, 125. Anal. found: C, 58.59; H, 3.71; N, 8.19; Cl, 19.72.
EXAMPLE 12 8-Hydroxy-N-[(4-nitrophenyl)methyl]-7-quinolinecarboxamide (Formula C-3 wherein R1 is —H, R2 is —H, and X is —NO2) Refer to Chart C
Figure US06310211-20011030-C00045
8-Hydroxyquinoline-7-carboxylic acid (0.51 g) of Preparation 1 is added to 20 mL DMF. 4-Nitrobenzylamine hydrochloride (0.53 g) followed by diisopropylethylamine (0.49 mL) is then added. After 10 minutes, all solids go into solution. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.54 g) and 1-hydroxybenzotriazole monohydrate (0.38 g) are added and the reaction stirred at room temperature overnight. The reaction is poured into 75 mL H2O. The resulting solid is filtered and dried to give the title product (0.53 g).
Physical characteristics are as follows:
MP 210-212° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.45, 8.91, 8.35, 8.20, 7.99, 7.64, 7.61, 7.43, 4.70. 13C NMR (75 MHz, DMSO-d6) δ 168.42, 156.84, 149.50, 147.82, 146.95, 139.50, 136.63, 131.16, 128.75, 125.85, 124.04, 117.49, 113.29, 42.73. IR (mull) 2450, 2292, 1927, 1612, 1602, 1575, 1556, 1518, 1344, 1325, 1296, 1107, 855, 837, 697. MS (electrospray) m/z 322 (M+). Anal. found: C, 62.80; H, 4.29; N, 12.99.
EXAMPLE 13 N(6-Chloro-2-benzothiazolyl)-8-hydroxy-7-quinolinecarboxamide (Formula I-7) Refer to Chart I
Figure US06310211-20011030-C00046
A solution of 8-hydroxyquinoline-7-carboxylic acid (0.30 g) of Preparation 1 in 75 mL xylenes is heated to reflux. PCl3 (0.07 mL) is added dropwise and the mixture stirred for 15 minutes. 2-Amino-6-chlorobenzothiazole (0.31 g) is added in one portion and the reaction refluxed overnight. The reaction is cooled to room temperature and H2O is added to quench excess PCl3. After stirring the solution for 30 minutes, a yellow solid is filtered, dried, and recrystallized from DMSO to give the title product (0.31 g).
Physical characteristics are as follows:
MP>320° C.; 1H NMR (300 MHz, TFA-d) δ 9.29, 9.23, 8.56, 8.35, 8.08, 8.01, 7.96, 7.81. 13C NMR (75 MHz, TFA-d) δ 167.92, 163.82, 154.19, 148.65, 145.25, 135.42, 133.94, 133.52, 131.34, 129.40, 128.01, 127.33, 125.86, 122.74, 120.06, 117.47, 113.33. IR (mull) 2188, 2026, 1954, 1918, 1661, 1657, 1612, 1598, 1546, 1531, 1494, 1441, 1258, 1210, 809. MS (EI) m/z 355 (M+), 357, 355, 186, 184, 173, 172, 117, 116, 89, 63. HRMS (EI) found 355.0179.
EXAMPLE 14 N-[5-(4-Chlorophenyl)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide (Formula I-9) Refer to Chart I
Figure US06310211-20011030-C00047
A suspension of 8-hydroxyquinoline-7-carboxylic acid (0.236 g) of Preparation 1 in 50 mL xylenes is heated to reflux. To this is added dropwise PCd3 (0.069 g). After 15 min, 2-amino-5-(4-chlorophenyl)-thiadiazole (0.264 g) is added. Refluxing is continued overnight. The reaction is then cooled and water is added to destroys excess PCl3. The resulting solid is collected, washed with water and dried. The crude product is recrystallized from DMSO to yield 0.204 g of the title product as a yellow-orange solid.
Physical characteristics are as follows:
1H NMR (300 MHz, TFA) δ 9.54, 9.48, 8.83, 8.59, 8.24, 7.95. 13C NMR (75 MHz, TFA) δ 167.9, 167.3, 159.9, 153.5, 147.9, 144.5, 142.7, 132.8, 130.4, 128.8, 126.6, 125.1, 121.5, 119.3. IR (mull) 2031, 1966, 1924, 1673, 1611, 1572, 1536, 1489, 1211, 1090, 1086, 829, 807, 740, 639 cm−1. MS (EI) m/z 382 (M+), 384, 383, 382, 173, 172, 155, 117, 116, 89, 63. HRMS (EI) found 382.0018.
EXAMPLE 15 5-Chloro-N-(4-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide (Formula G-3 wherein R1 is —Cl) Refer to Chart G
Figure US06310211-20011030-C00048
A suspension of 5-chloro-8-hydroxyquinoline-7-carboxylic acid (0.224 g) of Preparation 3 in 50 mL xylene is heated to reflux. To this is added dropwise PCl3 (0.069 g). After 15 min, 4-chloroaniline (0.128 g) is added. Refluxing is continued overnight. The reaction is then cooled and water is added to destroy excess PCl3. The resulting solid is collected, washed with water and dried. The solid is then partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with water, dried and condensed. The crude product is recrystallized from EtOAc to yield 0.073 g of the title product as an orange solid.
Physical characteristics are as follows:
MP 214-216° C.; 1H NMR (300 MHz, DMSO) δ 10.92, 9.02, 8.59, 8.09, 7.86, 7.75, 7.41. 13C NMR (75 MHz, DMSO-d6) δ 164.6, 154.9, 149.2, 139.6, 137.9, 134.3, 129.2, 128.3, 128.0, 126.9, 125.1, 122.2, 118.0, 116.4. IR (mull) 2055, 1962, 1931, 1658, 1597, 1553, 1532, 1525, 1495, 1482, 1402, 1393, 1293, 807, 640 cm−1. MS (EI) m/z 332 (M+), 333, 332, 208, 207, 206, 152, 150, 129, 115. Anal. found: C, 57.60; H, 3.03; N, 8.35; Cl, 20.96.
PREPARATION 3 5-Chloro-8-hydroxyquinoline-7-carboxylic Acid (Formula A-2 wherein R1 is —Cl and R2 is —H) Refer to Chart A
Figure US06310211-20011030-C00049
5Chloro-8-hydroxyquinoline (5.00 g) and potassium carbonate (11.54 g) are mixed together in a stainless steel bomb and heated to 170° C. under 800 p.s.i. CO2 for 7 days. The reaction is cooled and the resulting solid is dissolved in 800 mL water. The insoluble material is filtered and partitioned between 800 mL water and 400 mL EtOAc in a separatory funnel. The aqueous layer is washed with EtOAc (3×400 mL). The aqueous layer is then acidified to pH 4.5 with conc. HCl. The resulting solid is collected, washed with water and dried. The crude product is triturated with i-PrOH and dried to yield 1.481 g of the title product as a brown solid.
Physical characteristics are as follows:
MP 285-287° C.; 1H NMR (300 MHz, DMSO) δ 8.99, 8.58, 7.89, 7.78. IR (mull) 2471, 2420, 1994, 1964, 1902, 1393, 1296, 1232, 1222, 1115, 1109, 955, 923, 819, 788 cm−1. MS (EI) m/z 222 (M+), 223, 207, 205, 181, 179, 151, 150, 149, 115, 114. Anal. found: C, 53.63; H, 2.90; N, 6.17; Cl, 15.34.
PREPARATION 4 5-Fluoro-8-hydroxyquinoline-7-carboxylic Acid (Formula A-2 wherein R1 is —F and R2 is —H) Refer to Chart A
Figure US06310211-20011030-C00050
5-Fluoro-8-hydroxyquinoline (3.00 g) and potassium carbonate (7.62 g) are mixed together in a stainless steel bomb and heated to 170° C. under 800 p.s.i. CO2 for 7 days. The reaction is cooled and the resulting solid is partitioned between 800 mL water and 400 mL EtOAc in a separatory funnel. The aqueous layer is washed with EtOAc (3×400 mL). The aqueous layer is then acidified to pH 4.5 with conc. HCl and cooled. The resulting solid is collected, washed with water and dried. The crude product is triturated with i-PrOH and dried to yield 1.67 g of the title product as a brown solid.
Physical characteristics are as follows:
MP 277-279° C.; 1H NMR (300 MHz, DMSO) δ 9.01, 8.49, 7.79, 7.57. IR (mull) 2446, 2417, 1995, 1965, 1637, 1445, 1405, 1270, 1257, 1215, 1068, 1032, 819, 785, 742 cm−1. MS (EI) m/z 207 (M+), 207, 189, 163, 161, 135, 134, 133, 132, 107, 81. Anal. found: C, 57.95; H, 2.88; N, 6.66.
EXAMPLE 16 5-Fluoro-N-[[4-chlorophenyl]methyl]-8-hydroxy-7-quinolinecarboxamide (Formula C-3 wherein R1 is —F, R2 is —H, and X is —Cl) Refer to Chart C
Figure US06310211-20011030-C00051
To a solution of 5-fluoro-8-hydroxyquinoline-7-carboxylic acid (0.311 g) of reparation 4 and 4-chlorobenzylamine (0.219 g) in 20 mL DMF is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g). The mixture is stirred overnight. The solution is then poured into 30 mL ice-water. The resulting solid is collected and dried. The crude product is recrystallized from EtOAc/hexanes to yield 0.207 g of the title product as an off-white solid.
Physical characteristics are as follows:
MP 184-185° C.; 1H NMR (300 MHz, DMSO) δ 9.31, 9.00, 8.45, 7.82, 7.75, 7.38, 4.55. 13C NMR (75 MHz, DMSO-d6) δ 167.4, 153.7, 150.7, 149.4, 147.7, 139.7, 138.5, 132.0, 129.8, 129.5, 128.8, 124.5, 121.5, 111.8, 108.6, 42.6. IR (mull) 3303, 2302, 2185, 1971, 1940, 1910, 1648, 1634, 1545, 1531, 1494, 1435, 1402, 1066, 798 cm−1. MS (EI) m/z 330 (M+), 330, 191, 190, 163, 142, 140, 135, 134, 125, 107. Anal. found: C, 61.05; H, 3.74; N, 8.35; Cl, 10.56.
PREPARATION 5 2-Methyl-8-hydroxyquinoline-7-carboxylic Acid (Formula A-2 wherein R1 is —H and R2 is —CH3) Refer to Chart A
Figure US06310211-20011030-C00052
8-Hydroxyquinaldine (5.0 g) and potassium carbonate (13.02 g) are mixed together in a stainless steel bomb and heated to 170° C. under 800 p.s.i. CO2 for 6 days. The reaction is then cooled and the resulting solid is partitioned between EtOAc and water. The organic layer is extracted with water (3×). The combined aqueous layers are washed with EtOAc (3×). The aqueous layer is then acidified to pH 4.5 with conc. HCl. The resulting solid is collected, dried and recrystallized from i-PrOH to yield 1.86 g of the title compound as a gold solid.
Physical characteristics are as follows:
MP 217-219° C.; 1H NMR (300 MHz, DMSO) δ 8.54, 7.85, 7.71, 7.19, 2.79. IR (mull) 3414, 2181, 2044, 1995, 1959, 1921, 1668, 1639, 1611, 1589, 1486, 1432, 1324, 858, 757 cm−1. MS (EI) m/z 203 (M+), 203, 185, 159, 131, 130, 129, 103, 102, 77, 51. HRMS 203.0600. Anal. found: C, 59.53; H, 4.98; N, 6.37.
PREPARATION 6 5-Bromo-8-methoxy-2-methyl-7-quinolinesulfinic Acid, Lithium Salt (Formula J-2 wherein R1=Me and X1=Br) Refer to Chart J
Figure US06310211-20011030-C00053
Under N2, a flame dried, 250-mL, three-necked flask with attached addition funnel and bubbler is charged with 5,7-dibromo-8-methoxy-2-methyl-quinoline (3 g), ether (18 mL) and toluene (18 mL). The flask is cooled in a dry ice/acetone bath, degassed and flushed with N2. To facilitate stirring, additional ether (5 mL) and toluene (5 mL) are added. The addition funnel is charged with 1.6 M nBuLi (5.6 mL) which is then added dropwise over 7 min to the thick slurry. The reaction mixture is stirred at −78° C. for 3 hrs. Sulfur dioxide is then introduced via a needle positioned directly above the reaction surface. Within 5 min, the reaction mixture becomes a pale yellow opaque solution, and SO2 introduction is terminated. The reaction mixture is flushed with N2, the cooling bath is removed, and the reaction mixture is allowed to warm to room temperature over 1 hr. 100 mL hexane is added to aid precipitation of the solid, which is then collected by filtration. Drying under vacuum yields 2.844 g of the title compound as a yellow solid.
PREPARATION 7 5-Bromo-8-methoxy-2-methyl-7-quinolinesulfonyl Chloride (Formula J-3 wherein R1=Me and X1=Br) Refer to Chart J
Figure US06310211-20011030-C00054
Under N2, a flame-dried, 250-mL, three-necked flask is charged with the title compound of Preparation 6 (2.844 g) and CH2Cl2 (45 mL). The flask is cooled in an ice bath and N-chlorosuccinimide (1.178 g) is added in one portion. After 5 min, the cooling bath is removed and the reaction mixture is stirred for 3 hrs. The reaction mixture is then poured into H2O, a small amount of brine is added, and the layers are separated. The aqueous layer is extracted with two portions CH2Cl2. The combined organic layers are washed with brine, dried over MgSO4, filtered and concentrated to give the title compound as a pale orange solid, which is immediately used in the preparation of compounds of the formula J-4.
PREPARATION 8 5-Bromo-N-[(4-chlorophenyl)methyl]-8-methoxy-2-methyl-7-quinolinesulfonamide (Formula J-4 wherein R1=Me, X1 =Br, and R2=CH2-4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00055
Under N2, a flame-dried, 250-mL, three-necked flask is charged with 4-chlorobenzylamine (980 μL), pyridine (1.3 mL), and CH2Cl2 (10 mL). The title compound of Preparation 7 in 55 mL CH2Cl2 is transfered via cannula to the reaction flask and then is allowed to stir overnight at room temperature. The reaction mixture is concentrated and the residue is taken up in toluene and concentrated twice. Purification by column chromatography (elution with 0.5% MeOH/CH2Cl2) affords 1.47 g of the title compound as a yellow foam.
Physical characteristics are as follows:
MP 108-110° C.; 1H NMR (300 MHz, CDCl3) δ 8.43, 8.09, 7.51, 7.14-7.07, 5.50, 4.35, 4.08, 2.84 ppm. MS (ES−) m/z 453 (M−H).
EXAMPLE 17 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2-4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00056
A flame-dried, 100-mL, one-necked flask with attached oven-dried condensor is charged with the title compound of Preparation 8 (0.640 g) and pyridine hydrochloride (8.8 g). The reaction mixture is heated to 215-220° C. for 10 min., and then is poured onto ice. It is neutralized with saturated aqueous NaHCO3 and extracted with CH2Cl2 three times. The combined organic layers are washed with brine, dried over MgSO4, filtered and concentrated. The residue is taken up in toluene and concentrated four times. Crystallization from CH2Cl2/Et2O provides 0.247 g of the title compound as an off-white solid.
Physical characteristics are as follows:
MP 158-161° C. (decompose). 1H NMR (300 MHz, CDCl3) δ 8.44, 7.88, 7.56, 7.13-7.05, 5.42, 4.14, 2.80 ppm. MS (ES−) m/z 394.9 (M−H). Anal. found: C, 51.40; H, 3.73; N, 7.09.
PREPARATION 9 5-Chloro-N-[(4-chlorophenyl)methyl]-8-methoxy-7-quinolinesulfonamide (Formula J-4 wherein R1=H, X1=Cl, and R2=CH2-4-ClC6H4) and 5-Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-methoxy-7-quinolinesulfonamide (Formula J-4 wherein R1=t-Bu, X1=Cl, and R2=CH2-4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00057
A mixture of the title compounds is prepared according to the procedures described in Preparations 6-8 substituting 5-chloro-7-iodo-8-methoxy-quinoline for 5,7-dibromo-8-methoxy-2-methyl-quinoline and two equivalents of tBuLi for one equivalent of nBuLi in Preparation 6. The title compounds are separated by column chromatography (elution with 5-10% EtOAc/hexanes and 10% MeOH/CH2C2) to give 0.407 g of -Chloro-N-[(4-chlorophenyl)methyl]-8-methoxy-7-quinolinesulfonamide and 0.040 g of -Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-methoxy-7-quinolinesulfonamide.
Physical characteristics for -Chloro-N-[(4-chlorophenyl)methyl]-8-methoxy-7-quinolinesulfonamide are as follows:
1H NMR (300 MHz, CDCl3) δ 9.11, 8.68, 7.70-7.66, 7.14-7.09, 5.50, 4.16-4.11 ppm. MS (ES−) m/z 394.9 (M−H). MS (ES+) m/z 396.9 (M+H).
Physical characteristics for -Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-methoxy-7-quinolinesulfonamide are as follows:
1H NMR (300 MHz, CDCl3) δ 8.50, 7.93, 7.75, 7.16-7.09, 5.49, 4.42, 4.09, 1.50 ppm. MS (ES−) m/z 450.9 (M−H). MS (ES+) m/z 452.9 (M+H).
EXAMPLE 18 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinesulfonamide (Formula J-5 wherein R1=H, X1=Cl, and R2=CH2-4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00058
Under N2, a flame-dried, 50-mL, two-necked flask is charged with 5-chloro-N-[(4-chlorophenyl)methyl]-methoxy-7-quinolinesulfonamide (0.322 g), which is the first title compound of Preparation 9, and CH2C1 2 (20 mL) and is cooled in a dry ice/acetone bath. 1.0 M BBr3 (1.05 mL) is added dropwise. The cooling bath is removed and the reaction mixture is allowed to stir for 1.5 hrs. It is then poured into 75 mL 5% NaHCO3 aqueous solution, and the layers are separated. The aqueous layer is extracted twice with CH2Cl2. The combined organic layers are washed with H2O and then brine, dried over MGSO4, filtered and concentrated to a brown residue. Purification by column chromatography (elution with 2-5% MeOH/CH2Cl2 with <1% AcOH) yields 0.037 g of the title compound as a pale yellow solid.
Physical characteristics are as follows:
MP 189-190° C. (decompose). 1H NMR (300 MHz, CDCl3) δ 8.96, 8.67, 8.35, 7.81, 7.68, 7.09, 5.44, 4.15 ppm. IR (mull) 3302, 3088, 1586, 1506, 1492, 1326, 1151, 821, 779 cm−1. MS (EI) m/z 382 (M+) 382, 243, 179, 150, 140, 125, 115. HRMS (EI) found 381.9917.
EXAMPLE 19 5-Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-hydroxy-7-quinolinesulfonamide (Formula J-5 wherein R1=t-Bu, X1=Cl, and R2=CH2-4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00059
The title compound is prepared from 5-Chloro-N-[(4-chlorophenyl)methyl]-2-(1,1-dimethylethyl)-8-methoxy-7-quinolinesulfonamide, which is the second title compound of Preparation 9, and 6 equivalents of BBr3 according to the procedure described in Example 18. Crystallization from Et2O/hexane affords 0.035 g of tie title compound as a dark tan solid.
Physical characteristics are as follows:
MP 162-163° C. (decompose). 1H NMR (300 MHz, CDCl3) δ 8.50, 7.91, 7.82, 7.14-7.06, 5.45, 4.16, 1.51 ppm. IR (mull) 3334, 3302, 2725, 1597, 1562, 1491, 1333, 1320, 1308, 1161, 11.53, 1139, 1129 cmn−1. MS (EI) m/z 438 (M+) 235, 220, 218, 193, 179, 150, 140. Anal. found: C, 54.30; H, 4.52; N, 6.23.
PREPARATION 10 5-Chloro-N-(4-chlorophenyl)-8-methoxy-7-quinolinesulfonamide (Formula J-4 wherein R1=H, X1=Cl, and R2=p-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00060
The title compound is prepared according to the procedures described in Preparations 6-8, substituting 5-chloro-7-iodo-8-methoxy-quinoline for 5,7-dibromo-8-methoxy-2-methyl-quinoline and two equivalents of tBuLi for one equivalent of nBuLi in Preparation 6 and 4-chloroaniline for 4-chlorobenzylamine in Preparation 8. Column chromatography (elution with 5-15% EtOAc/hexanes and 2% MeOH/CH2Cl2) affords 0.373 g of the title compound as a solid.
Physical characteristics are as follows:
1H NMR (300 MHz, CDCl3) δ 9.08, 8.73, 7.66, 7.57, 7.18-7.07, 4.08 ppm. MS (ES−) m/z 380.9 (M−H).
EXAMPLE 20 5-Chloro-N-(4-chlorophenyl)-8-hydroxy-7-quinolinesulfonamide (Formula J-5 wherein R1=H, X1=Cl, and R2=4-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00061
The title compound is prepared from 5-chloro-N-(4-chlorophenyl)-8-methoxy-7-quinolinesulfonamide, which is the fist title compound of Preparation 9, and 6 equivalents of BBr3 according to the procedure described in Example 18. Crystallization from Et2O/hexane/CH2Cl2 affords 0.015 g of the title compound as a red-brown solid.
Physical characteristics are as follows:
MP 97° C. (decompose). 1H NMR (300 MHz, CDCl3) δ 8.94, 8.71, 8.30, 7.76, 7.70, 7.17-7.07 ppm. MS (EI) m/z 368 (M+) 370, 368, 178, 150, 128, 127, 126, 115, 99, 63.
PREPARATION 11 5-Chloro-8-methoxy-N-(3-phenylpropyl)-7-quinolinesulfonamide (Formula J-4 wherein R1=H, X1=Cl, and R2=(CH2)3C6H5) Refer to Chart J
Figure US06310211-20011030-C00062
The title compound is prepared according to the procedures described in Preparations 6-8, substituting 5-chloro-7-iodo-8-methoxy-quinoline for 5,7-dibromo-8-methoxy-2-methyl-quinoline and two equivalents of tBuLi for one equivalent of nBuLi in Preparation 6 and 3-phenyl-1-propylamine for 4-chlorobenzylamine in Preparation 8. Column chromatography (elution with 0.5% MeOH/CH2Cl2) affords 0.143 g of the title compound as a solid.
Physical characteristics are as follows:
1H NMR (CDCl3) δ 9.10, 8.74, 7.70, 7.67, 7.23-7.14, 7.05-7.02, 5.16, 4.15, 3.03-2.97, 2.64-2.59, 1.86-1.77 ppm. MS (ES−) m/z 389.0 (M−H).
EXAMPLE 21 5-Chloro-8-hydroxy-N-(3-phenylpropyl)-7-quinolinesulfonamide monohydrobromide (Formula J-5 wherein R1=H, X1=Cl, and R2=(CH2)3C6H5) Refer to Chart J
Figure US06310211-20011030-C00063
The title compound is prepared from 5-chloro-8-methoxy-N-(3-phenylpropyl)-7-quinolinesulfonamide, which is the title compound of Preparation 11, and 6 equivalents of BBr3 according to the procedure described in Example 18. Crystallization from CHCl3/acetone/EtOH affords 0.063 g of the title compound as a red-brown solid.
Physical characteristics are as follows:
MP 210-212° C. (decompose). 1H NMR (300 MHz, CDCl3) δ 9.35, 9.18, 8.06, 7.95, 7.27-7.12, 7.11-7.05, 3.16-3.02, 2.63, 1.83 ppm. IR (mull) 3273, 2757, 1626, 1550, 1444, 1353, 1326, 1297, 1281, 1152 cm−1. MS (EI) m/z 376 (M+) 376, 258, 181, 180, 179, 178, 150, 118, 115, 91. HRMS (EI) found 376.0631. Anal found: C, 46.96; H, 4.09; N, 6.08.
EXAMPLE 22 5-Chloro-8-hydroxy-N-(phenylmethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2Ph) Refer to Chart J
Figure US06310211-20011030-C00064
The title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 17, substituting benzylamine for 4-chlorobenzylamine. Crystallization from CH2Cl2/Et2O gives 0.104 g of the title compound as a pale orange solid.
Physical characteristics are as follows:
MP 114-117° C.; 1H NMR (300 MHz, DMSO) δ 9.06, 8.54, 8.12, 7.87, 7.77, 7.22, 7.11, 7.03, 4.13 ppm. IR (mull) 3326, 1501, 1415, 1403, 1341, 1152, 1141, 1061, 952, 811, 741, 724, 675, 637, 604 cm−1. MS (EI) m/z 348 (M+). Anal found: C, 54.88; H, 3.79; N, 7.90.
EXAMPLE 23 5-Chloro-N-[2-(4-chlorophenyl)ethyl]-8-hydroxy-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2-p-ClC6H4) Refer to Chart J
Figure US06310211-20011030-C00065
The title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 17, substituting 2-(4-chlorophenyl)ethylamine for 4-chlorobenzylamine. Crystallization from CH2Cl2 gives 0.100 g of the title compound as a pale yellow solid.
Physical characteristics are as follows:
MP 192-194° C.; 1H NMR (300 MHz, CDCl3) δ 8.94, 8.59, 7.98, 7.72, 7.12, 7.00, 5.07, 3.26, 2.79 ppm. IR (mull) 3332, 1499, 1401, 1329, 1272, 1188, 1155, 1088, 1081, 952, 824, 819, 724, 677, 633 cm−1. MS (EI) m/z 396 (M+). Anal found: C, 51.27; H, 3.61; N, 6.98.
EXAMPLE 24 5-Bromo-8-hydroxy-N-(phenylmethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2Ph) Refer to Chart J
Figure US06310211-20011030-C00066
The title compound is prepared from 5,7-dibromo-8-methoxy-quinoline, which is commercially available, according to the procedures described in Preparations 6-8 and Example 18, substituting benzylamine for 4-chlorobenzylamine. Crystallization from CH2Cl2 gives 0.150 g of the title compound as a light peach solid.
Physical characteristics are as follows:
MP 191-192° C. 1H NMR (300 MHz, DMSO) δ 9.04, 8.47, 8.12, 7.94, 7.87, 7.22, 7.11, 7.03, 4.14 ppm. 13C NMR (75 MHz, DMSO) δ 152.3, 149.8, 139.2, 137.5, 135.2, 128.9, 128.4, 127.7, 127.4, 126.6, 125.2, 123.4, 107.5, 46.1 ppm. IR (mull) 3325, 1498, 1414, 1401, 1340, 1153, 1139, 1060, 932, 810, 791, 725, 695, 674, 630 cm−1. MS (EI) m/z 392 (M+). HRMS (EI) found 391.9813. Anal found: C, 49.17; H, 3.59; N, 6.88.
EXAMPLE 25 5-Chloro-N-[2-(2,4-dichlorophenyl)ethyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2-2,3-Cl2C6H3) Refer to Chart J
Figure US06310211-20011030-C00067
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 2,4-dichlorophenethylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 1-2% MeOH/CHCl3) followed by crystallization from CH2Cl2/hexane gives 0.35 g of the title compound as a yellow solid.
Physical characteristics are as follows:
MP 132-135° C.; 1H NMR (300 MHz, CDCl3) δ 8.53, 7.94, 7.59, 7.19-7.04, 5.30, 3.28, 2.92, 2.88 ppm. IR (mull) 3343, 3321, 3299, 1504, 1419, 1349, 1339, 1330, 1152, 1144, 955, 824, 727, 634, 612 cm−1. MS (EI) m/z 444 (M+). HRMS (EI) found 443.9845.
EXAMPLE 26 5-Chloro-8-hydroxy-2-methyl-N-[2-(phenylthio)ethyl]-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2SPh) Refer to Chart J
Figure US06310211-20011030-C00068
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 2-aminoethyl phenyl sulfide for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 1-2% MeOH/CHCl3) followed by crystallization from CH2Cl2/hexane gives 0.40 g of the title compound as a yellow solid.
Physical characteristics are as follows:
MP 136-139° C.; 1H NMR (300 MHz, CDCl3) δ 8.43, 7.89, 7.56, 7.24-7.07, 5.60, 3.14, 3.02, 2.81 ppm. IR (mull) 3355, 3271, 1438, 1419, 1342, 1329, 1308, 1153, 1141, 1078, 711, 702, 692, 632, 610 cm−1. MS (EI) m/z 408 (M+). Anal found: C, 52.50; H, 4.14; N, 6.73; Cl, 8.77; S, 15.31.
EXAMPLE 27 5-Chloro-8-hydroxy-2-methyl-N-(phenylmethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2Ph) Refer to Chart J
Figure US06310211-20011030-C00069
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting benzylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) followed by crystallization from EtOAc/hexanes gives 0.197 g of the title compound as orange crystals.
Physical characteristics are as follows:
MP 113-114° C.; 1H NMR (300 MHz, CDCl3) δ 8.46, 7.94, 7.57, 7.22-7.08, 5.40, 4.15, 2.82 ppm. IR (mull) 3035, 3010, 1548, 1504, 1445, 1440, 1425, 1313, 1148, 1041, 803, 734, 698, 681, 611 cm−1. MS (EI) m/z 362 (M+). Anal found: C, 56.49; H, 4.25; N, 7.64.
EXAMPLE 28 5-Chloro-N-(4-chlorophenyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=4-Cl-C6H4) Refer to Chart J
Figure US06310211-20011030-C00070
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 4-chloroanline for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 1% MeOH/CHCl3) followed by crystallization from EtOAc/hexane and rinsing with additional EtOAc gives 0.056 g of the title compound as a beige solid.
Physical characteristics are as follows:
MP 284-287° C. (decomposition). 1H NMR (300 MHz, CDCl3) δ 8.20, 7.56, 7.41, 6.94-6.90, 2.56 ppm. IR (mull) 1530, 1492, 1335, 1313, 1288, 1276, 1152, 1125, 1109, 1095, 827, 742, 647, 635, 610 cm−1. MS (EI) m/z 382 (M+). HRMS (EI) found 381.9940.
EXAMPLE 29 5-Chloro-8-hydroxy-2-methyl-N-octyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=(CH2)7CH3) Refer to Chart J
Figure US06310211-20011030-C00071
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting n-octylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 1-2% MeOH/CHCl3) followed by crystallization from EtOAc/hexane gives 0.045 g of the title compound as an orange solid.
Physical characteristics are as follows:
MP 85-100° C.; 1H NMR (300 MHz, CDCl3) δ 8.47, 7.93, 7.56, 5.22, 3.31, 2.82, 1.49-1.44, 1.32-1.09, 0.84 ppm. IR (mull) 3301, 1504, 1415, 1328, 1250, 1158, 1142, 1082, 948, 826, 725, 688, 653, 634, 614 cm−1. MS (EI) m/z 384 (M+). HRMS (EI) found 384.1270.
EXAMPLE 30 5-Chloro-N-[4-fluorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2-4-F-C6H4) Refer to Chart J
Figure US06310211-20011030-C00072
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 4-fluorobenzylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) gives 0.135 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 143-146° C.; 1H NMR (300 MHz, CDCl3) δ 8.46, 7.92, 7.57, 7.18-7.15, 6.83, 5.40, 4.12, 2.82 ppm. IR (mull) 3318, 3270, 1510, 1425, 1352, 1330, 1319, 1250, 1221, 1152, 1143, 835, 829, 634, 613 cm−1. MS (EI) m/z 380 (M+). Anal found: C, 53.96; H, 4.03; N, 7.15.
EXAMPLE 31 5-Chloro-8-hydroxy-2-methyl-N-(1-naphthalenylmethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2-1-naphthyl) Refer to Chart J
Figure US06310211-20011030-C00073
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 1-naphthalenemethylamine for 4-chlorobenzylamine in the former procedure. Crystallization from CH2Cl2/hexanes gives 0.127 g of the title compound as light brown crystals.
Physical characteristics are as follows:
MP 203-204° C.; 1H NMR (300 MHz, CDCl3) δ 8.39, 7.97, 7.80, 7.60, 7.53, 7.46, 7.36, 7.29-7.17, 5.58, 4.63, 2.77 ppm. IR (mull) 3265, 1440, 1350, 1329, 1155, 1146, 851, 836, 800, 783, 776, 690, 640, 631, 608 cm−1. MS (EI) m/z 412 (M+). HRMS (EI) found 412.0643.
EXAMPLE 32 5-Chloro-N-(cyclohexylmethyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2-cyclohexyl) Refer to Chart J
Figure US06310211-20011030-C00074
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting cyclohexanemethylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with MeOH/CH2Cl2) gives 0.257 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 113-115° C.; 1H NMR (300 MHz, CDCl3) δ 8.46, 7.95, 7.57, 5.12, 2.82, 2.74, 1.75-1.62, 1.53-1.42, 1.29-1.08, 0.95-0.82 ppm. IR (mull) 3284, 1503, 1413, 1344, 1338, 1329, 1249, 1159, 1143, 1061, 9413, 825, 725, 688, 610 cm−1. MS (EI) m/z 368 (M+). Anal found: C, 55.62; H, 5.89; N, 7.46.
EXAMPLE 33 5-Chloro-N-[(3-chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2-3-Cl-C6H4) Refer to Chart J
Figure US06310211-20011030-C00075
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 3-chlorobenzylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-2% MeOH/CH2Cl2) gives 0.154 g of the title compound as a solid.
Physical characteristics are as follows:
MP 52-54° C.; 1H NMR (300 MHz, CDCl3) δ 8.43, 7.88, 7.56, 7.18-7.00, 5.48, 4.16, 2.80 ppm. IR (mull) 3311, 1600, 1503, 1433, 1329, 1251, 1158, 1143, 952, 829, 727, 704, 687, 634, 617 cm−1. MS (EI) m/z 396 (M+). Anal found: C, 51.27; H, 3.64; N, 7.00.
EXAMPLE 34 5-Chlorohydroxy-2-methyl-N-(3-phenylpropyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2CH2Ph) Refer to Chart J
Figure US06310211-20011030-C00076
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 3-phenylpropylamine for 4-chorobenzylamine in the former procedure. Column chromatography (elution with 0.5% MeOH/0.005% NH4OH/CH2Cl2 to 1% MeOH/0.01% NH4OH/CH2C2) gives 0.343 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 131-134° C.; 1H NMR (300 MHz, CDCl3) δ 8.45, 7.93, 7.56, 7.24-7.10, 7.08, 5.11, 2.97, 2.80, 2.63, 1.83 ppm. IR (mull) 3231, 1416, 1350, 1329, 1253, 1154, 1151, 949, 827, 755, 727, 701, 687, 634, 612 cm−1. MS (EI) m/z 390 (M+). HRMS (EI) found 390.0798. Anal found: C, 58.40; H, 5.00; N, 7.04.
EXAMPLE 35 5-Chloro-8-hydroxy-2-methyl-N-(2-phenoxyethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2OPh) Refer to Chart J
Figure US06310211-20011030-C00077
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 2-phenoxyethylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) followed by crystallization from CH2Cl2/hexanes gives 0.310 g of the title compound as orange crystals.
Physical characteristics are as follows:
MP 106-107° C.; 1H NMR (300 MHz, CDCl3) δ 8.38, 7.95, 7.51, 7.12, 6.82, 6.65, 5.72, 3.92, 3.43, 2.77 ppm. IR (mull) 2801, 1550, 1499, 1430, 1421, 1408, 1319, 1246, 1233, 1162, 1150, 782, 758, 699, 689 cm−1. MS (EI) m/z 392 (M+). HRMS (EI) found 392.0586.
EXAMPLE 36 5-Chloro-8-hydroxy-2-methyl-N-[3-(4-morpholinyl)propyl]-7-quinoline-sulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2CH2-morpholine) Refer to Chart J
Figure US06310211-20011030-C00078
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting N-(3-aminopropyl)morpholine for 4-chlorobenzylamine in the former procedure. Washing with CH2Cl2 gives 0.029 g of the title compound as a beige solid.
Physical characteristics are as follows:
MP 245-257° C.; 1H NMR (300 MHz, CDCl3) δ 8.50, 7,93, 7.58, 6.34, 4.30, 4.00, 3.57, 3.23, 2.98-2.86, 2.85, 2.21 ppm. Ms (EI) m/z 399 (M+). HRMS (EI) found 399.1021.
EXAMPLE 37 5-Chloro-8-hydroxy-N-[3-(1H-imidazol-1-yl)propyl]-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH2CH2CH2-1-imidazole) Refer to Chart J
Figure US06310211-20011030-C00079
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 1-(3-aminopropylimidazole for 4-chlorobenzylamine in the former procedure. Washing with CH2Cl2 gives 0.042 g of the title compound as a light brown solid.
Physical characteristics are as follows:
MP 194-196° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.46, 7.81, 7.67, 7.09, 6.94, 4.11, 2.91, 2.79, 1.95 ppm. MS (EI) m/z 380 (M+). HRMS (EI) found 380.0703.
EXAMPLE 38 5-Chloro-N-(diphenylmethyl)-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH(Ph)2) Refer to Chart J
Figure US06310211-20011030-C00080
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting 1,1-diphenylmethylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) gives 0.156 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 115-119° C.; 1H NMR (300 MHz, CDCl3) δ 8.35, 7.73, 7.51, 7.11-6.98, 5.76, 5.58, 2.76 ppm. IR (mull) 3298, 1495, 1422, 1329, 1251, 1161, 1144, 952, 743, 727, 699, 689, 652, 634, 614 cm−1. MS (EI) m/z 438 (M+). HRMS (EI) found 438.0971.
EXAMPLE 39 (R)-5-Chloro-8-hydroxy-2-methyl-N-(1-phenylethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH(Me)Ph) Refer to Chart J
Figure US06310211-20011030-C00081
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quiolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting (R)-(+)-α-methylbenzylnine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) followed by precipitation of contaminant from CH2Cl2/hexanes gives 0.178 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 84-88° C.; [α]D (CHCl3)=49°. 1H NMR (300 MHz, CDCl3) δ 8.35, 7.72, 7.51, 7.05, 6.93, 6.84, 5.41, 4.48, 2.77, 1.47 ppm. IR (mull) 3290, 1503, 1496, 1427, 1329, 1251, 1160, 1145, 1120, 952, 727, 701, 689, 635, 623 cm−1. MS (EI) m/z 376 (M+).
EXAMPLE 40 (S)-5-Chloro-8-hydroxy-2-methyl-N-(1-phenylethyl)-7-quinolinesulfonamide (Formula J-5 wherein R1=Me, X1=Cl, and R2=CH(Me)Ph) Refer to Chart J
Figure US06310211-20011030-C00082
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinolinesulfonyl chloride, which is the title compound of Preparation 7, according to the procedures described in Preparation 8 and Example 17, substituting (S)-(−)-α-methylbenylamine for 4-chlorobenzylamine in the former procedure. Column chromatography (elution with 0.5-1% MeOH/CH2Cl2) gives 0.196 g of the title compound as an orange foam.
Physical characteristics are as follows:
MP 83-87° C.; [α]D (CHCl3)=+57°. 1H NMR (300 MHz, CDCl3) δ 8.36, 7.73, 7.52, 7.05, 6.93, 6.85, 5.40, 4.49, 2.78, 1.48 ppm. IR (mull) 3299, 1503, 1496, 1423, 1329, 1251, 1160, 1146, 1085, 952, 727, 701, 689, 635, 624 cm−1. MS (EI) m/z 376 (M+). Anal found: C, 57.73; H, 4.63; N, 7.32.
PREPARATION 11 5-Chloro-8-[(1,1-dimethylethyl)dimethylsilyloxy]-7-iodoquinoline (Formula K-2 wherein X1=Cl, X2=I, (R)3=(Me2)t-Bu) Refer to Chart K
Figure US06310211-20011030-C00083
A flame-dried, 50-mL, three-necked flask is charged with 5-chloro-8-hydroxy-7-iodoquinoline (2.814 g), which is commercially available, t-butyldimethylchlorosilane (1.76 g), and 10 mL of DMF. Imidazole (1.66 g) is added, and the resulting mixture is stirred at room temperature for 18 h. The reaction mixture is then quenched with 10 mL of saturated aqueous NaHCO3 and extracted with hexane three times. The combined organic layers are dried over MgSO4, filtered and concentrated to give 3.898 g of the title compound as a pale green solid.
Physical characteristics are as follows:
MP 65-67° C.; 1H NMR (300 MHz, DMSO) δ 8.94, 8.48, 8.07, 7.73, 1.08, 0.32 ppm IR (mull) 1570, 1485, 1408, 1356, 1255, 1250, 1244, 1097, 868, 838, 806, 782, 678, 654, 640 cm−1. MS (FAB) m/z 420 (MH+). Anal found: C, 43.05; H, 4.63; N, 3.31; Cl, 8.38.
EXAMPLE 41 5-Chloro-7-[(1,1-dimethylethyl)dimethylsilyl]-8-quinolinol (Formula K-3 wherein X1=Cl, and (R)3=(Me2)t-Bu) Refer to Chart K
Figure US06310211-20011030-C00084
A flame-dried, 25-mL, two-necked flask is charged with the title compound of Preparation 11 (0.431 g) and 7 mL of THF. The resulting solution is cooled to −78° C., and t-butyllithium (1.2 mL of 1.7 M solution in pentane) is added dropwise over 2 min. The reaction mixture is stirred for an additional 15 min at −78° C., the quenched by pouring into 5 mL of half-saturated NH4Cl (aq). The mixture is extracted with 50 mL of EtOAc. The organic layer is separated, washed with 15 mL of saturated NaHCO3 (aq), dried over MgSO4, filtered and concentrated to give 0.289 g of an off-white solid. Column chromatography (elution with 2% EtOAc/hexane) yields 0.101 g of the title compound as a white solid.
Physical characteristics are as follows:
MP 107-108° C.; 1H NMR (300 MHz, DMSO) δ 10.08, 8.94, 8.47, 7.74, 7.49, 0.88, 0.36 ppm. 13C NMR (75 MHz, DMSO) δ 158.0, 149.0, 138.2, 132.6, 132.2, 126.4, 123.7, 118.4, 118.3, 26.9, 17.6, 4.8 ppm. IR (mull) 3446, 1408, 1398, 1322, 1255, 1194, 949, 875, 836, 823, 810, 786, 775, 718, 675 cm−1. MS (FAB) m/z 294 (MH+). HRMS (FAB) found 294.1075.
EXAMPLE 42 5-Chloro-7-[(tris(1-methylethyl)silyl]-8-quinolinol (Formula K-3 wherein X1=Cl, and R=i-Pr) Refer to Chart K
Figure US06310211-20011030-C00085
The title compound is prepared in two steps from 5-chloro-8-hydroxy-7-iodoquinoline, which is commercially available, according to the procedures described in Preparation 11 and Example 41, substituting triisopropylchlorosilane for t-butyldimethylchlorosilane in the former procedure. Column chromatography (elution with hexane) gives 0.202 g of the title compound as a white solid.
Physical characteristics are as follows:
MP 107-108° C.; 1H NMR (300 MHz, CDCl3) δ 8.80, 8.76, 8.52, 7.57, 7.56, 1.58, 1.13 ppm. IR (mull) 3430, 1485, 1399, 1321, 1256, 1196, 1181, 949, 882, 789, 719, 681, 670, 644, 610 cm−1. MS (FAB) m/z 336 (MH+). HRMS (FAB) found 392.2167. Anal found: C, 64.68; H, 7.87; N, 4.04.
EXAMPLE 43 5-Chloro-7-[(1,1-dimethylethyl)diphenylsilyl]-8-quinolinol (Formula K-3 wherein X1=Cl, and (R)3=Ph2t-Bu) Refer to Chart K
Figure US06310211-20011030-C00086
The title compound is prepared in two steps from 5-chloro-8-hydroxy-7-iodoquinoline, which is commercially available, according to the procedures described in Preparation 11 and Example 41, substituting t-butyldiphenylchlorosilane for t-butyldimethylchlorosilane in the former procedure. Column chromatography (elution with 1% EtOAc/hexane) gives 0.078 g of the title compound as a white foam.
Physical characteristics are as follows:
Mp 133-139° C.; 1H NMR (300 MHz, CDCl3) δ 8.95, 8.83, 8.54, 7.62-7.56, 7.42-7.31, 1.26 ppm. IR (mull) 3317, 1485, 1428, 1398, 1339, 1198, 1110, 1103, 950, 786, 741, 719, 699, 666, 605 cm−1. MS (FAB) m/z 418. HRMS (FAB) found 418.1393. Anal found: C, 71.73; H, 5.72; N, 3.29.
EXAMPLE 44 5-Chloro-7-(trimethylsilyl)-8-quinolinol (Formula K-3 wherein X1=Cl, and R=Me) Refer to Chart K
Figure US06310211-20011030-C00087
The title compound is prepared in two steps from 5-chloro-8-hydroxy-7-iodoquinoline, which is commercially available, according to the procedures described in Preparation 11 and Example 41, substituting trimethylchlorosilane for t-butyldimethylchlorosilane in the former procedure. Column chromatography (elution with 0-1% EtOAc/hexane) gives 0.147 g of the title compound as a white solid.
Physical characteristics are as follows:
MP 109-111° C.; 1H NMR (300 MHz, CDCl3) δ 8.80, 8.55, 8.50, 7.55, 0.41 ppm. IR (mull) 3414, 3377, 1398, 1334, 1243, 1202, 950, 883, 839, 788, 757, 717, 628, 613, 605 cm−1. MS (FAB) m/z 252 (MH+). HRMS (FAB) found 252.0597. Anal found: C, 57.50; H, 5.54; N, 5.48.
EXAMPLE 45 5-Chloro-7-dimethylphenylsilyl)-8-quinolinol (Formula K-3 wherein X1=Cl, and (R)3=Me2Ph) Refer to Chart K
Figure US06310211-20011030-C00088
The title compound is prepared in two steps from 5-chloro-8-hydroxy-7-iodoquinoline, which is commercially available, according to the procedures described in Preparation 11 and Example 41, substituting triisopropylchlorosilane for t-butyldimethylchlorosilane in the former procedure. Column chromatography (elution with 1% EtOAc/hexane) gives 0.065 g of the title compound as a white solid.
Physical characteristics are as follows:
MP 101-103° C.; 1H NMR (300 MHz, CDCl3) δ 8.80, 8.61, 8.49, 7.65-7.62, 7.55, 7.45, 7.39-7.37. 0.70 ppm. IR (mull) 3323, 1427, 1396, 1324, 1249, 1188, 949, 879, 837, 819, 783, 719, 700, 696, 665 cm−1. MS (FAB) m/z 314 (MH+). HRMS (FAB) found 314.0763. Anal found: C, 64.85; H, 5.24; N, 4.46.
EXAMPLE 46 N-[(4-Chlorophenyl)methyl]-4,8-dihydroxy-2-trifluoromethyl-7-quinolinecarboxamide
Figure US06310211-20011030-C00089
To a solution of the title compound of Preparation 20 (0.273 g) in 10 mL DMF is added 4-chlorobenzylamine (0.134 mL), EDC-HCl (0.210 g) and HOBt-H2O (0.149 g). The mixture is allowed to stir for 3 days, then poured into 50 mL of ice-water. The resulting precipitate is collected and dried. The crude product is recrystallized from EtOAc/hexanes to yield 0.245 g of the title compound as a tan solid.
Physical characteristics are as follows:
MP 135-140° C. (dec). 1H NMR (DMSO) δ 13.83, 12.46, 9.60, 8.02, 7.61, 7.39, 7.20, 4.54. IR (mull) 1924, 1905, 1644, 1629, 1600, 1585, 1558, 1527, 1428, 1338, 1270, 1254, 1189, 1174, 1137 cm−1. MS (EI) m/z 396 (M+), 398, 396, 256, 255, 229, 140, 127, 126, 125, 89. Anal. found: C, 54.42; H, 3.17; N, 6.85; Cl, 8.66.
PREPARATION 12 2-[2-(4-Methoxyphenyl)ethenyl]-8-quinolinol
A mixture of 8-hydroxyquinaldine (9.93 g) and p-anisaldehyde (20 mL) is heated at 180° C. overnight. The reaction is then cooled to room temperature and vacuum distilled. Once the majority of the p-anisaldehyde is distilled off (below 100° C.), the residue remaining in the flask is taken up in hot 95% EtOH. Any undissolved material is filtered off. H2O is added to the EtOH filtrate and the product is obtained as a yellow solid (3.42 g).
Physical characteristics are as follows:
MP 108-110° C.; 1H NMR (300 MHz, CDCl3) δ 8.15, 7.69, 7.59, 7.39, 7.30, 7.27, 7.18, 6.95, 3.86. 13C NMR (75 MHz, DMSO-d6) δ 160.21, 154.25, 153.30, 138.60, 136.84, 134.58, 129.56, 129.10, 127.97, 127.24, 126.10, 121.25, 118.02, 114.84, 111.59, 55.66. IR (mull) 3420, 2290, 2039, 1943, 1603, 1598, 1558, 1513, 1505, 1273, 1255, 1240. MS (OAMS) 278.2 (M+). Anal. found: C, 77.48; H, 5.37; N, 5.14.
PREPARATION 13 2-(2-Phenylethenyl)-8-quinolinol
A mixture of 8-hydroxyquinaldine (10.02 g) and benzaldehyde (16.8 mL) is heated at reflux overnight. The reaction is cooled to room temperature and vacuum distilled. After the excess benzaldehyde has distilled off, the residue remaining in the flask is dissolved in hot 95% EtOH. Any undissolved material is filtered off. The EtOH filtrate is cooled slowly to give the product as light yellow crystals (5.17 g).
Physical characteristics are as follows:
MP 70-72° C.; 1H NMR (300 MHz, CD3OD) δ 8.17, 7.82, 7.77, 7.68, 7.66, 7.44, 7.39, 7.36, 7.31, 7.08. 13C NMR (75 MHz, CD3OD) δ 154.09, 152.60, 138.23, 136.63, 136.18, 134.19, 128.41, 128.23, 127.97, 127.92, 126.89, 126.74, 119.54, 117.53, 110.55. IR (mull) 1949, 1915, 1903, 1444, 1337, 1260, 1089, 960, 956, 836, 756, 747, 724, 697, 689 cm−1. MS (OAMS) 248.2 (M+). Anal. found: C, 82.38; H, 5.28; N, 5.68.
EXAMPLE 47 N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00090
The title compound of Preparation 14 (0.25 g) and 4-chlorobenzylamine (0.10 mL) are dissolved in 10 mL DMF. EDC.HCl (0.16 g) and HOBt.H2O (0.11 g) is added in one portion and the reaction is allowed to stir at room temperature overnight. The reaction is then poured into 50 mL ice/water. The resulting orange solid is filtered and chromatographed on silica gel (eluent 2% MeOH:CH2Cl2). The product-containing fractions are evaporated under reduced pressure to give the product as a light brown solid (0.029 g).
Physical characteristics are as follows:
MP 200-201° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.28, 8.27, 7.95, 7.88, 7.66, 7.40, 7.37, 7.33, 7.00, 4.56, 3.78. 13C NMR (75 MHz, DMSO-d6) δ 168.46, 160.33, 156.50, 155.32, 139.29, 138.64, 136.80, 134.97, 131.96, 129.83, 129.71, 129.37, 129.23, 128.82, 126.11, 124.85, 122.46, 117.37, 114.86, 113.31, 60.93, 55.70. IR (mull) 2428, 2287, 2050, 2016, 1951, 1640, 1600, 1535, 1514, 1439, 1266, 1237, 1173, 1107, 846 cm−1. MS (OAMS) 322.2 (M+). HRMS (EI) found 444.1247. Anal. found: C, 67.36; H, 4.70; N, 6.11.
PREPARATION 14 8-Hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxylic Acid
The title compound of Preparation 12 (3.00 g) is mixed with K2CO3 (4.51 g) and loaded into a small stainless steel bomb. The bomb is flushed 3× with 100 psi CO2 and then pressurized to the pressure of the CO2 tank. The bomb is heated at 170° C. for 7 days, maintaining a final pressure of approximately 1200 psi. The bomb is de-pressurized and cooled to room temperature. The residue is dissolved in a minimal amount of warm water. The aqueous mixture is acidified with concentrated HCl. The material which precipitates at pH 7 (starting material) is filtered and the filtrate is further acidified to pH 4. The product is obtained as a yellow/orange solid which is further purified by trituration in iPrOH (0.74 g).
Physical characteristics are as follows:
MP 217-219° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.51, 8.17, 7.96, 7.84, 7.67, 7.58, 7.28, 7.03, 3.80. 13C NMR (75 MHz, DMSO-d6) δ 171.49, 161.15, 159.55, 153.84, 140.30, 138.81, 135.38, 131.05, 129.84, 128.68, 127.56, 122.21, 121.57, 115.41, 115.05, 112.74, 55.79. IR (mull) 2035, 1932, 1628, 1596, 1573, 1515, 1428, 1338, 1328, 1315, 1289, 1269, 1250, 1176, 836 cm−1. MS (EI) m/z 321 (M+), 321, 303, 302, 277, 276, 275, 274, 260, 232, 151. HRMS (EI) found 321.1001. Anal. found: C, 66.11; H, 4.77; N, 4.02.
PREPARATION 15 8-Hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxylic Acid
The title compound of Preparation 13 (3.50 g) and K2CO3 (6.00 g) are mixed and placed in a stainless steel bomb. The bomb is flushed 2× with 100 psi CO2 and then pressurized to approximately 800 psi CO2. The reaction us heated at 170° C. for 7 days, maintaining a pressure of 1300 psi. The bomb is then cooled to room temperature and the pressure released. The residue is dissolved in 900 mL H2O warm water. The aqueous mixture is acidified to pH 4 with concentrated HCl to give a bright orange solid. The solid is then triturated in iPrOH to give the product (2.21 g).
Physical characteristics are as follows:
MP 208-210° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.43, 8.10, 7.94, 7.82, 7.72, 7.62, 7.43, 7.31. 13C NMR (75 MHz, DMSO-d6) δ 171.87, 160.31, 154.06, 138.74, 137.54, 136.76, 136.36, 131.34, 129.67, 129.42, 127.90, 127.06, 126.74, 122.10, 116.00, 111.82. IR (mull) 1945, 1904, 1722, 1687, 1617, 1596, 1579, 1563, 1489, 1435, 1419, 15 1410, 1351, 1304, 1208 cm−1. MS (EI) m/z 291 (M+) 291, 291, 273, 272, 248, 247, 246, 245, 244, 217, 216. HRMS (EI) found 291.0910. % Water (KF): 1.42. Anal. found: C, 72.28; H, 4.71; N, 4.76.
EXAMPLE 48 N-Heptyl-8-hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00091
The title compound of Preparation 14 (0.16 g) and heptylamine (0.08 mL) are dissolved in 6 mL DMF. EDC.HCl (0.10 g) and HOBt.H2O (0.07 g) are added in one portion and the reaction is stirred at room temperature for 3 days. The reaction is poured into 50 mL ice/H2O. The aqueous solution is extracted 3× with EtOAc. The organic layers are combined, dried over MgSO4, evaporated, and adsorbed onto silica. The product is purified by silica gel chromatography (eluent 2% MeOH:CH2Cl2). The product containing fractions are evaporated and the resulting residue is crystallized with Et2O/hexanes to give the product as a tan solid (0.019 g).
Physical characteristics are as follows:
MP 115-116° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.77, 8.26, 7.91, 7.87, 7.66, 7.33, 7.31, 7.00, 3.79, 3.33, 1.57, 1.28, 0.84. MS (EI) m/z 418 (M+), 418, 305, 304, 302, 278, 277, 276, 275, 260, 152. HRMS (FAB) found 419.2335. Anal. found: C, 72.67; H, 6.87; N, 6.45.
EXAMPLE 49 N-Heptyl-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00092
The title compound of Preparation 15 (0.31 g) and heptylamine (0.17 mL) are dissolved in 12 mL DMF. EDC.HCl (0.22 g) and HOBt.H2O (0.16 g) are added and the reaction is stirred at room temperature for 3 days. The reaction is then poured into 50 mL ice/H2O and the aqueous solution is extracted 3× with EtOAc. The EtOAc extracts are combined, dried over MgSO4, evaporated, and the residue is adsorbed onto silica. The product is purified by chromatography (eluent 1% MeOH:CH2Cl2). The product containing fractions are evaporated under reduced pressure and the residue crystallized with Et2O/hexanes to give the product as a light brown solid (0.10 g).
Physical characteristics are as follows:
MP 113-115° C.; 1H NMR (300 MH, DMSO-d6), δ 8.78, 8.26, 7.94, 7.89, 7.90, 7.69, 7.47, 7.40, 7.33, 3.33, 1.54, 1.24, 0.81. R (mull) 3387, 2281, 1960, 1944, 1927, 1643, 1600, 1547, 1504, 1441, 1152, 989, 751, 690, 622 cm−1. MS (OAMS) 389.2 (M+). HRMS (EI) found: 388.2127. Anal. found: C, 76.75; H, 7.38; N, 7.28.
EXAMPLE 50 8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-(2-phenylethenyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00093
The title compound of Preparation 15 (0.33 g) and 2-amino-1-phenylethanol (0.18 g) are dissolved in 10 mL DMF. EDC.HCl (0.24 g) and HOBt.H2O (0.17 g) are added in one portion and the reaction is allowed to stir at room temperature for 4 days. The reaction is poured into 50 mL ice/H2O and the resulting solid is filtered. The solid is dissolved in EtOAc. To remove unreacted starting material, hexanes are added and the solid is filtered. The product is obtained as a foamy orange solid upon evaporation of the filtrate (0.17 g).
Physical characteristics are as follows:
MP 83-86° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.92, 8.31, 8.10, 7.96, 7.89, 7.72, 7.49, 7.34, 5.68, 4.80, 3.65. 13C NMR (75 MHz, DMSO-d6) δ 167.42, 155.51, 154.83, 144.02, 139.21, 136.93, 136.83, 135.30, 129.81, 129.39, 129.22, 128.58, 128.33, 127.71, 127.62, 126.44, 125.79, 122.84, 117.43, 113.84, 71.45, 60.67, 47.73. IR (mull) 3376, 3059, 3028, 1950, 1640, 1600, 1545, 1506, 1495, 1436, 1418, 1350, 1329, 751, 699 cm−1. MS (FAB) m/z 411 (MH+), 487, 413, 412, 411, 410, 304, 303, 275, 274, 248. HRMS (FAB) found 411.1710. Anal. found: C, 75.00; H, 5.40; N, 7.23.
EXAMPLE 51 N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00094
The title compound of Preparation 15 (0.25 g) and 4-chlorobenzylamine (0.12 mL) are dissolved in 10 mL DMF. EDC.HCl (0.19 g) and HOBt.H2O (0.13 g) are added and the reaction is stirred at room temperature for 3 days. The reaction is poured into 50 mL ice/H2O and the resulting solid is filtered and dried. The solid is recrystallized from EtOAc to give the product as a yellow solid (0.12 g).
Physical characteristics are as follows:
MP 192-194° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.29, 8.31, 8.01, 7.92, 7.71, 7.49, 7.39, 4.57. 13C NMR (75 MHz, DMSO-d6) δ 168.44, 156.56, 154.97, 139.35, 138.62, 136.89, 136.77, 135.16, 131.97, 130.01, 129.72, 129.38, 129.22, 128.82, 128.53, 27.71, 125.10, 122.68, 117.43, 113.38, 42.50. IR (mull) 3383, 2285, 1946, 1930, 1641, 1603, 1536, 1506, 1435, 1425, 1341.5, 106, 963, 750, 612 cm−1. MS (FAB) m/z 415 (MH+), 418, 417, 416, 415, 414, 275, 274, 247, 125, 123. HRMS (FAB) found 415.1206. Anal. found: C, 70.89; H, 4.72; N, 6.52.
EXAMPLE 52 8-Hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00095
The title compound of Preparation 15 (0.23 g) and CDI (0.14 g) are dissolved in 15 mL DMF and stirred at room temperature overnight. 2-Aminoethyl phenylsulfide (0.14 g) is added and the reaction is allowed to stir for 5 days. The reaction is then poured into 50 mL ice/H2O and stirred for 2 hours. The resulting light yellow solid is filtered and dried. The solid is recrystallized from EtOAc/hexanes to give the product as a light brown solid (0.18 g).
Physical characteristics are as follows:
MP 131-132° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.00, 8.30, 8.00, 7.92, 7.87, 7.72, 7.49, 7.40, 7.33, 7.18, 3.58, 3.21. 13C NMR (75 MHz, DMSO-d6) δ 168.47, 156.63, 154.97, 139.38, 136.88, 136.77, 135.96, 135.14, 130.02, 129.60, 129.39, 129.22, 128.68, 128.57, 127.72, 126.31, 125.06, 122.65, 117.37, 113.20, 31.81. IR (mull) 3378, 2294, 1943, 1932, 1645, 1603, 1536, 1505, 1435, 1424, 1144, 747, 731, 683, 622 cm−1. MS (OAMS) 427.3 (MH+). HRMS (EI) found 426.1390. Anal. found: C, 72.48; H, 5.22; N, 6.55.
EXAMPLE 53 8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00096
The title compound of Preparation 14 (0.57 g) and 2-amino-1-phenylethanol (0.26 g) are dissolved in 15 mL DMF. EDC.HCl (0.37 g) and HOBt.H2O (0.25 g) Acre added and the reaction is stirred at room temperature for 4 days. The reaction is poured into 100 mL ice/H2O. The resulting solid is filtered, dried, and recrystallized from EtOAc/hexanes to give the product as an orange solid (0.26 g).
Physical characteristics are as follows:
MP 203-205° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.92, 8.27, 8.04, 7.93, 7.84, 7.66, 7.42, 7.34, 7.25, 7.01, 4.81, 3.79, 3.64, 3.42. IR (mull) 3365, 2068, 1929, 1638, 1620, 1601, 1555, 1531, 1514, 1438, 1422, 1269, 1236, 1176, 828 cm−1. MS (FAB) m/z 441 (MH+), 883, 882, 442, 441, 440, 333, 305, 304, 123, 121. HR;MS (FAB) found 441.1818. Anal. found: C, 73.05; H, 5.39; N, 6.32.
EXAMPLE 54 8-Hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00097
The title compound of Preparation 14 (0.57 g) and 2-aminoethyl phenylsulfide (0.30 g) are dissolved in 15 mL DMF. EDC.HCl (0.36 g) and HOBt.H2O (0.26 g) are added and the reaction is stirred at room temperature for 4 days. The reaction is poured into 100 mL ice/H2O. The resulting solid is filtered, dried, and recrystallized from EtOAc/hexanes. The product is obtained as an orange solid (0.29 g).
Physical characteristics are as follows:
MP 163-165° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.00, 8.27, 7.95, 7.87, 7.84, 7.66, 7.42, 7.34, 7.18, 7.00, 3.79, 3.57, 3.20. 13C NMR (75 MHz, DMSO-d6) δ 168.48, 160.33, 156.56, 155.31, 139.35, 136.72, 135.98, 134.92, 129.83, 129.58, 129.38, 129.21, 128.68, 126.29, 126.19, 124.84, 122.39, 117.29, 114.84, 113.18, 55.67, 31.84. IR (mull) 2425, 2349, 2294, 2042, 1942, 1644, 1599, 1535, 1513, 1442, 1258, 1245, 1176, 826, 739 cm−1. MS (EI) m/z 456 (M+), 456, 333, 320, 305, 304, 303, 302, 275, 260, 232. HRMS (EI) found 456.1489. Anal. found: C, 69.99; H, 5.36; N, 5.95.
PREPARATION 16 8-Methoxy-2-(trifluoromethyl)-4-quinolinol
A mixture of o-anisidine (28 mL), ethyl trifluoroacetoacetate (36 mL), and 12 drops 6N HCl is stirred overnight to form the enamine. The water formed during the reaction is removed by evaporation under reduced pressure. The residue is then poured into 60 mL diphenyl ether in a flask equipped with a Dean-Stark trap and condenser. The reaction is heated at 250° C. for 3 hours, cooled, and the resulting solid is filtered. The solid is rinsed thoroughly with hexanes and dried (18.77 g).
Physical characteristics are as follows:
MP 151-153° C.; 1H NMR (300 MHz, CDCl3) δ 7.90, 7.37, 7.15, 6.83, 4.05. 13C (75 MHz, DMSO-d6) δ 163.20, 155.74, 146.63, 146.21, 140.56, 128.02, 122.79, 113.71, 110.36, 100.89, 56.17. IR (mull) 2498, 2471, 1549, 1527, 1481, 1438, 1415, 1288, 1270, 1202, 1182, 1150. MS (OAMS) 244.1 (MH+). Anal. found: C, 54.16; H, 3.36; N, 5.77.
PREPARATION 17 4-Chloro-8-methoxy-2-(trifluoromethyl)quinoline
4-Hydroxy-8-methoxy-2-trifluoromethylquinoline (18.77 g) is dissolved in. 450 mL 8:1 C2Cl2:DMF. POCl3 (50 mL) is added dropwise and the reaction is allowed to stir overnight. The reaction is then poured into 500 mL ice/H2O and the aqueous is extracted 2× with CH2Cl2. The organic portions are combined, washed 1× with brine, dried over MgSO4, and evaporated. The resulting oil crystallizes upon standing. The solid is recrystallized from 95% EtOH. A second crop of crystals could be obtained by concentrating down the EtOH filtrate. The total yield of product is 15.36 g.
Physical characteristics are as follows:
1H NMR (300 MHz, DMSO-d6) δ 8.26, 7.81, 7.44, 4.02.
PREPARATION 18 8-Methoxy-2-(trifluoromethyl)quinoline
To a solution of 4-chloro-8-methoxy-2-trifluoromethylquinoline (0.57 g) in 5 mL absolute EtOH is added 10% Pd/C (125 mg) and NEt3 (0.3 mL). The reaction is hydrogenated under atmospheric pressure for 0.75 h. The reaction is then filtered. over Celite and the filtrate is evaporated. The residue is taken up in Et2O and the triethylamine hydrochloride salt is filtered. The desired product is obtained as a light yellow solid by evaporation of the Et2O filtrate (0.38 g).
Physical characteristics are as follows:
MP 88-89° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.63, 7.95, 7.68, 7.63, 7.32, 3.99. 13C NMR (75 MHz, DMSO-d6) δ 155.71, 145.50, 139.35, 138.83, 130.37, 0.02, 119.81, 117.86, 117.83, 110.20, 56.28. IR (mull) 2354, 2151, 2030, 1996, 1934, 1507, 1442, 1341, 1319, 1287, 1275, 210. MS (OAMS) 228.2 (MH+). Anal. found: C, 57.85; H, 3.34; N, 6.00.
PREPARATION 19 8-Hydroxy-2-(trifluoromethyl)-7-quinolinecarboxylic Acid
8-Hydroxy-2-trifiuoromethylquinoline (3.2 g) and K2CO3 (6.22 g) are placed in stainless steel bomb. The bomb is pressurized slightly with CO2 and flushed 3×, hen pressurized to approximately 800 psi CO2. The bomb is heated to 170° C., reaching a final pressure of approximately 1200 psi. This temperature and pressure are maintained for 7 days after which time the bomb is cooled and the pressure released. The solid residue is dissolved in a minimal amount of warm water. Any undissolved material is filtered and the aqueous filtrate is acidified to pH 4 with conc. HCl. The resulting tan solid is filtered and dried. The product is recrystallized with Et2O to give a light tan solid (1.87 g).
Physical characteristics are as follows:
MP 209-211° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.66, 8.06, 7.98, 7.54. 13C NMR (75 MHz, DMSO-d6) δ 172.69, 160.38, 146.32, 139.54, 138.44, 133.29, 128.55, 123.74, 120.09, 120.01, 117.96, 111.33. IR (mull) 3076, 3044, 1988, 1928, 1654, 1623, 1434, 1330, 1264, 1211, 1188, 1150. MS (EI) m/z 257 (M+), 257, 240, 239. Anal. found: C, 51.78; H, 2.67; N, 5.46.
EXAMPLE 55 N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(trifluoromethyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00098
The title compound of Preparation 19 (0.52 g) and 4-chlorobenzylamine (0.26 mL) are dissolved in 10 mL DMF at room temperature. EDC.HCl (0.40 g) and HOBt.H2O (0.29 g) are added in one portion and the reaction is stirred at room temperature overnight. The reaction is then poured into 50 mL ice/H2O and the resulting yellow solid is filtered and dried. The product is purified by silica gel chromatography (eluent 2% MeOH:CH2Cl2 followed by 5% MeOH:CH2Cl2). The appropriate fractions are rotovapped to give an oily residue which crystallizes upon addition of CHCl3. The product is obtained as a tan solid (0.49 g).
Physical characteristics are as follows:
MP 92-94° C.; 1H NMR (300 MHz, DMSO-d6) δ 13.98, 9.63, 8.63, 8.15, 8.04, 7.57, 7.39, 4.56. IR (mull) 3363, 1996, 1613, 1600, 1552, 1493, 1440, 1352, 1342, 1326, 1136, 1130. MS (EI) m/z 380 (M+), 240, 214, 213. Anal. found: C, 57.37; H, 3.47; N, 7.13.
EXAMPLE 56 N-Heptyl-8-hydroxy-2-(trifluoromethyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00099
The title compound of Preparation 19 (0.35 g) and heptylamine (0.22 mL) are dissolved in 10 mL DMF. EDC.HCl (0.28 g) and HOBt.H2O (0.21 g) are added and the reaction is stirred at room temperature overnight. The reaction is poured into 50 mL ice/H2O and the aqueous is extracted 2× with EtOAc. The combined EtOAc layers are dried over MgSO4, filtered, and evaporated to give an orange oil. The residue is adsorbed onto silica and chromatographed eluting with 2% MeOH:CH2Cl2 followed by 5% MeOH:CH2Cl2. The fractions containing desired product are evaporated under reduced pressure to give a pale yellow oil which crystallizers with CH2Cl2hexanes (0.15 g).
Physical characteristics are as follows:
MP 97-99° C. 1H NMR (300 MHz, DMSO-d6) δ 14.4, 9.06, 8.61, 8.11, 8.02, 7.53, 3.34, 1.56, 1.25, 0.82. 13C NMR (75 MHz, DMSO-d6) δ 169.65, 159.52, 146.12, 145.66, 139.32, 138.98, 132.23, 126.60, 119.52, 117.14, 112.67, 31.68, 31.58, 29.19, 28.86, 26.89, 22.51, 14.38. IR (mull) 3371, 1938, 1613, 1602, 1558, 1440, 1358, 1329, 1280, 1211, 1190, 1140. MS (OAMS) 355.1 (MH+). Anal. found: C, 60.68; H, 5.96; N, 7.80.
PREPARATION 20 4,8-Dihydroxy-2-(trifuoromethyl)-7-quinolinecarboxylic Acid
2-Trifuoromethyl-4,8-dihydroxyquinoline (6.0 g) and K2CO3 (11.0 g) are mixed in a stainless steel bomb. The bomb is flushed and evacuated 3× with 100 psi CO2. The reaction vessel is then pressurized to 800 psi CO2 and heated to 170° C., reaching a final pressure of 1200 psi. The bomb remains at this temperature and pressure for 7 days. The reaction vessel is cooled to room temperature, the pressure is released, and the reaction mixture is dissolved in 300 mL hot water. Any undissolved material is filtered and the filtrate is acidified with conc. HCl. A precipitate at pH 7 is collected (starting material). The filtrate is further acidified to pH 4 where a tan solid is collected (starting material+desired product). Since most of the solid collected is starting material, this material is reacted in the bomb for 7 more days. The same workup as before is done, with the only precipitate collected at pH 4.5. The desired product is filtered, dried, and recrystallized very slowly with EtOAc/hexanes (0.41 g).
Physical characteristics are as follows:
MP 232-234° C. 1H NMR (300 MHz, DMSO-d6) δ 8 7.88, 7.62, 7.22. MS (EI) m/z 273 (M+), 256, 255, 243, 229, 228, 227, 199, 179, 151. HRMS (EI) found 273.0252. Anal. found C, 46.37; H, 3.11; N, 4.69.
PREPARATION 21 2-[2-(2-furyl)ethenyl]-8-quinolinol
A mixture of 8-hydroxyquinaldine (5.09 g) and 2-furaldehyde (8.0 mL) are heated at reflux overnight. The reaction is cooled to room temperature. The residue is taken up in acetone and adsorbed onto silica. A silica gel column eluting with 100% CH2Cl2 is run and the product-containing fractions evaporated under reduced pressure to give an orange/yellow oil. The product is crystallized with EtOH/H2O, filtered, washed thoroughly with water, and dried (1.18 g).
Physical characteristics are as follows:
MP 80-82° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.55, 8.24, 7.97, 7.78, 7.71, 7.33, 7.19, 7.05, 6.70, 6.61. IR (mull) 3340, 1555, 1508, 1336, 1259, 1229, 1205, 1184, 1158, 1150, 1007, 969, 926, 835, 732 cm−1. MS (electrospray) 238.1 (MH+). Anal. found: C, 75.74; H, 4.68; N, 5.85.
PREPARATION 22 2-[2(2-furyl)ethenyl]-8-hydroxy-7-quinolinecarboxylic Acid
The title compound of Preparation 21 (2.85 g) and K2CO3 (5.11 g) are mixed in a stainless steel bomb. The bomb is pressurized with 100 psi CO2 and flushed 3×. The reaction vessel is then pressurized to 800 psi and heated to 175° C., reaching a final pressure of 1200 psi CO2 where it remained for 7 days. The bomb is cooled to room temperature and de-pressurized. The reaction residue is taken up in 900 mL hot water. Any undissolved material is filtered. The filtrate is acidified to pH 4 with c.HCl and the resulting orange solid filtered and dried. The solid is then recrystallized with iPrOH to give the product as an orange solid (0.37 g).
Physical characteristics are as follows:
MP 190-192° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.40, 8.02, 7.84, 7.81, 7.35, 7.28, 6.83, 6.64. IR (mull) 1691, 1651, 1608, 1551, 1482, 1342, 1307, 1287, 1238, 1205, 1019, 960, 883, 747, 729 cm−1. HRMS (EI) found 281.0678. Anal. found: C, 67.25; H, 4.04; N, 4.79.
EXAMPLE 57 N-[(4-Chlorophenyl)methyl]-2-[2-(2-furyl)ethenyl]-8-hydroxy-7-quinolinecarboxamide
Figure US06310211-20011030-C00100
The title compound of Preparation 22 (0.26 g) and 4-chlorobenzylamine (0.13 mL) are dissolved in 10 mL DMF. EDC.HCl (0.19 g), and HOBt.H2O (0.14 g) are added in one portion and the reaction stirred at room temperature over 3 days. The reaction is then poured into 75 mL ice/H2O. The resulting solid is filtered, taken up in EtOAc, and adsorbed onto silica. A column eluting with 2% MeOH/CH2Cl2 is run and the product-containing fractions are evaporated under reduced pressure to give an oil. The product residue is crystallized with CH2Cl2/hexanes. The product is filtered and dried on the vacuum pump (0.19 g).
Physical characteristics are as follows:
MP 165-167° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.60, 8.28, 7.90, 7.89, 7.84, 7.79, 7.40, 7.38, 7.21, 6.76, 6.61, 4.56. IR (mull) 3382, 1642, 1602, 1536, 1483, 1439, 1433, 1342, 1135, 1106, 1017, 961, 846, 737, 728 cm−1. HRMS (EI) calcd 404.0913. Anal. found (av): C, 60.98; H, 3.90; N, 6.13; Cl, 7.56.
EXAMPLE 58 N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinoline-N-oxide Carboxamide
Figure US06310211-20011030-C00101
Hydrogen peroxide (0.2 mL of a 30% solution) is added to a solution of the title compound of Example 1 (0.100 g) in acetic acid (2.0 mL) and the solution is refluxed for 2 h. The solution is poured over ice and saturated sodium bicarbonate is slowly added until the pH of the mixture is basic. The mixture is extracted with chloroform and the organic layer is concentrated to give 0.128 g yellow solid. Column chromatography on silica gel (50 g) using 100% chloroform then 1% and 2% methanol/chloroform as eluant yields 35 mg (33%) of the desired product as a yellow solid. An analytical sample is crystallized from ethyl acetate/hexane to give the title compound as an orange solid.
Physical characteristics are as follows:
MP 178-183° C.; IR (mull) 3370, 1649, 1612, 1531, 1492, 1425, 1403, 1394, 1269, 1091, 1049, 830, 807, 693, 608 cm−1. MS (FAB) m/z 329 (MH+), 331, 330, 329, 315, 314, 313, 188, 184, 172, 125. HRMS (FAB) 329.0699.
PREPARATION 23 5-Chloro-8-hydroxy-2-methyl-7-quinolinesulfonyl Flouride (Formula P-2) Refer to Chart P
Figure US06310211-20011030-C00102
A solution of 5-chloro-8-hydroxy-2-methylquinoline (9.2 g) in 55 mL of fluorosulfonic acid is stirred at 120° C. for 18 h in a tightly stoppered flask. The mixture is then cooled to −78° C. and poured onto an intimate mixture of 250 mL of crushed ice and 250 mL of powdered dry ice. The mixture is allowed to warm to 25° C., and then diluted with distilled water until further addition causes no additional solid to precipitate (ca. 100 mL). The mixture is filtered, and the solid obtained is washed with four 50 mL-portions of 0° C. distilled water and then dried in a stream of air to give 10.7 g of the title compound as an orange powder.
Physical characteristics are as follows:
MP 196-198° C.; 1H NMR (400 MHz, DMSO) δ 8.55, 7.89, 7.83, 2.82; MS (ESI+) m/e 276 (M+H), 278.
EXAMPLE 59 5-Chloro-8-hydroxy-2-methyl-N-(2-pyridinylmethyl)-7-quinoline-sulfonamide (Formula P-3 where R=CH22-pyridyl) Refer to Chart P
Figure US06310211-20011030-C00103
The title compound of Preparation 23 (0.300 g) is added to a solution of 2-(aminomethyl)pyridine (0.23 mL) and N,N-diisopropylethylamine (0.58 mL) in 4 mL of chlorobenzene and warmed to 140° C. for 2 h. The reaction mixture is then allowed to cool to room temperature and diluted with 75 mL of EtOAc. The organic layer is washed with three 25-mL portions of half-sat'd NaH2PO4 (aq), washed with brine, dried over MgSO4, filtered and concentrated to give a white solid. Crystallization from CH2Cl2/hexanes yields 0.205 g of the title compound as white crystals.
Physical characteristics are as follows:
MP 185-186° C.; 1H NMR (300 MHz, DMSO) δ 8.39, 8.30, 8.08, 7.72, 7.70, 7.60, 7.37, 7.11-7.07, 4.22, 2.76 ppm; 13C NMR (75 MHz, DMSO), δ 159.1, 157.0, 150.9, 148.4, 138.4, 136.4, 132.7, 126.0, 125.9, 123.9, 122.3, 122.1, 121.4, 118.1, 47.8, 24.4 ppm; IR (mull) 3331, 1445, 1395, 1327, 1305, 1157, 1143, 1062, 1015, 838, 833, 825, 643, 632, 610 cm−1; MS (EI) m/z 363 (M+), 195, 194, 193, 165, 164, 129, 128, 108, 107, 79; HRMS (FAB) found 364.0523; Anal. Found: C, 52.54; H, 4.00; N, 11.41; Cl, 9.59; S, 8.63.
EXAMPLE 60 5-Chloro-N-[2-(4-chlorophenyl)ethyl]-8-hydroxy-2-methyl-7-quinolinesulfonamide (Formula P-3 where R=CH2CH24-ClC6H4) Refer to Chart P
Figure US06310211-20011030-C00104
The title compound is prepared according to the procedure described in Example 59, substituting 2-(4-chlorophenyl)ethylamine for 2-(aminomethyl)pyridine. Crystallization from HOAc/H2O/EtOH gives 0.409 g of the title compound as light orange crystals.
Physical characteristics are as follows:
MP 131-133° C.; 1H NMR (300 MHz, CDCl3) δ 8.45, 7.91, 7.57, 7.12, 6.99, 5.08, 3.27-3.21, 2.82, 2.78 ppm; 13C NMR (75 MHz, DMSO) δ 159.1, 150.8, 130.5, 137.7, 132.8, 130.6, 130.4, 127.8, 125.8, 125.9, 123.8, 122.2, 118.1, 43.8, 34.4, 24.4 ppm; IR (mull) 3366, 3346, 1492, 1428, 1346, 1328, 1317, 1246, 1162, 1143, 1083, 1020, 830, 726, 643 cm−1; MS (EI) m/z 410 (M+), 287, 285, 258, 256, 208, 195, 194, 193, 192, 164; Anal. Found: C, 52.40; H, 4.07; N, 6.72; Cl, 17.00.
EXAMPLE 61 5-Chloro-8-hydroxy-2-methyl-N-(4-phenylbutyl)-7-quinolinesulfonamide (Formula P-3 where R=(CH2)4Ph) Refer to CHART P
Figure US06310211-20011030-C00105
The title compound is prepared according to the procedure described in Example 59, substituting 4-phenylbutylamine for 2-(aminomethyl)pyridine. Column chromatography on silica gel (elution with 25% EtOAc/hexanes and 0-0.5% MeOH/CH2Cl2) gives 0.422 g of the title compound as an orange solid.
Physical characteristics are as follows:
MP 84-86° C.; 1H NMR (300 MHz, CDCl3) δ 8.45, 7.94, 7.57, 7.25-7.12, 7.07, 5.06-5.04, 2.96, 2.80, 2.54, 1.65-1.48 ppm; 13C NMR (75 MHz, DMSO) δ 223.3, 159.15, 150.81, 141.8, 138.5, 132.8, 128.1, 128.0, 126.0, 125.9, 125.4, 123.9, 122.5, 118.1, 42.2, 34.5, 28.7, 27.8, 24.0 ppm; IR (mull) 3368, 3296, 1504, 1418, 1342, 1327, 1251, 1149, 1143, 1087, 952, 771, 701, 669, 612 cm−1; MS (EI) m/z 404 (M+), 219, 208, 195, 194, 193, 192, 164, 148, 131, 91; HRMS (EI) found 404.0965; Anal. Found: C, 59.63; H, 5.39; N, 6.79.
EXAMPLE 62 5-Chloro-8-hydroxy-2-methyl-N-[2-(2-pyridinyl)ethyl]-7-quinolinesulfonamide (Formula P-3 where R=CH2CH22-pyridyl) Refer to Chart P
Figure US06310211-20011030-C00106
The title compound is prepared according to the procedure described in Example 59, substituting 2-(2-aininoethyl)pyridine for 2-(aminomethyl)pyridine. Crystallization from EtOAc/hexanes gives 0.374 g of the title compound as a light yellow solid.
Physical characteristics are as follows:
MP 153-155° C.; 1H NMR (300 MHz, DMSO) δ 8.41, 8.35, 7.73, 7.57, 7.17, 7.08, 3.23, 2.84, 2.76 ppm; 13C NMR (75 MHz, DMSO) δ 159.2, 158.3, 150.8, 148.7, 138.5, 136.3, 132.8, 126.0, 125.9, 123.9, 123.2, 122.0, 121.4, 118.2, 42.2, 37.1, 24.4 ppm; IR (mull) 1422, 1335, 1314, 1161, 1152, 1138, 1086, 1058, 948, 884, 824, 819, 35 781, 771, 611 cm−1; MS (EI) m/z 377 (M+), 377, 256, 208, 195, 193, 192, 164, 121, 94, 93; Anal. Found: C, 53.94; H, 4.33; N, 10.93.
PREPARATION 24 5,7-Dibromo-8-methoxy-2-(2-phenylethenyl)quinoline (Formula Q-2) Refer to Chart Q
Figure US06310211-20011030-C00107
A mixture of 5,7-dibromo-2-methyl-8-methoxyquinoline (10.29 g) and benzaldehyde (15.84 g) is heated at reflux for 18 hrs. Upon cooling to room temperature, a precipitate forms. Methanol is added, and the reaction mixture is sonicated. The solid material is then collected by filtration. Crystallization from hot absolute ethanol yields 10.872 g of the title compound as a yellow solid.
Physical characteristics are as follows:
MP 150-152° C.; 1H NMR (300 MHz, CDCl3) δ 8.42, 7.91, 7.81-7.73, 7.66, 7.47-7.35, 4.25 ppm; 13C NMR (75 MHz, CDCl3) δ 156.3, 153.3, 143.6, 136.3, 136.2, 135.8, 132.8, 129.0, 128.9, 128.2, 127.4, 127.0, 120.8, 116.5, 116.1, 62.5 ppm; IR (mull) 3061, 3023, 1589, 1495, 1487, 1311, 1143, 993, 971, 966, 913, 865, 819, 745, 685 cm−1; MS (EI) m/z 417 (M+), 421, 420, 419, 418, 417, 416, 390, 308, 228, 107; Anal. Found: C, 51.22; H, 3.27; N, 3.32.
EXAMPLE 63 (E)-5-Chloro-8-hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinesulfonamide (Formula Q-3, R=CH2CH2SPh) Refer to Chart Q
Figure US06310211-20011030-C00108
The title compound is prepared according to the procedures described in Preparations 6-8 and Example 17, substituting the title compound of Preparation 24 for 5,7-dibromo-8-methoxy-2-methylquinoline in Preparation 6 and 2-aminoethyl phenyl sulfide for 4-chlorobenzylamine in Preparation 8. Triteration with hot EtOH gives 0.282 g of the title compound as a tan solid.
Physical characteristics are as follows:
MP 187-193° C.; 1H NMR (300 MHz, CDCl3) δ 8.51, 7.90-7.88, 7.79, 7.67, 7.50-7.38, 7.26-7.08, 5.61, 3.19-3.15, 3.07-3.04 ppm; 13C NMR (75 MHz, CDCl3) δ 155.9, 151.7, 139.5, 137.3, 136.6, 135.5, 133.9, 129.6, 129.5, 128.5, 127.9, 127.1, 127.0, 126.3, 125.0, 124.6, 122.9, 118.9, 42.5, 32.3 ppm; IR (mull) 3275, 3246, 1597, 1440, 1420, 1342, 1326, 1162, 1149, 1145, 749, 693, 668, 633, 607 cm−1; MS (EI) m/z 496 (M+), 373, 344, 325, 323, 296, 282, 281, 280, 217, 216; HRMS (EI) found 496.0670; Anal. Found: C, 60.08; H, 4.37; N, 5.50.
EXAMPLE 64 5-Chloro-8-hydroxy-N-[2-1H-indol-3-yl)ethyl]-2-methyl-7-quinolinesulfonamide (Formula J-5 where X1=Cl, R1=Me and R2=CH2CH23-indolyl) Refer to Chart J
Figure US06310211-20011030-C00109
The title compound is prepared in two steps from 5-bromo-8-methoxy-2-methyl-7-quinoline sulfonyl chloride according to the procedures described in Preparation 8 and Example 17, substituting 3-(2-aminoethyl)indole for 4-chlorobenzylamine in the former procedure. Preparative HPLC gives 0.082 g of the title compound as a tan solid.
Physical characteristics are as follows:
MP 163-165° C.; 1H NMR (300 MHz, CDCl3) δ 8.44, 8.07, 7.90, 7.53, 7.26-7.20, 7.05, 7.01-6.90, 6.77-6.72, 3.35-3.31, 2.99-2.94, 3.81 ppm; 13C NMR (75 MHz, CDCl3) δ 159.7, 151.4, 139.1, 136.6, 133.3, 127.3, 126.6, 126.4, 124.5, 123.4, 122.8, 121.3, 118.8, 118.6, 118.3, 111.8, 111.3, 44.0, 26.0, 24.9 ppm; IR (mull) 3397, 3302, 1666, 1552, 1488, 1425, 1331, 1306, 1302, 1200, 1175, 1143, 745, 638, 601 cm−1; MS (EI) m/z 415 (M+), 322, 285, 256, 208, 193, 143, 131, 130, 103, 77; HRMS (EI) found 415.0750.
PREPARATION 25 5-Chloro-8-hydroxy-7-iodo-2-methylquinoline (Formula R-2) Refer to Chart R
Figure US06310211-20011030-C00110
Iodine monchloride (19.0 g) is added to a solution of 5-chloro-8-hydroxy-2-methylquinoline (21.5 g) in 250 mL of MeOH, and the resulting mixture is stirred for 3 h. Additional iodine monochloride (4.5 g) is then added, and the mixture is stirred for another 18 h. The reaction mixture is quenched with sated Na2SO3 (aq), then neutralized with sat'd NaHCO, (aq). The solid precipitate is collected by filtration and dried under vacuum to give 31.22 g of the title compound as a pale green solid.
Physical characteristics are as follows:
MP 85-93° C.; 1H NMR (300 MHz, DMSO) δ 8.33, 7.88, 7.61, 2.72 ppm; IR (mull) 3383, 1589, 1434, 1403, 1344, 1322, 1315, 1255, 1249, 1190, 11.37, 947, 719, 617, 607 cm−1; MS (ESI+) m/z 320 (M+H)+; MS (ESI−) m/z 318 (M−H)−.
PREPARATION 26 5-Chloro-8-hydroxy-2-methyl-7-quinolinesulfinic acid (Formula R-3) Refer to Chart R
Figure US06310211-20011030-C00111
A solution of 5-chloro-8-hydroxy-7-iodo2-methylquinoline (30.8 g) in 500 mL of THF is cooled to −78° C., and methyl magnesium bromide (34.4 mL of 3.0 M solution in ether) is added over 12 min. The resulting mixture is stirred for 20 min, then n-butyllithium (65 mL of 1.6 M solution in pentane) is added over 25 min. The reaction mixture is allowed to stir at −78° C. for 2 h, then SO2 (g) is introduced via a needle positioned above the reaction surface. After 42 min. the reaction mixture turns a yellow opaque color and gas introduction is terminated (pH=5-6). Sat'd NaHCO3 (aq) is added until the pH=8, and the precipitate is collected by filtration. The aqueous layer of the filtrate is separated, and the pH is adjusted to 4 with 10% HCl (aq). Gradually, a precipitate forms. This is collected by filtration to afford 8.73 g of the title compound as an orange solid.
Physical characteristics are as follows:
1H NMR (300 MHz, DMSO) δ 8.43, 7.73, 7.70, 2.76 ppm; MS (ESI−) m/z 256 (M−H)−.
PREPARATION 27 5-Chloro-8-hydroxy-2-methyl-7-quinolinesulfonyl Chloride (Formula R-4) Refer to Chart R
Figure US06310211-20011030-C00112
N-Chlorosuccinimide (2.07 g) is added to a solution of the title compound of Preparation 26 (4.0 g) in 70 mL of CH2Cl2, and the resulting mixture is stirred at room temperature for 2 h. The yellow-orange solid precipitate is collected by filtration and dried under vacuum at 56° C. for 1.5 h to afford 2.75 g of the title compound, which is used immediately without further purification.
PREPARATION 28 5-Chloro-8-hydroxy-2-methyl-N-[2-(4-aminophenyl)ethyl]-7-quinolinesulfonamide (Formula R-5) Refer to Chart R
Figure US06310211-20011030-C00113
A solution of the title compound of Preparation 27 (1.51 g), 2-(4-aminophenyl)ethylamine (0.68 mL), and pyridine (0.83 mL) in 30 mL of CH2Cl2 is stirred at room temperature for 18 h. The resulting precipitate is isolated by filtration and rinsed with CH2Cl2 to give 1.82 g of the title compound as an orange solid which is used without further purification.
Physical characteristics are as follows:
MP 249-253° C.; 1H NMR (300 MHz, CDCl) δ 8.31, 7.70, 7.65, 7.07-6.98, 2.94-2.84, 2.70, 2.69-2.63 ppm.
EXAMPLE 65 5-Chloro-8-hydroxy-2-methyl-N-[2-[4-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]ethyl]-7-quinolinesulfonamide (Formula R-6, R=3,5-dimethyl-4-isoxazolyl) Refer to Chart R
Figure US06310211-20011030-C00114
A solution of the title compound of Preparation 28 (0.62 g) and 3,5-dimethylisoxazole-4-sulfonyl chloride (0.31 mL) in 6 mL of pyridine is stirred at room temperature for 54 h. Additional sulfonyl chloride (0.31 mL) is added at 18 h and 36 h. The reaction mixture is then concentrated in vacuo, and the residue is partitioned between EtOAc, pH 4 phosphate buffer and water. The organic layer is separated and concentrated in vacuo to give 1.22 g of an orange solid. Column chromatography on 75 g of silica gel (elution with 0-20% MeOH/CHCl3) followed by crystallization from CH2Cl2hexanes provides 0.041 g of the title compound as a yellow solid.
Physical characteristics are as follows:
MP 147-152° C. (decomposition); 1H NMR (300 MHz, CDCl3) δ 8.39, 7.89, 7.47, 7.15, 7.08, 2.95, 2.73, 2.57, 2.50, 2.48 ppm; IR (mull) 1608, 1594, 1506, 1413, 1269, 1234, 1202, 1169, 1147, 1129, 1071, 807, 796, 637, 611 cm−1; MS (EI) m/z 551 (MH+), 553, 552, 551, 153, 139, 123, 106, 105, 103, 91; HRMS (EI) found 551.0850.
EXAMPLE 66 5-Chloro-8-hydroxy-2-methyl-N-[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]-7-quinolinesulfonamide (Formula R-6, R=Ph) Refer to Chart R
Figure US06310211-20011030-C00115
The title compound is prepared according to the procedure described in Example 65, substituting benzenesulfonyl chloride for 3,5-dimethylisoxazole-4-sulfonyl chloride. Column chromatography (elution with 0-10% MeOH/CHCl3) followed by trituration with CHCl3 gives 0.247 g of the title compound as an off-white solid.
Physical characteristics are as follows:
MP 269-272° C.; 1H NMR (300 MHz, CDCl3) δ 8.08, 7.32, 7.68-7.53, 6.92, 6.86, 2.90-2.78, 2.64 ppm; 13C NMR (75 MHz, DMSO), 223.2, 184.1, 165.3, 154.8, 145.3, 140.2, 137.4, 133.7, 132.3, 132.2, 129.0, 128.7, 127.5, 126.3, 124.4, 123.9, 121.3, 116.8, 104.9, 43.7, 34.3, 24.2 ppm; IR (mull) 3231, 1532, 1510, 1394, 1329, 1309, 1296, 1266, 1159, 1147, 1126, 1108, 1094, 708, 691 cm−1; MS (EI) m/z 531 (M+), 195, 193, 167, 165, 164, 130, 107, 106, 77, 64.
PREPARATION 29 5-fluoro-8-hydroxy-7-quinolinesulfonyl chloride (Formula S-2) Refer to Chart S
Figure US06310211-20011030-C00116
A solution of 5-fluoro-8-hydroxyquinoline (0.50 g) in 4.0 mL of chlorosulfonic acid is stirred for 3 h at 90° C. and then 13 h at 105° C. The mixture is then cooled to 0° C. and poured onto 50 mL of finely divided −15° C. ice. The bright orange-red precipitate is collected by filtration, washed with four 10-mL portions of 0° C. distilled water and three 2 mL portions of diethyl ether, and dried in a stream of air to give 0.208 g of the title compound as a red-orange powder.
Physical characteristics are as follows:
MP 248-250° C. (decomposition); Anal. found: C, 41.01; H, 2.05; N, 5.32; S, 12.25.
EXAMPLE 67 5-Flouro-8-hydroxy-N-(phenylmethyl)-7-quinolinesulfonamide (Formula S-3) Refer to Chart S
Figure US06310211-20011030-C00117
A suspension of 5-fluoro-8-hydroxy-7-quinolinesulfonyl chloride (0.150 g) in 2 mL of THF is cooled to −78° C. and treated with benzylamine (0.186 mL). The mixture is allowed to warm to 25° C. over several hours, then diluted with 50 μL of glacial acetic acid and 2 mL of distilled water. The oil which forms is crystallized by scratching, and the resulting suspension is stirred for one hour. The solid is filtered, washed with two 2 mL portions of distilled water and dried in a stream of air to give 0.121 g of the title compound as a solid.
Physical characteristics are as follows:
MP 185.5-186° C.; 1H NMR (400 MHz, DMSO) δ 9.04, 8.48, 8.03, 7.81, 7.47, 7.22, 7.11, 7.03, 4.12; MS (ESI, positive ion mode) m/e 333 (M+H).
EXAMPLE 68 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinecarboxamide
Figure US06310211-20011030-C00118
To a solution of 5-chloro8-hydroxy-2-methyl-7-quinolinecarboxylic acid (0.500 g) and 4-chlorobenzylamine (0.28 mL) in 20 mL DMF is added EDC hydrochloride (0.444 g) and hydroxybenzotriazole hydrate (0.312 g). The reaction is stirred at room temperature for 48 h. The mixture is then partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried over sodium sulfate and condensed. The residue is stirred in 20 mL 1:1 THF/1N HCl overnight. The solution is neutralized with saturated aqueous NaHCO3. The reaction is partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried and condensed. The crude product is chromatographed on silica, eluting with 3% MeOH/CH2Cl2. Fractions homogeneous by TLC are combined and condensed. The residue taken up in a minimal amount of CH2Cl2. Toluene is added to the solution and the mixture is sonicated while adding hexanes until a white solid formed. The solid is collected and dried to yield 0.3310 g of the title product as a white solid.
Physical characteristics are as follows:
MP 128-130° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.54, 8.35, 8.09, 7.66, 7.39, 4.54, 2.71; IR (mull) 3399, 3299, 1660, 1603, 1565, 1531, 1500, 1492, 1428, 1350, 1332, 1251, 1226, 798, 630 cm−1. MS (EI) m/z 360 (M+), 362, 360, 221, 220, 195, 194, 193, 164, 140, 125. Anal. Found: C, 59.53; H, 4.11; N, 7.71; Cl, 19.38.
EXAMPLE 69 5-chloro-8-hydroxy-2-methyl-N-(3-phenylpropyl)-7-quinolinecarboxamide
Figure US06310211-20011030-C00119
To a solution of 5-chloro-8-hydroxy-2-methyl-7-quinolinecarboxylic acid (0.500 g) and 3-phenylpropylamine (0.33 mL) in 20 mL DMF is added EDC hydrochloride (0.444 g) and hydroxybenzotriazole hydrate (0.312 g). The reaction is stirred at room temperature for 48 h. The mixture is then partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried over sodium sulfate and condensed. The residue is stirred in 20 mL 1:1 THF/1N HCl overnight. The solution is neutralized with saturated aqueous NaHCO3. The reaction is partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried and condensed. The crude product is chromatographed on silica, eluting with 3% MeOH/CH2Cl2. Fractions homogeneous by TLC are combined and condensed. The residue taken up in a minimal amount of CH2Cl2. Toluene is added to the solution and the mixture is sonicated while adding hexanes until a white solid formed. The solid is collected and dried to yield 0.310 g of the title product as a white solid.
Physical characteristics are as follows:
MP 109-111° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.95, 8.36, 8.08, 7.66, 7.30-7.16, 3.35, 2.71, 2.65, 1.87; IR (mull) 3305, 1638, 1602, 1574, 1556, 1503, 1496, 1424, 1350, 1319, 1302, 1265, 943, 745, 698 cm31 1. MS (EI) m/z 354 (M+), 354, 250, 222, 221, 220, 195, 194, 193, 164, 91. Anal. Found: C, 67.75; H, 5.48; N, 7.81; Cl, 9.92.
EXAMPLE 70 5-chloro-8-hydroxy-2-methyl-N-[(2-phenylthio)ethyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00120
To a solution of 5-chloro-8-hydroxy-2-methyl-7-quinolinecarboxylic acid (0.500 g) and aminoethylphenyl sulfide (0.354 g) in 20 mL DMF is added EDC hydrochloride (0.444 g) and hydroxybenzotriazole hydrate (0.312 g). The reaction is stirred at room temperature for 48 h. The mixture is then partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried over sodium sulfate and condensed. The residue is stirred in 20 mL 1:1 THF/1N HCl overnight. The solution is neutralized with saturated aqueous NaHCO3. The reaction is partitioned between EtOAc and water. The aqueous layer is extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried and condensed. The residue taken up in a minimal amount of CH2Cl2. Toluene is added to the solution and the mixture is sonicated while adding hexanes until a solid formed. The solid is collected and dried to yield 0.499 g of the title product as an off-white solid.
Physical characteristics are as follows:
MP 131-134° C.; 1H NMR (300 MHz, DMSO-d6) δ 9.28, 8.35, 8.02, 7.66, 7.41, 7.30, 7.17, 3.55, 3.19, 2.71; IR (mull) 3322, 1631, 1612, 1602, 1567, 1553, 1501, 1483, 1439, 1423, 1341, 1317, 1268, 1247, 744 cm−1. MS (EI) m/z 372 (M+), 372, 238, 236, 222, 221, 220, 219, 164, 136, 135. IRMS (EI) found 372.0701.
EXAMPLE 71 8-hydroxy-N-[5-[[[4-(1-methylethyl)phenylsulfonyl]amino]pentyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00121
To a solution of 8-hydroxyquinoline-7-carboxylic acid (0.147 g) and N-(5-aminopentyl)-4-(1-methylethyl)benzenesulfonamide monohydrochloride (0.250 g) in 5 mL DMF is added EDC hydrochloride (0.149 g) and hydroxybenzotriazole hydrate (0.105 g), followed by diisopropylethylamine (0.271 mL). The reaction is stirred overnight at room temperature, then poured into 50 mL water. The resulting solution is partitioned between EtOAc and water. The aqueous layers are extracted with EtOAc (3×). The combined organic layers are washed with brine (1×), dried over sodium sulfate and condensed. The crude product is chromatographed on silica, eluting with 3% MeoH/CH2Cl2. Fractions homogeneous by TLC are combined, concentrated and recrystallized from acetone/hexanes to yield 0.060 g of the title product as a gold solid.
Physical characteristics are as follows:
MP 106-108° C.; 1H NMR (300 MHz, DMSOd6) δ 8.89, 8.79, 8.31, 7.94, 7.68, 7.62, 7.49-7.38, 3.27, 2.93, 2.71, 1.49, 1.38, 1.27, 1.18; MS (EI) m/z 455 (M), 283, 266, 255, 189, 173, 172, 171, 145, 116, 84. HRMS (EI) found 455.1875. Anal. Found: C, 62.61; H, 6.39; N, 9.00.
EXAMPLE 72 N-(cyanomethyl-8-hydroxy-7-quinolinecarboxamide
Figure US06310211-20011030-C00122
8-hydroxyquinoline-7-carboxylic acid (0.51 g), aminoacetonitrile.HCl (0.27 g), and triethylamine (0.38 mL) are dissolved in 10 mL dimethylformamide. EDC.HCl (0.54 g) and HOBt.H2O (0.38 g) are added and the reaction is stirred at room temperature for 2 days. The reaction is poured into 50 mL ice/H2O and stirred.
After approximately 30 minutes, a solid is collected and dried. The desired product is recrystallized from ethyl acetate (0.12 g).
Physical characteristics are as follows:
MP 206-208° C. (dec); 1H NMR (300 MHz, DMSO-d6) δ 9.26, 8.93, 8.39, 7.96, 7.68, 7.44, 4.40. IR (mull) 3309, 3284, 1645, 1625, 1536, 1405, 1397, 1345, 1301, 1279, 1264, 1205, 846, 785, 723 cm−1. MS (electrospray) 228.2 (M+H1), 250.1 (M+Na), 226.1 (M−H1). Anal. Found: C, 63.43; H, 4.14; N, 18.40.
EXAMPLE 73 8-hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethyl]-7-quinolinecarboxamide
Figure US06310211-20011030-C00123
The title compound of Example 53 (0.090 g) is dissolved in 6 mL 1:1 THF:MeOH. Triethylamine (0.04 mL) followed by 20 mg 10% Pd/C is added to the reaction mixture. The reaction is placed under a hydrogen balloon and stirred at room temperature for 2 hours. The reaction is filtered over Celite and the filter cake rinsed thoroughly with ethyl acetate. The filtrate is evaporated under reduced pressure to give a solid which is then recrystallized from EtOAc/hexanes very slowly. The resulting solid is filtered and dried to give the desired product (0.048 g).
Physical characteristics are as follows:
MP 69-72° C.; 1H NMR (300 MHz, DMSO-d6) δ 8.95, 8.20, 7.94, 7.51, 7.41, 7.33, 7.25, 7.17, 6.81, 4.82, 3.68, 3.62, 3.39, 3.21, 3.06. IR (mull) 3398, 1636, 1603, 1549, 1512, 1425, 1344, 1241, 1179, 1064, 1032, 839, 744, 729, 698 cm−1. MS (electrospray) 443.1 (M+H1), 465.0 (M+Na), 441.0 (M−H1). HRMS (FAB) found 443.1985. Anal. Found: C, 70.43; H, 5.96; N, 6.03.
PREPARATION 30 8-Hydroxyquinoline, 7-carboxylic Acid (formula T-2) Refer to Chart T
A finely ground mixture of 27.8 g of 8-hydroxyquinoline (T-1) and 79.2 g of potassium carbonate is placed in a bomb and heated to 175° C. under 800 psi carbon dioxide gas. After seven days, the reaction is cooled to room temperature. The resulting mixture is treated with 1.2 L of hot water to dissolve most of the material. The suspension is filtered, cooled to room temperature and acidified to pH=7 with concentrated hydrochloric acid. The precipitate is removed by filtration. The filtrate is acidified to pH=3.5 with concentrated hydrochloric acid. The new precipitate is collected by suction filtration, washed with repeatedly isopropanol followed by hexanes. The yellow solid is dried in vacuo to afford 26 g of the title acid.
Physical characteristics are as follows:
1H-NMR (DMSO): 8.9, 8.6, 7.9, 7.8, 7.3.
EXAMPLE 74 N-[2-(3-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide (uninverted CAS name) (formula T-3 wherein R0 is 2-(3-chlorophenyl)ethyl) Refer to Chart T
To a suspension of 1.89 g of T-2 of Preparation 30, 1.50 g of 1-hydroxbenzotriazole and 2.30 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 50 mL of dichloromethane is added 1.55 mL of 2-(3-chlorophenyl)ethylamine. The reaction is stirred overnight at room temperature. The resulting orange solution is diluted with dichloromethane and partioned against saturated aqueous sodium bicarbonate. The aqueous phase is extracted with additional portions of dichloromethane. The organic layers are combined and washed with pH=4 aqueous phosphate buffer followed by brine. The organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue is crystallized from ethyl acetate to afford 2.55 g of the title compound.
Physical characteristics are as follows:
1H-NMR (CDCl3): 10.0, 8.8, 8.2, 8.0, 7.5, 7.3, 7.2, 7.1, 3.8, 3.0; Elem. Anal.: C, 65.82, H, 4.63, N, 8.56; MS-ESI: 327 (+ mode), 325 (− mode).
EXAMPLES 75-151
Following similar procedures to those described above, these additional analogues are prepared:
8-Hydroxy-N-[2-(3-indolyl)ethyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[2-(4-hydroxyphenyl)ethyl]-7-quinolinecarboxamide;
8-Hydroxy-N-[2-(2-[4-phenoxy]phenyl)ethyl]-7-quinolinecarboxamide;
N-[(2,4-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-[(3,4-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-Decyl-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(4-phenylbutyl)-7-quinolinecarboxamide;
8-Hydroxy-N-octyl-7-quinolinecarboxamide;
8-Hydroxy-N-[[4-(trifluoromethyl)phenyl]methyl]-7-quinolinecarboxamide;
8-Hydroxy-N-[[2-(trifluoromethyl)phenyl]methyl]-7-quinolinecarboxamide;
N-[2-(1-Cyclohexenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[2-(2,4-Dichlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(cis-myrtanyl)-7-quinolinecarboxamide;
N-[(2-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-[(2-methylphenyl)methyl]-7-quinolinecarboxamide;
8-Hydroxy-N-[(3-methylphenyl)methyl]-7-quinolinecarboxamide;
N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-7-quinolinecarboxamide;
N-(2,2-Diphenylethyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(2-phenylpropyl)-7-quinolinecarboxamide;
N-[1-(2-Ethyl)hexyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-undecyl-7-quinolinecarboxamide;
8Hydroxy-N-otadecyl-7-quinolinecarboxamide;
N-[2-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[2-(4-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-[2-(4-methylphenyl)ethyl]-7-quinolinecarboxamide;
N-(3,3-Diphenylpropyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(3-phenylpropyl)-7-quinolinecarboxamide;
8Hydroxy-N-nonyl-7-quinolinecarboxamide;
N-[(2,6-Difluorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-[(3-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(2-methylcyclohexyl)-7-quinolinecarboxamide;
N-(2,3-Dimethylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(3-methylcyclohexyl)-7-quinolinecarboxamide;
8-Hydroxy-N-(4-methylcyclohexyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-7-quinolinecarboxamide;
N-Cyclooctyl-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(1-indanyl)-7-quinolinecarboxamide;
N-Cycloheptyl-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(diphenylmethyl)-7-quinolinecarboxamide;
8-Hydroxy-N-(1-phenylethyl)-7-quinolinecarboxamide;
N-(2-Heptyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(2-octyl)-7-quinolinecarboxamide;
N-(4-tert-Butylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
S-N-[7-(7-Carboxy-8-hydroxy)quinolyl]-tyrosine, tert-butyl ester;
R-8-Hydroxy-N-[1-(1-naphthyl)ethyl]-7-quinolinecarboxamide;
S-8-Hydroxy-N-[1-(1-naphthyl)ethyl]-7-quinolinecarboxamide;
R-8-Hydroxy-N-(1-phenylethyl)-7-quinolinecarboxamide;
R-N-[1-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
S-N-[1-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[2-((1S,2R)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[2-((1R,2S)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(2-exo-norboranyl)-7-quinolinecarboxamide;
8-Hydroxy-N-[(4-hydroxy-3-methoxyphenyl)methyl]-7-quinolinecarboxamide;
S-8-Hydroxy-N-[2-(1-hydroxy-3-[4-hydroxyphenyl])propyl]-7-quinolinecarboxamide;
S-N-[7-(7-Carboxy-8-hydroxy)quinolyl]-serine, benzyl ester;
N-[7-(7-Carboxy-8-hydroxy)quinolyl]-tyrosine, methyl ester;
N-[7-(7-Carboxy-8-hydroxy)quinolyl]-tryptophan, ethyl ester;
N-(2-Adamantyl)8-hydroxy-7-quinolinecarboxamide;
S-O-Benzyl-N-[7-(7-Carboxy-8-hydroxy)quinolyl]-tyrosine, methyl ester;
S-N-[7-(7-Carboxy-hydroxy)quinolyl]-4-nitrophenylalanine, methyl ester;
N-[(2,5-Difluorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-[1-(1-hydroxymethyl)cyclopentyl]-7-quinolinecarboxamide;
N-[(3-Chloro-4-flurorophenylmethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[(2,3-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-[(2,5-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
N-(2-[([2-chloro-6-fluorophenyl]methyl)thio]ethyl)-8-hydroxy-7-quinolinecarboxamide;
N-[2-([(2,6-Dichlorophenyl)methyl]thio)ethyl]-8-hydroxy-7-quinolinecarboxamide;
N-[(2-Chloro-6-phenoxy-phenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-[(2-[(2-(hydroxymethyl]phenyl)thio]phenyl)methyl]-7-quinolinecarboxamide;
8-Hydroxy-N-(2-[(4-[2-trifiluoromethyl]quinolyl)thio]ethyl)-7-quinolinecarboxamide;
N-(Cyclohexylmethyl)-8-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-(1-naphthalenylmethyl)-7-quinolinecarboxamide;
N-[2-(3-Chlorophenyl)ethyl]-hydroxy-7-quinolinecarboxamide;
8-Hydroxy-N-[[3-(trifluoromethyl)phenyl]methyl]-7-quinolinecarboxamide;
8-Hydroxy-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide; and
N-Heptyl-8-hydroxy-7-quinolinecarboxamide.
PREPARATION 31 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Anhydride U-1, Procedure for Single Compounds (GP II) (Refer to Chart U)
Anhydride U-1 (1 eq.) is dissolved in CHCl3 (n mL) at r.t. Pyridinium chloride (1 eq) and then the arylamine (about 1 eq.) are added. The solution is stirred for 6 h at r.t. 1M HCl/H2O (n mL) is added and the biphasic mixture is stirred efficiently overnight. The precipitate is filtered, washed with a little water and CH2Cl2 and dried under high vacuum.
PREPARATION 32 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Anhydride U-1, Procedure for Parallel Synthesis (GP III) (Refer to Chart U)
The aryl amines (0.20 mmol) are laid into syringes corked at their output and set with a frit at the bottom of their large section. A sol. of anhydride U-1 (0.1M) and pyridinium chloride (0.1M) in CHCl3 is prepared. This solution (2 mL/syringe) is added into the syringes; if the arylamine is a liquid, it is added at this stage only; if the arylamine is a hydrochloride salt, DIPEA (33 μL, 1 eq) is added. The syringes are tightly closed at their bottoms and shaken for 6 h at r.t. 1M HCl/H2O (2 mL) is added and the biphasic mixture is shaken efficiently overnight. The precipitate is isolated by sucking the solvent from the bottom of the syringes, washed with a little water and CH2Cl2 and dried under high vacuum.
PREPARATION 33 N-Aryl-8-hydroxy-7-quinolinecarboxamides from the Ester U-3, Procedure for Single Compounds (GP IV) (Refer to Chart U)
Ester U-3 is dissolved in CH2C4 and the arylamine (about 1 eq) and DIPEA (about 1 eq.) are added. The reaction mixture is stirred between 6 h and 6 days. MeOH (same amount as CH2Cl2) is added and the mixture is stirred between 6 h and 18 h. For the work-up procedures, see specific examples below.
PREPARATION 34 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Ester U-3, Procedure for Parallel Synthesis (GP V) (Refer to Chart U)
The aryl amines (0.2 mmol) are put into syringes corked at their output and set with a frit at the bottom of their large section. A sol. of ester 3 (0.05M) and DIPEA (0.05M) in CH2Cl2 is prepared and added to the arylamines (4 mL for each amine); if the arylamine is a liquid, it is added at this stage only; if the arylamine is a salt, DIPEA (33 μL, 1 eq) is added. The syringes are tightly closed and shaken for 5 days. MeOH (2-4 mL) is added and the mixture is shaken for 6 h. The precipitate, if any, is isolated by sucking the solvent from the bottom of the syringes, washed with AcOEt and dried under high vacuum (P-fraction). The filtrate is washed with sat. NaHCO3/H2O (1×) and an aq. buffer sol. at pH4 (1×); each time, the aq. phase is pipetted out of the seringe. If a precipitate appears during the work-up, it is filtered and dried (WU-fraction). The filtrate is blown down with a nitrogen stream; AcOEt (4 mL) is added and the mixture heated to 65° C. for 30 min. and cooled to 0° C. The solvent is pipetted out and the residue dried under high vacuum (T-fraction). The org. phase is blown down and the residue dried under high vacuum as well (S-fraction). The degree of hydration of the obtained products was not determined.
PREPARATION 35 8-{[(2,2,2-Trichloroethoxy)carbonyl]oxy}-7-quinolinecarboxylic Acid Anhydride with 2,2,2-trichloroethyl Hydrogen carbonate (U-1) (Refer to Chart U)
In a flame-dried flask, 8-hydroxy-7-quinolinecarboxylic acid (2.00 g) is suspended into CH2Cl2 (100 mL) and DIPEA (3.70 mL) is added. The mixture is stirred until homogeneity is reached and cooled to 0° C. Trichloroethyl chloroformate (3.00 mL) is added and the solution is stirred for 3 h at 0° C., then stirred for another hour while allowed to warm up slowly to r.t. The solution is washed with 1M HCl/H2O (1×), dried over Na2CO3 and the solvent removed under reduced pressure. Crystallization of the residue from CHCl3/hexanes yielded the desired product (5.20 g).
Physical characteristics are as follows:
mp: 133-4° C.; 1H-NMR (CDCl3, 300 MHz) δ 9.05, 8.26, 8.11, 7.88, 7.61, 4.97, 4.95. 13C-NMR (CDCl3, 75 MHz) δ: 157.56, 152.13, 151.59, 149.25, 147.71, 141.09, 135.82, 132.64, 126.57, 126.45, 124.44, 119.67, 93.96, 93.42. MS (FAB) m/z 538, 540 and 542 (MH+), 172. HRMS (FAB): found: 537.8609. Anal. Found: C, 35.12; H, 1.85; N, 2.65.
PREPARATION 36 8-Acetoxy-7-quinolinecarboxylic Acid (U-2) (Refer to Chart U)
This compound is prepared according to literature procedure (German patent number 540842, Dec. 10, 1931).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 13.35, 8.99, 8.46, 8.00, 7.95, 7.67, 2.38. 13C-NMR (d6-DMSO, 75 MHz) δ 172.46, 169.22, 166.21, 152.08, 147.95, 141.42, 136.61, 131.35, 127.08, 126.13, 124.07, 21.20.
PREPARATION 37 7-(Fluorocarbonyl)quinolin-8-yl acetate (U-3) (Refer to Chart U)
In a flame-dried flask under Ar, 8-acetoxy-7-quinolinecarboxylic acid U-2 (4.30 g) is suspended into CH2Cl2 (110 mL). Pyridine (1.50 mL) is added and the suspension cooled to −40° C. Cyanuric fluoride (3.00 mL) is added and the mixture stirred for 3 h, while the temperature rose slowly to 0° C. Ice and water and CH2Cl2 (100 mL) are added. Phases are shaken, separated and the aq. phase extracted with CH2Cl2 (1×). The combined org. phases are dried over MgSO4, filtered, and the solvent is removed under reduced pressure. Crystallization of the residue from hexanes yielded ester U-3 as white needles (4.10 g).
Physical characteristics are as follows:
mp: 130-132° C.; 1H-NMR (CDCl3, 300 MHz) δ 9.05, 8.22, 8.02, 7.80, 7.58, 2.58. 13C-NMR (CDCl3, 75 MHz) δ 169.06, 156.59, 151.89, 141.42, 136.07, 132.92, 126.77, 126.03, 124.41, 118.10, 117.30, 20.88. MS (FAB) m/z 234 (MH+), 192, 172. HRMS (FAB): 234.0569. Anal. C, 60.98; H, 3.55; N, 6.24.
EXAMPLE 152 8-Hydroxy-N-(4-methoxyphenyl)-7-quinolinecarboxamide Monohydrochloride (V-4) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (50 mg), pyridinium chloride (10.8 mg) and 4-methoxyaniline (11.4 μg) in CHCl3 (2 mL), amide U-4 is obtained as a pale yellow precipitate (10 mg).
Physical characteristics are as follows:
1H-NMR (CD3OD, 300 MHz) δ 9.15, 8.43, 8.18, 7.83, 7.63, 6.96, 3.82. 13C-NMR (CD9OD, 75 MHz) δ 167.37, 157.63, 153.46, 146.28, 144.61, 131.70, 130.07, 129.69, 126.73, 123.92, 123.51, 117.56, 115.33, 113.67, 54.52. MS (EI) m/z 294 (M+), 172, 123, 116, 108, 89. HRMS (EI): 294.1003.
EXAMPLE 153 N-(4-Cyanophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-5) (Refer to Chart V)
According to GP II, starting with anhydride U-1 (200 mg), pyridinium chloride (42 mg) and 4-aminobenzonitrile (44 mg) in CHCl3 (8 mL), amide V-5 is obtained as a red powder (50 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.8, 8.96, 8.68, 8.08, 7.94, 7.82, 7.45). 13C-NMR (d6-DMSO, 75 MHz) δ 166.42, 146.73, 143.49, 140.96, 133.77, 131.59, 128.3, 124.18, 120.66, 119.51, 116.81, 115.57, 105.84. MS (EI) m/z 289 (M+), 172, 116, 89. HRMS (EI): 289.0848.
EXAMPLE 154 N-(3-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-6) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 3-chloroaniline (39 μL) and CHCl3 (8 mL), amide V-6 is obtained as a yellow powder (50 mg).
Physical characteristics are as follows:
1H-NMR (CD3OD, 300 MHz) δ 8.82, 8.28, 7.96, 7.90, 7.62, 7.36, 7.18. 13C-NMR (d6-DMSO, 75 MHz) δ 166.45, 155.03, 147.30, 140.94, 140.42, 135.93, 133.56, 131.43, 130.95, 127.92, 124.23, 120.43, 119.35, 116.50. MS (EI) m/z 298 and 300 (MH+), 172, 116. Anal. Found: C, 57.09; H, 3.78; N, 8.28.
EXAMPLE 155 N-[3,5-Bis(trifluoromethyl)phenyl]-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-7) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 3,5-bis(trifluoromethyl)anihine (58 μL and CHCl3 (8 mL), amide V-7 is obtained as an orange powder (30 mg, 20%).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.90, 8.97, 8.64, 8.46, 8.05, 7.84, 7.81, 7.47. 13C-NMR (d6-DMSO, 75 MHz) δ 166.77, 155.62, 147.30, 141.18, 140.21, 131.55, 131.03, 127.94, 125.53, 124.23, 121.92, 120.37, 116.38. MS (EI) m/z 400 (M+), 172, 116, 89. HRMS (EI) 400.0653.
EXAMPLE 156 N-Fluoren-2-yl-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-8) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 2-aminofluorene (67 mg) and CHCl3 (8 mL), amide V-8 is obtained as a yellow powder (55 mg).
Physical characteristics are as follows:
1H-NMR (CDCl3, 300 MHz) δ 11.10, 9.02, 8.69, 8.23, 8.07, 7.89, 7.84, 7.72, 7.57, 7.36, 7.27. 13C-NMR (d6-DMSO, 75 MHz) δ 166.27, 154.91, 147.55, 144.24, 143.42, 141.33, 140.72, 137.77, 137.67, 135.96, 131.34, 127.64, 127.25, 126.81, 125.53, 124.25, 120.66, 120.12, 120.03, 118.04, 116.88, 116.31, 37.01. MS (EI) m/z 352 (M+), 181, 172, 116, 89. HRMS (EI) 352.1190.
EXAMPLE 157 N-{[4-[(3,4-Dimethylisoxazol-5-ylamino)sulfonyl]phenyl}-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-9) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 4-amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide (99 mg) and CHCl3, (8 mL), amide V-9 is obtained as an orange powder (47 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.85, 10.95, 8.94, 8.61, 8.04, 7.95, 7.81, 7.75, 7.41, 2.08, 1.63. 13C-NMR (d6-DMSO, 75 MHz) δ 166.19, 161.90, 156.19, 155.99, 146.92, 143.67, 140.05, 137.29, 134.44, 131.58, 128.47, 128.24, 124.08, 120.27, 116.43, 115.20, 105.64, 10.80, 6.34. MS (EI) m/z 438 (M+), 369, 343, 327, 263, 172, 156, 116. HRMS (FAB) 439.1091.
EXAMPLE 158 N-1,3-Benzodioxol-5-yl-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-10) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 5-amino-1,3-benzodioxol (51 mg) and CHCl3 (8 mL), amide V-10 is obtained as a yellow powder (60 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 10.95, 8.98, 8.64, 8.15, 7.82, 7.53, 7.44, 7.11, 6.92, 6.02. 13C-NMR (d6-DMSO, 75 MHz) δ 166.21, 155.12, 147.72, 147.91, 144.02, 140.15, 132.89, 131.28, 127.35, 124.19, 116.83, 115.92, 114.39, 108.55, 103.40, 101.63, 61.06. MS (EI) m/z 308 (M+), 172, 137, 116, 89. HRMS (EI) 308.0797.
EXAMPLE 159 8-Hydroxy-N-[4-(trifluoromethyl)coumarin-7-yl]-7-quinolinecarboxamide Monohydrochloride (V-11) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 7-amino-4-(trifluoromethyl)coumarin (85 mg) and CHCl3 (8 ml.), amide V-11 is obtained as a yellow powder (25 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.94, 8.65, 8.11, 8.05, 7.83, 7.71, 7.66, 7.38, 6.91. 13C-NMR (d6-DMSO, 75 MHz) δ 166.40, 159.13, 155.28, 146.35, 143.73, 140.72, 131.77, 128.52, 125.91, 124.11, 117.29, 116.40, 114.67, 114.57, 108.91, 107.41. MS (EI) m/z 400 (M+), 172, 116, 89. HRMS (EI) 400.0664.
EXAMPLE 160 N-(3-Fluorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-12) (Refer to Chart V)
According to GP II, startng from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 3-fluoroaniline (36 μL) and CHCl3 (8 mL), amide V-12 is obtained as a white powder (45 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.35, 8.96, 8.62, 8.07, 7.83-7.76, 7.47, 7.43, 7.39, 6.95. 13C-NMR (d6-DMSO, 75 MHz) δ 166.78, 164.09, 160.89, 154.39, 146.87, 142.46, 140.45, 134.36, 131.49, 130.83, 128.13, 124.41, 117.06, 116.90, 126.08. MS (EI) m/z 282 (M+), 172, 116, 89. HRMS (EI) 282.0804.
EXAMPLE 161 N-(3,4-Difluorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-13) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 3,4-difluoroaniline (37 μL) and CHCl3 (8 mL), amide V-13 is obtained as a light yellow powder (35 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.20, 8.95, 8.60, 8.05, 7.97, 7.79, 7.45. 13C-NMR (d6-DMSO, 75 MHz) δ 166.25, 155.39, 147.45, 140.03, 136.87, 136.08, 131.38, 127.75, 124.13, 118.46, 117.20, 116.25, 110.42. MS (EI) m/z 300 (M+), 172, 116, 89. HRMS (EI) 300.0724.
EXAMPLE 162 N-(3,5-Difluorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-14) (Refer to Chart V)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), 3,5-difluoroaniline (48 mg) and CHCl3 (8 mL), amide V-14 is obtained as a yellow powder (42 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 11.60, 8.99, 8.73, 8.07, 7.88, 7.50, 7.50 (m, 2H), 6.97, 6.29. 13C-NMR (d6-DMSO, 300 MHz) δ 166.53, 164.48, 161.26, 154.99, 146.85, 141.54, 135.64, 131.52, 128.14, 124.27, 116.84, 116.07, 103.62, 99.44. MS (EI) m/z 300 (M+), 172, 129, 116, 102, 89. HRMS 300.0716.
EXAMPLE 163 8-Hydroxy-N-(4-nitrophenyl)-7quinolinecarboxamide (V-15) (Refer to Chart V)
According to GP IV, starting from ester U-3 (100 mg), 4-nitroaniline (60 mg), DIPEA (75 μL) and CH2Cl2 (2 mL), stirred for 30 h, then overnight with MeOH. Amide V-15 appears as a red precipitate that is filtered and dried (10 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.90, 8.58, 8.25, 7.97, 7.81, 7.33. MS (EI) m/z 309 (M+), 172, 116, 89. HRMS (EI) 309.0741.
EXAMPLE 164 N-[2-Chloro-5-(trifluoromethyl)phenyl]-8-hydroxy-7-quinolinecarboxamide (V-16) (Refer to Chart V)
According to GP IV, starting from ester U-3 (50 mg), 2-chloro-5-(trifluoromethyl)aniline (30 μL), DIPEA (40 μL) and CH2Cl2 (2 mL), stirred for 5 days, then for 6 h with MeOH. The mixture is diluted in some AcOEt, washed with sat. NaHCO3/H2O (1×), with an aq. buffer sol. at pH4 (1×), dried over MgSO4 and the solvent removed under reduced pressure. Crystallization from AcOEt/hexanes leads to amide V-16 as a yellow powder (26 mg).
Physical characteristics are as follows:
mp: 210-211° C.; 1H-NMR (CD3OD, 300 MHz) δ 10.18, 10.05, 8.38, 8.38, 8.09, 7.79, 7.62. MS (EI) m/z 366 and 368 (M+), 172, 116, 89. HRMS (EI) 366.0374.
EXAMPLE 165 N-(5-Fluoro-2-methylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-17) (Refer to Chart V)
According to GP IV, starting from ester U-3 (500 mg), 5-fluoro-2-methylaniline (0.30 mL), DIPEA (0.30 mL) and CH2Cl2 (10 mL), stirred for 24 h, then overnight with MeOH. An orange powder precipitated, that is filtered and dried under high vacuum. The filtrate is evaporated under reduced pressure, which leads to another fraction of orange precipitate, that is triturated in hot AcOEt/hexanes. After cooling to r.t., the orange powder is filtered and dried under high vacuum. Both fractions proves to be amide V-17 (366 mg, 58%).
Physical characteristics are as follows:
mp: 209-210° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 11.95, 8.87, 8.63, 8.25, 8.17, 7.79, 7.27, 6.84, 2.36. 13C-NMR (d6-DMSO, 75 MHz) δ 164.38, 161.99, 158.83, 157.66, 144.94, 140.14, 138.77, 136.97, 131.45, 131.07, 128.65, 123.35, 122.63, 115.15, 112.53, 109.25, 106.15. MS (EI) m/z 296 (M+), 268, 172, 116, 89. Anal. Found C, 68.67; H, 4.49; N, 9.43.
Also: According to GP V starting with 5-fluoro-2-methylaniline (26 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 297 (MH+); neg. mode: 295 (M−H+).
EXAMPLE 166 N-(2,4-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-18) (Refer to Chart V)
According to GP IV, starting from ester U-3 (500 mg), 2,4-dimethylaniline (0.27 mL), DIPEA (0.30 mL) and CH2Cl2 (10 mL), stirred for 24 h, then overnight with MeOH. After adding some CH2Cl2, the sol. is washed with an aq. buffer sol. at pH4 (2×) and sat. NaHCO3/H2O (1×). The org. phase is dried over MgSO4 and the solvent removed under reduced pressure. The residue is triturated in AcOEt/hexanes at r.t. Amide V-18 precipitates as a white powder that is filtered and dried (378 mg).
Physical characteristics are as follows:
mp: 164-167° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 11.0, 8.90, 8.49, 8.14, 7.96, 7.74, 7.38, 7.06, 7.01, 2.29, 2.26. 13C-NMR (d6-DMSO, 75 MHz) δ 184.14, 164.49, 156.15, 146.22, 138.04, 137.91, 134.28, 133.07, 130.87, 130.74, 128.64, 127.38, 126.64, 123.32, 122.18, 114.80, 20.24, 17.71. MS (EI) m/z 292 (M+), 264, 172, 121, 106, 89. HRMS (EI) 292.1206. Anal. Found: C, 73.28; H, 5.51; N, 9.50.
Also: According to GP V starting with 2,4-dimethylaniline (25 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos mode: 293 (MH+); neg. mode: 291 (M−H+).
EXAMPLE 167 8-Hydroxy-N-(3-methylphenyl)-7-quinolinecarboxamide (V-19) (Refer to Chart V)
According to GP IV, starting from ester U-3 (500 mg), 3-methylaniline (0.23 mL), DIPEA (0.30 mL) and CH2Cl2 (10 mL), stirred for 24 h, then overnight with MeOH. After adding some CH2Cl2, the sol. is washed with an aq. buffer sol. at pH4 (2×) and sat. NaHCO3/H2O (1×). The org. phase is dried over MgSO4 and the solvent removed under reduced pressure. The residue is triturated with AcOEt/hexanes at 40° C. and amide V-19 precipitated as a red powder that is filtered and dried under high vacuum (276 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 10.90, 8.92, 8.45, 8.03, 7.70, 7.55, 7.41, 7.24, 6.94. 13C-NMR (d6-DMSO, 75 MHz) δ 165.10, 155.37, 147.65, 138.45, 138.17, 137.96, 137.37, 130.61, 128.60, 126.83, 124.39, 123.33, 120.60, 117.29, 115.63, 115.29, 21.09. MS (EI) m/z 278 (M+), 172, 116, 107, 89. HRMS (EI) 278.1049. Anal. Found: C, 72.95; H, 5.19; N, 9.95.
Also: According to GP V starting with 3-methylaniline (21 mg).
Physical characteristics are as follows:
MS (ES) m/z WU-fraction: Pos mode: 279 (M+); neg. mode: 277 (M−H+).
EXAMPLE 168 N-(2-Chloro-5-methoxyphenyl)-8-hydroxy-7-quinolinecarboxamide (V-20) (Refer to Chart V)
According to GP IV, starting from ester U-3 (500 mg), 2-chloro-5-methoxyaniline hydrochloride (420 mg), DIPEA (0.06 mL) and CH2Cl2 (10 mL), are stirred for 6 days, then for 24 h with MeOH. After adding some CH2Cl2, the sol. is washed with an aq. buffer sol. at pH4 (2×) and sat. NaHCO3/H2O (1×). The org. phase is dried over MgSO4 and the solvent removed under reduced pressure. The residue, is triturated with AcOEt/hexanes at r.t. and the precipitated grey amide V-20 is filtered and dried under high vacuum (280 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 12.3, 8.85, 8.58, 8.33, 8.17, 7.77, 7.40, 7.25, 6.70, 3.76. 13C-NMR (d6-DMSO, 75 MHz) δ 184.16, 164.39, 158.28, 145.09, 145.04, 139.80, 139.74, 136.80, 131.56, 129.40, 128.66, 123.40, 114.72, 113.58, 109.54, 107.31, 55.30. MS (EI) m/z 328 and 330 (M+), 172, 157 and 159, 116, 89. HRMS (EI) 328.0615. Anal. Found: C, 61.38; H, 4.17; N, 8.45.
Also: According to GP V starting with 2-chloro-5-methoxyaniline hydrochloride (39 mL) and DIPEA (33 μL).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 329 and 331 (MH+); neg. mode: 327 and 329 (M−H+).
EXAMPLE 169 8-Hydroxy-N-naphth-2-yl-7-quinolinecarboxamide Monohydrochloride (V-21) (Refer to Chart V)
Following GP III starting from 2-aminonaphthalene (29 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 315 (MH+); neg. mode: 313 (M−H+).
EXAMPLE 170 8-Hydroxy-N-{4-[(indazo-6-ylamino)sulfonyl]phenyl}-7-quinolinecarboxamide Monohydrochloride (V-22) (Refer to Chart V)
Following GP III starting with N1-indazo-6-ylsulfanilamide (60 mg).
Physical characteristics are as follows:
MS (ES) m/z: Pos. mode 460 (MH+); neg. mode: 458 (M−H+). Contaminated with sulfanilamide.
EXAMPLE 171 N-(3-Bromophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-23) (Refer to Chart V)
Following GP III starting from 3-bromoaniline (22 μL).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 343, 345 (MH+); neg. mode: 341, 343 (M−H+).
EXAMPLE 172 N-(3,4-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-24) (Refer to Chart V)
Following GP III starting from 3,4-dichloroaniline (33 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 333, 335, 337 (MH+); neg. mode: 331, 333, 335 (M−H+). Contaminated with carbamate.
EXAMPLE 173 N-(3,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-25) (Refer to Chart V)
Following GP III starting from 3,5-dichloroaniline (33 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 333, 335, 337 (MH+); neg. mode: 331, 333, 335 (M−H+).
EXAMPLE 174 8-Hydroxy-N-(3-iodophenyl)-7-quinolinecarboxamide Monohydrochloride (V-26) (Refer to Chart V)
Following GP III starting from 3-iodoaniline (44 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 391 (MH+); neg. mode: 389 (M−H+).
EXAMPLE 175 N-(3-Benzoxyphenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-27) (Refer to Chart V)
Following GP III starting from 3-benzoxyaniline (40 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 371 (MH+); neg. mode: 369 (M−H+).
EXAMPLE 176 8-Hydroxy-N-[3-(methylmercapto)phenyl]-7-quinolinecarboxamide Monohydrochloride (V-28) (Refer to Chart V)
Following GP III starting from 3-(methylmercapto)aniline (25 μL).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 311 (MH+); neg. mode: 309 (M−H+).
EXAMPLE 177 N-(3,5-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-29) (Refer to Chart V)
Following GP III starting from 3,5-dimethylaniline (25 μL).
MS (ES) m/z: Pos. mode: 293 (MH+); neg. mode: 291 (M−H+).
EXAMPLE 178 N-(4-Bromophenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-30) (Refer to Chart V)
Following GP III starting from 4-bromoaniline (35 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 343, 345 (MH+); neg. mode: 341, 343 (M−H+). Contaminated with carbamate.
EXAMPLE 179 8-Hydroxy-N-(4-phenoxyphenyl)-7-quinolinecarboxamide Monohydrochloride (V-31) (Refer to Chart V)
Following GP III starting from 4-phenoxyaniline (37 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 357 (MH+); neg. mode: 355 (M−H+).
EXAMPLE 180 N-(3,5-Dichloro-4-hydroxyphenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-32) (Refer to (Chart V)
Following GP III starting from 3,5-dichloro-4-hydroxyaniline (36 mg).
MS (ES) m/z: Pos. mode: 349, 351, 353 (MH+); neg. mode: 347, 349, 351 (M−H+).
EXAMPLE 181 8-Hydroxy-N-biphen-4-yl-7-quinolinecarboxamide Monohydrochloride (V-33) (Refer to Chart V)
Following GP III starting from 4-aminobiphenyl (34 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 341 (MH+); neg. mode: 339 (M−H+).
EXAMPLE 182 8-Hydroxy-N-[4-(4-nitrophenylmercapto)phenyl]-7-quinolinecarboxamide Monohydrochloride (V-34) (Refer to Chart V)
Following GP III starting from 4-(4-nitrophenylmercapto)aniline (49 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 418 (MH+); neg. mode: 416 (M−H+).
EXAMPLE 183 N-(4-Benzoxyphenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-35) (Refer to Chart V)
Following GP III starting from 4-benzoxyaniline (47 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 371 (MH+); neg. mode: 369 (M−H+).
EXAMPLE 184 8-Hydroxy-N-[4-(4-nitrophenoxy)phenyl]-7-quinolinecarboxamide Monohydrochloride (V-36) (Refer to Chart V)
Following GP III starting from 4-(4-nitrophenoxy)aniline (46 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 402 (MH+); neg. mode: 400 (M−H+).
EXAMPLE 185 N-(4-cyclohexylphenyl)-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (V-37) (Refer to Chart V)
Following GP V starting from 4-cyclohexylaniline (35 mg).
Physical characteristics are as follows:
MS (ES) m/z Pos. mode: 347 (MH+); neg. mode: 345 (M−H+).
EXAMPLE 186 8-Hydroxy-N-naphth-1-yl-7-quinolinecarboxamide (V-38) (Refer to Chart V)
Following GP V starting from 1-aminonaphthalene (29 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 315 (MH+); neg. mode: 313 (M−H+).
EXAMPLE 187 N-(4-Bromonaphth-1-yl)-8-hydroxy-7-quinolinecarboxamide (V-39) (Refer to Chart V)
Following GP V starting from 1-amino-4-bromonaphthalene (44 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg. mode: 391 and 393 (M−H+).
EXAMPLE 188 8-Hydroxy-N-(2-pyrrol-1-ylphenyl)-7-quinolinecarboxamide (V-40) (Refer to Chart V)
Following GP V starting from 1-(2-aminophenyl)pyrrole (32 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 330 (MH+); neg. mode: 328 (M−H+).
EXAMPLE 189 8-Hydroxy-N-indol-5-yl-7-quinolinecarboxamide (V-41) (Refer to Chart V)
Following GP V starting from 5-aminoindole (26 mg).
Physical characteristics are as follows:
MS (ES) m/z P- and WU-fractions: Pos. mode: 304 (MH+); neg. mode: 302 (M−H+).
EXAMPLE 190 N-Benzo-2,1,3-thiadiazol-4-yl-8-hydroxy-7-quinolinecarboxamide (V-42) (Refer to Chart V)
Following GP V starting from 4-aminobenzo-2,1,3-thiadiazole (30 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: neg. mode: 302 (M−H+).
EXAMPLE 191 8-Hydroxy-N-quinolin-5-yl-7-quinolinecarboxamide (V-43) (Refer to Chart V)
Following GP V starting from 5-aminoquinoline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P- and WU-fractions: Pos. mode: 316 (MH+) and 338 (MNa+); neg. mode: 314 (M−H+).
EXAMPLE 192 8-Hydroxy-N-quinolin-8-yl-7-quinolinecarboxamide (V-44) (Refer to Chart V)
Following GP V starting from 8-aminoquinoline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 316 (MP+); neg. mode: 314 (M−H+).
EXAMPLE 193 8-Hydroxy-N-isoquinolin-5-yl-7-quinolinecarboxamide (V-45) (Refer to Chart V)
Following GP V starting from 5-aminoisoquinoline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 316 (MH+); neg. mode: 314 (M−H+).
EXAMPLE 194 8-Hydroxy-N-(4-methoxy-2-nitrophenyl)-7-quinolinecarboxamide (V-46) (Refer to Chart V)
Following GP V starting from 4-methoxy-2-nitroaniline (34 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg. mode: 338 (M−H+). Contaminated with quinoline methyl ester.
EXAMPLE 195 8-Hydroxy-N-[2-nitro-4-(trifluoromethyl)phenyl]-7-quinolinecarboxamide (V-47) (Refer to Chart V)
Following GP V starting from 2-nitro-4-(trifluoromethyl)aniline (41 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos mode: 378 (MH+); neg. mode: 338 (M−H+).
EXAMPLE 196 N-(3,5-Dinitrophenyl)-8-hydroxy-7-quinolinecarboxamide (V-413) (Refer to Chart V)
Following GP V starting from 3,5-dinitroaniline (37 mg).
Physical characteristics are as follows:
MS (ES) m/z: P-fraction: Neg. mode 353 (M−H+).
EXAMPLE 197 8-Hydroxy-N-[4-nitro-2-(trifluoromethyl)phenyl]-7-quinolinecarboxamide (V-49) (Refer to Chart V)
Following GP V starting from 4-nitro-2-(trifluoromethyl)aniline (41 mg).
Physical characteristics are as follows:
MS (ES) m/z: P-fraction Pos. mode: 378 (MH+), 400 (MNa+); neg. mode: 376 (M−H+).
EXAMPLE 198 N-(2-Cyanophenyl)-8-hydroxy-7-quinolinecarboxamide (V-50) (Refer to Chart V)
Following GP V starting from 2-aminobenzonitrile (24 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 290 (MH+), 312 (MNa+); neg. mode: 388 (M−H+).
EXAMPLE 199 N-(2-Bromophenyl)-8-hydroxy-7-quinolinecarboxamide (V-51) (Refer to Chart V)
Following GP V starting from 2-bromoaniline (35 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 343 and 345 (MH+); neg. mode: 341 and 343 (M−H+).
EXAMPLE 200 N-(2,4-Dibromophenyl)-8-hydroxy-7-quinolinecarboxamide (V-52) (Refer to Chart V)
Following GP V starting from 2,4-dibromoaniline (50 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg. mode: 419, 421 and 423 (M−H+). Contaminated with 8-hydroxy-7-quinoline carboxylic acid.
EXAMPLE 201 N-(2,5-Dibromophenyl)-8-hydroxy-7-quinolinecarboxamide (V-53) (Refer to Chart V)
Following GP V starting from 2,5-dibromoaniline (50 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 421, 423 and 425 (MH+); neg. mode: 419, 421 and 423 (M−H+).
EXAMPLE 202 N-(2-Fluorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-54) (Refer to Chart V)
Following GP V starting from 2-fluoroaniline (22 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 283 (MH+), 305 (MNa+); neg. mode: 281 (M−H+).
EXAMPLE 203 N-(4-Cyano-2,3,5,6-tetrafluorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-55) (Refer to Chart V)
Following GP V starting from 4-amino-2,3,5,6-tetrafluorobenzonitrile (38 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 362 (MH+); neg. mode: 260 (M−H+).
EXAMPLE 204 N-(2,4-Difluorophenyl-8-hydroxy-7-quinolinecarboxamide (V-56) (Refer to Chart V)
Following GP V starting from 2,4-difluoroaniline (26 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 301 (MH+), 323 (MNa+); neg. mode: 299 (M−H+).
EXAMPLE 205 8-Hydroxy-N-(2,4,5-trifliuorophenyl)-7-quinolinecarboxamide (V-57) (Refer to Chart V)
Following GP V starting from 2,4,5-trifluoroaniline (30 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 319 (MH+); neg. mode: 317 (M−H+).
EXAMPLE 206 N-(2-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-58) (Refer to Chart V)
Following GP V starting from 2-chloroaniline (26 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 299 and 301 (MH+); neg. mode: 297 and 299 (M−H+). Contaminated with quinoline methyl ester.
EXAMPLE 207 N-(4-Bromo-2-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-59) (Refer to Chart V)
Following GP V starting from 4-bromo-2-chloroaniline (42 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 377, 379 and 381 (MH+); neg. mode: 375, 377 and 379 (M−H+).
EXAMPLE 208 N-(2,4-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-60) (Refer to Chart V)
Following GP V starting from 2,4-dichloroaniline (32 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 333, 335 and 337 (MH+); neg. mode: 331, 333 and 335 (M−H+).
EXAMPLE 209 N-(2-Chloro-4-nitrophenyl)-8-hydroxy-7-quinolinecarboxamide (V-61) (Refer to Chart V)
Following GP V starting with 2-chloro-4-nitroaniline (35 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg. mode: 342 and 344 (M−H+).
EXAMPLE 210 N-(2,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide (V-62) (Refer to Chart V)
Following GP V starting from 2,5-dichloroaniline (33 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction Pos. mode: 333, 335 and 337 (MH+); neg. mode: 331, 333 and 335 (M−H+).
EXAMPLE 211 N-(2-Chloro-5-methylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-63) (Refer to Chart V)
Following GP V starting from 2-chloro-5-methylaniline (29 mg).
Physical charactezistics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 313 and 315 (MH+); neg. mode: 311 and 313 (M−H+).
EXAMPLE 212 8-Hydroxy-N-(2-iodophenyl)-7-quinolinecarboxamide (V-64) (Refer to Chart V)
Following GP V starting from 2-iodoaniline (44 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 391 (MH+); neg. mode: 389 (M−H+). Contaminated with quinoline methyl ester.
EXAMPLE 213 8-Hydroxy-N-(2-nitrophenyl)-7-quinolinecarboxamide (V-65) (Refer to Chart V)
Following GP V starting from 2-nitroaniline (28 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Neg. mode: 308 (M−H+), 331 (MNa−H+). Contaminated with quinoline methyl ester.
EXAMPLE 214 N-(5-Chloro-2-hydroxyphenyl)-8-hydroxy-7-quinolinecarboxamide (V-66) (Refer to Chart V)
Following GP V starting from 5-chloro-2-hydroxyaniline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 357 and 359 (MH+), 379 and 381 (MNa+); neg. mode: 355 and 357 (M−H+).
EXAMPLE 215 8-Hydroxy-N-(2-hydroxy-5-nitrophenyl)-7-quinolinecarboxamide (V-67) (Refer to Chart V)
Following GP V starting from 2-hydroxy-5-nitroaniline (31 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg mode: 324 (M−H+).
EXAMPLE 216 8-Hydroxy-N-(2-hydroxy-5-methylphenyl)-7-quinolinecarboxamide (V-68) (Refer to Chart V)
Following GP V starting from 2-hydroxy-5-methylaniline (25 mg).
Physical characteristics are as follows:
MS (ES) m/z WU-fraction: Pos. mode: 295 (M+); neg. mode: 293 (M−H+).
EXAMPLE 217 N-Biphen-2-yl-8-hydroxy-7-quinolinecarboxamide (V-69) (Refer to Chart V)
Following GP V starting from 2-aminobiphenyl (34 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 341 (MH+); neg. mode: 339 (M−H+).
EXAMPLE 218 8-Hydroxy-N-[2-methylmercapto)phenyl]-7-quinolinecarboxamide (V-70) (Refer to Chart V)
Following GP V starting from 2-methylmercaptoaniline (28 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 311 (MH+); neg. mode: 309 (M−H+).
EXAMPLE 219 8-Hydroxy-N-[2-(trifluoromethyl)phenyl]-7-quinolinecarboxamide (V-71) (Refer to Chart V)
Following GP V starting from 2-(trifluoromethyl)aniline (33 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Neg. mode: 331 (M−H+). Contaminated with quinoline methyl ester.
EXAMPLE 220 8-Hydroxy-N-(2-methylphenyl)-7-quinolinecarboxamide (V-72) (Refer to Chart V)
Following GP V starting from 2-methylaniline (22 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 279 (MH+); neg. mode: 277 (M−H+).
EXAMPLE 221 8-Hydroxy-N-(2-methyl-3-nitrophenyl)-7-quinolinecarboxamide (V-73) (Refer to Chart V)
Following GP V starting with 2-methyl-3-nitroaniline (31 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 324 (MH+); neg. mode: 322 (M−H+).
EXAMPLE 222 N-(2,3-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-74) (Refer to Chart V)
Following GP V starting with 2,3-dimethylaniline (25 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 293 (MH+); neg. mode: 291 (M−H+).
EXAMPLE 223 8-Hydroxy-N-(2,4,6-trimethylphenyl)-7-quinolinecarboxamide (V-75) (Refer to Chart V)
Following GP V starting from 2,4,6-trimethylaniline (25 mg).
Physical characteristics are as follows:
MS (ES) m/z T- and WU-fractions: Pos. mode: 307 (MH+); neg. mode: 305 (M−H+).
EXAMPLE 224 N-(2-Ethylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-76) (Refer to Chart V)
Following GP V starting with 2-ethylaniline (25 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 293 (MH+); neg. mode: 291 (M−H+).
EXAMPLE 225 8-Hydroxy-N-[3-(trifluoromethyl)phenyl]-7-quinolinecarboxamide (V-77) (Refer to Chart V)
Following GP V starting with 3-(trifluoromethyl)aniline (32 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 333 (MH+); neg. mode: 231 (M−H+).
EXAMPLE 226 8-Hydroxy-N-(2-methyl-4-fluorophenyl)-7-quinolinecarboxamide (V-78) (Refer to Chart V)
Following GP V starting with 2-methyl-4-fluoroaniline (25 mg).
Physical charactezistics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 297 (MH+); neg. mode: 295 (M−H+).
EXAMPLE 227 N-(4-Chloro-2-methylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-79) (Refer to Chart V)
Following GP V starting with 2-chloro-2-methylaniline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 313 and 315 (MH+), 335 and 335 (MNa+); neg. mode: 311 and 313 (M−H+).
EXAMPLE 228 N-(4-Chloro-2-methoxy-5-methylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-80) (Refer to Chart V)
Following GP V startng with 4-chloro-2-methoxy-5-methylaniline (55 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 343 and 345 (MH+); neg. mode: 341 and 343 (M−H+).
EXAMPLE 229 N-(4-tert-Butylphenyl)-8-hydroxy-7-quinolinecarboxamide (V-81) (Refer to Chart V)
Following GP V starting with 4-tert-butylaniline (31 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 321 (MH+); neg. mode: 319 (M−H+).
EXAMPLE 230 8-Hydroxy-N-(4-propylphenyl)-7-quinolinecarboxamide (V-82) (Refer to Chart V)
Following GP V starting with 4-propylaniline (28 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 307 (MH+); neg. mode: 305 (M−H+).
EXAMPLE 231 N-(2,6-Di-i-propylphenyl)-8-hydroxy-7-quinolinecarboxamide V-83) (Refer to Chart V)
Following GP V starting from 2,6-di-i-propylaniline (36 mg).
Physical characterislics are as follows:
MS (ES) m/z T-fraction: Neg. mode: 347 (M−H+).
EXAMPLE 232 N-(4-Bromo-2-fluorophenyl)-8-hydroxy-7-quinolinecaboxamide (V-84) (Refer to Chart V)
Following GP V starting from 4-bromo-2-fluoroaniline (31 mg).
Physical characteristics are as follows:
MS (ES) m/z T- and P-fractions: Pos. mode: 361 and 363 (MH+); neg. mode: 359 and 361 (M−H+).
EXAMPLE 233 8-Hydroxy-N-(2,3,4-trifluorophenyl)-7-quinolinecarboxamide (V-85) (Refer to Chart V)
Following GP V starting from 2,3,4-trifluoroaniline (30 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 319 (MH+), 341 (MNa+); neg. mode: 317 (M−H+).
EXAMPLE 234 N-(2-Fluoro-4-iodophenyl)-8-hydroxy-7-quinolinecarboxamide (V-86) (Refer to Chart V)
Following GP V starting from 2-fluoro-4-iodoaniline (48 mg).
Physical characteristics are as follows:
MS (ES) m/z T- and P-fractions: Pos. mode: 409 (MH+); neg. mode: 407 (M−H+).
EXAMPLE 235 8-Hydroxy-N-[4-(hydroxymethyl)phenyl]-7-quinolinecarboxamide (V-87) (Refer to Chart V)
Following GP V starting from 4-(hydroxymethyl)aniline (29 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 295 (MH+); neg. mode: 293 (M−H+).
EXAMPLE 236 N-Benzo-1,3-thiazol-6-yl-8-hydroxy-7-quinolinecarboxamide (V-88) (Refer to Chart V)
Following GP V starting from 6-amino-benzo-1,3-thiazole (31 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 322 (MH+); neg. mode: 320 (M−H+).
EXAMPLE 237 8-Hydroxy-N-indazol-5-yl-7-quinolinecarboxamide (V-89) (Refer to Chart V)
Following GP V starting from 5-aminoindazole (27 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Neg. mode: 303 (M−H+).
EXAMPLE 238 8-Hydroxy-N-[2-methoxy-5-(trifluoromethyl)phenyl]-7-quinolinecarboxamide (V-90) (Refer to Chart V)
Following GP V staring from 2-methoxy-5-(trifluoromethyl)aniline (39 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Pos. mode: 363 (MH+); neg. mode: 361 (M−H+).
EXAMPLE 239 8-Hydroxy-N-(5-iodo-2-methylphenyl)-7-quinolinecarboxamide (V-91) (Refer to Chart V)
Following GP V starting with 5-iodo-2-methylaniline (47 mg).
Physical characteristics are as follows:
MS (ES) m/z T- and P-fractions: Pos. mode: 405 (MH+); neg. mode: 403 (M−H+).
EXAMPLE 240 N-(2-Chloro-4-cyanophenyl)-8-hydroxy-7-quinolinecarboxamide (V-92) (Refer to Chart V)
Following GP V starting with 4-amino-3-chlorobenzonitrile (31 mg).
Physical characteristics are as follows:
MS (ES) m/z T-fraction: Neg. mode: 322 and 324 (M−H+).
EXAMPLE 241 N-(5-Bromopyridin-2-yl)-8-hydroxy-7-quinolinecarboxamide (V-93) (Refer to Chart V)
Following GP V starting with 2-amino-5-bromopyridine (35 mg).
Physical characteristics are as follows:
MS (ES) m/z P-fraction: Pos. mode: 344 and 342 (MH+); neg. mode: 340 and 342 (M−H+).
EXAMPLE 242 8-Hydroxy-N-(8-hydroxyquinolin-2-yl)-7-quinolinecarboxamide (V-94) (Refer to Chart V)
Following GP V starting with 2-amino-8-hydroxyquinoline (33 mg).
Physical characteristics are as follows:
MS (ES) m/z T- and P-fractions: Pos. mode: 332 (MH+); neg. mode: 330 (M−H+).
PREPARATION 38 2-Amino-5-alkylamino-1,3,4-thiadiazoles (GP I) (Refer to Chart W.)
2-Amino-5-bromo-1,3,4-thiadiazole W-95 (1 eq.) is dissolved in DMF at r.t;. The alkyl amine (about 1 eq.) and DIPEA (1-3 eq.) are added respectively and the solution stirred for 20 h. The solvent is removed under reduced pressure, the residue is diluted in AcOEt and washed with an aq. buffer sol. at pH 4 (2×). The org. phase is dried over MgSO4, filtered, and the solvent removed under reduced. pressure. The residue is either crystallized from AcOEt/hexanes or purified by FC.
PREPARATION 39 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Anhydride U-1, Procedure for Single Compounds (GP II)
Anhydride U-1 (1 eq.) is dissolved in CHCl3 (n mL) at r.t. Pyridinium chloride (1 eq) and then the arylamine (about 1 eq.) are added. The solution is stirred for 6 h at r.t. 1M HCl/H2O (n mL) is added and the biphasic mixture is stirred efficierntly overnight. The precipitate is filtered, washed with a little water and CH2Cl2 aad dried under high vacuum.
PREPARATION 40 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Anhydride U-1, Procedure for Parallel Synthesis (GP III)
The aryl amines (0.20 mmol) are laid into syringes corked at their output and set with a frit at the bottom of their large section. A sol. of anhydride U-1 (0.1M) and of pyridinium chloride (0.1) in CHCl3 is prepared. This solution (2 mL/syringe) is added into the syringes; if the arylamine is a liquid, it is added at this stage only; if the arylamine is a hydrochloride salt, DIPEA (33 μL, 1 eq) is added. The syringes are tightly closed at their bottoms and shaken for 6 h at r.t. 1M HCl/H2O (2 mL) is added and the biphasic mixture is shaken efficiently overnight. The precipitate is isolated by sucking the solvent from the bottom of the syringes, is washed with a little water and CH2Cl2 and dried under high vacuum.
PREPARATION 41 N-Aryl-8-hydroxy-7-quinolinecarboxamides from the Ester U-3, Procedure for Single Compounds (GP IV)
Ester U-3 is dissolved in CH2Cl2 and the arylamine (about 1 eq) and DIPEA (about 1 eq.) are added. The reaction mixture is stirred between 6 h and 6 days. MeOH (same amount as CH2Cl2) is added and the mixture is stirred between 6 h and 18 h. For the work-up procedures, see specific examples below.
PREPARATION 42 N-Aryl-8-hydroxy-7-quinolinecarboxamides from Ester U-3, Procedure for Parallel Synthesis (GP V)
The aryl amines (0.2 mmol) are put into syringes corked at their output and set with a frit at the bottom of their large section. A sol. of ester U-3 (0.05M) and of DIPEA (0.05M) in CH2C2 is prepared and added to the arylamines (4 mL for each amine); if the arylamine is a liquid, it is added at this stage only; if the arylamine is a salt, DIPEA (33 μL, 1 eq) is added. The sringes are tightly closed and shaken for 5 days. MeOH (2-4 mL) is added and the mixture is shaken for 6 h. The precipitate, if any, is isolated by sucking the solvent from the bottom of the syringes, washed with AcOEt and dried under high vacuum (P-fraction). The filtrate is washed with sat. NaHCO3/H2O (1×) and an aq. buffer sol. at pH4 (1×); each time, the aq. phase is pipetted out of the seringe. If a precipitate appeared during the work-up, it is filtered and dried (WU-fraction). The filtrate is blown down with a nitrogen stream, AcOEt (4 mL) is added and the mixture heated to 65° C. for 30 min. and cooled to 0° C. The solvent is pipetted out and the residue dried under high vacuum (T-fraction). The org. phase is blown down and the residue dried under high vacuum as well (S-fraction). The degree of hydration of the obtained products was not determined.
PREPARATION 43 Hydrolysis of the Tert-butyl Esters to the Carboxylic Acids (GP VI)
tert-Butyl ester is dissolved in TFA at 0° C. and the solution stirred for 4 h at r.t. The solvent is removed under reduced pressure and the residue triturated in hot EtOH (95%). After cooling down to r.t. or 0° C., the precipitated is filtered, washed with AcOEt and dried under high vacuum.
PREPARATION 44 8-{[(2,2,2-Trichloroethoxy)carbonyl]oxy}-7-quinolinecarboxylic Acid Anhydride with 2,2,2-trichloroethyl Hydrogen Carbonate (U-1)
In a flame-dried flask, 8-hydroxy-7-quinolinecarboxylic acid (2.00 g) is suspended into CH2Cl2 (100 mL) and DIPEA (3.70 mL) is added. The mixture is stirred until homogeneity is reached and cooled to 0° C. Trichloroethyl chloroformate (3.00 mL) is added and the solution is stirred for 3 h at 0° C., then stirred for another hour while allowed to warm up slowly to r.t. The solution is washed with 1M HCl/H2O (1×), dried over Na2CO3 and the solvent removed under reduced pressure. Crystallization of the residue from CHCl3/hexanes yields the desired product (5.20 g).
Physical characteristics are as follows:
mp: 133-4° C.; 1H-NMR (CDCl3, 300 MHz) δ 9.05, 8.26, 8.11, 7.88, 7.61, 4.97, 4.95. 13C-NMR (CDCl3, 75 MHz) δ: 157.56, 152.13, 151.59, 149.25, 147.71, 141.09, 135.82, 132.64, 126.57, 126.45, 124.44, 119.67, 93.96, 93.42. MS (FAB) m/z 538, 540 and 542 (MH+), 172. HRMS (FAB): found: 537.8609. Anal. Found: C, 35.12; H, 1.85; N, 2.65.
PREPARATION 45 8-Acetoxy-7-quinolinecarboxylic Acid (U-2)
This compound is prepared according to literature procedure. (German Patent No. 540842, Dec. 10, 1931.)
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 13.35, 8.99, 8.46, 8.00, 7.95, 7.67, 2.38. 13C-NMR (d6-DMSO, 75 MHz) δ 172.46, 169.22, 166.21, 152.08, 147.95, 141.42, 136.61, 131.35, 127.08, 126.13, 124.07, 21.20.
PREPARATION 46 7-(Fluorocarbonyl)quinolin-8-yl Acetate (U-3)
In a flame-dried flask under Ar, 8acetoxy-7-quinolinecarboxylic acid U-2(4.30 g) is suspended into CH2Cl2 (110 mL). Pyridine (1.50 mL) is added and the suspension cooled to −40° C. Cyanuric fluoride (3.00 mL) is added and the mixture stirred for 3 h, while the temperature rose slowly to 0° C. Ice and water and CH2Cl2 (100 mL) were added. Phases were shaken, separated and the aq. phase extracted with CH2Cl2 (1×). The combined org. phases were dried over MgSO4, filtered, and the solvent is removed under reduced pressure. Crystallization of the residue from hexanes yields ester U-3 as white needles (4.10 g).
Physical characteristics are as follows:
mp: 130-132° C.; 1H-NMR (CDCl3, 300 MHz) δ 9.05, 8.22, 8.02, 7.80, 7.58, 2.58. 13C-NMR (CDCl3, 75 MHz) δ 169.06, 156.59, 151.89, 141.42, 136.07, 132.92, 126.77, 126.03, 124.41, 118.10, 117.30, 20.88. MS (FAB) m/z 234 (MH+), 192, 172. HRMS (FAB): 234.0569. Anal. C, 60.98; H, 3.55; N, 6.24.
PREPARATION 47 2-Amino-5-bromo-1,3,4-thiadiazole (W-95) (Refer to Chart W.)
To a stirred sol. of 2-amino-1,3,4-thiadiazole (40.5 g) in acetic acid (250 mL) is added bromine (22.7 ml) over about 20 minutes. The flask is surrounded by an ice bath during the addition to maintain the reaction temperature near 25° C. Following the addition, the ice bath is removed and the clear red sol. stirred at r.t. for 18 hours, then added to 1L of cracked ice. Excess bromine is quenched with 10% NaHSO3/H2O and 40 ml of 50% NaOH/H2O is added. The precipitated solid is isolated by filtration and washed well with water, then dissolved in 300 ml of water containing 40 ml conc. HCl. The solution is filtered from a small amount of solid, then 87 g of K2HPO4 in a small quantity of water is added. The resulting slurry is chilled in ice and filtered, and the solid washed well with water. Recrystalization of the product from 400 ml of ethanol provides thiadiazole W-95 (26.3 g) as tan crystals.
Physical characteristics are as follows:
1H-NMR (d6-DMSO) δ 7.51.
PREPARATION 48 2-Amino-5-(2-phenylethyl)amino-1,3,4-thiadiazole (W-96) (Refer to Chart W.)
A mixture of 2-amino-5-bromo-1,3,4-thiadiazole W-95 (360 mg), of phenethylamine (0.38 mL) and of K2HPO4 (522 mg) in DMF (2 mL) is heated under nitrogen at 100° C. for 2 h, then partitioned between water and AcOEt. The organic phase is washed with water and brine, dried over MgSO4, and concentrated under reduced pressure. FC (MeOH/CH2Cl2 5:95) provides thiadiazole W-96 (261 mg). Recrystallization of 238 mg of this from acetonitrile/toluene affords 205 mg of fine white crystals.
Physical characteristics are as follows:
mp: 156-157° C.; 1H-NMR δ 2.92, 3.50, 7.2-7.3. IR 3186, 1565, 1505 cm−1 EI MS m/z 221 Anal. Found: C, 54.51; H, 5.47; N, 25.26; S, 14.30.
PREPARATION 49 2-Amino-5-butylamino)-1,3,4-thiadiazole (W-97) (Refer to Chart W.)
To a stirred, cooled (0° C.) mixture of 2-amino-5-bromothiadiazole W-95 (5.40 g) and of K2HPO4 (5.7 g) in DMF (20 mL) is added n-butylamine (5.9 ml). The ice bath is removed and the mixture stirred at room temperature for 18 h, then partitioned between water and AcOEt. Continuous extraction with CH2Cl2 is necessary to remove all product from the aqueous phase. The combined organic phase is dried over MgSO4 and concentrated under reduced pressure. FC (MeOH/CH2Cl2 7:93) provides thiadiazole W-97 (3.49 g). Recrystallization from acetonitrile/toluene affords 3.34 g of white needles.
Physical characteristics are as follows:
mp: 152-154° C.; 1H-NMR δ 0.94, 1.4, 1.6, 3.21, 3.6. IR 3184, 2957, 1562, 1507 cm−1 EI MS m/z 173
PREPARATION 50 2-Amino-5-([2-[(tert-butoxy)amido]ethyl}amino)-1,3,4-thiadiazole (W-98) (Refer to Chart W.)
A mixture of 2-amino-5-bromo-1,3,4-thiadiazole W-95 (5.40 g), of K2HPO4 (7.84 g) and Boc-ethylenediamine (9.60 g) in DMF (20 mL) is stirred at r.t. for 18 h. The solid paste obtained is recrystallized from acetonitrile/water to provide thiadiazole W-98 (6.18 g) as pink platelets.
Physical characteristics are as follows:
mp: 219-220° C.; 1H-NMR (CD3OD) δ 1.40, 3.2-3.3. IR 2989, 1676, 1577, 1512, 1366 cm−1 EI MS m/z 260
PREPARATION 51 Amino-1,3-benzodioxol-5-ylacetonitrile (W-99) (Refer to Chart W.)
Piperonal (6.00 g) is dissolved in THF (25 mL) and aq. NH3 (58%, 4.2 mL), NH4Cl (3.3 g) and KCN (3.9 g) are added. The mixture is stirred efficiently for 24 h. MgSO4 is added and the mixture stirred for 30 min., filtered and washed with THF The filtrate is evaporated under reduced pressure and the residue purified by FC (Et2O/petrol ether 1:2,→2:1,→Et2O). Aminonitrile W-99 is obtained as a brown, unstable oil (2.87 g). The hydrochloride salt is precipitated from sat. HCl/Et2O for analytical purposes.
Physical characteristics are as follows:
Free amino nitrile: Rf=0.45 (AcOEt/hexanes 1:1). Hydrochloride salt: mp: 159-164° C. (dec). 1H-NMR (D2O, 300 MHz) δ 7.03, 7.02, 6.88, 5.96, 5.58. 13C-NMR (D2O, 75 MHz) δ 149.43, 148.22, 122.80, 121.74, 115.21, 109.16, 108.00, 102.07. MS (EI) m/z 176 (M+), 160, 150, 122. Anal. Found: C, 50.59; H, 4.25; N, 12.90.
PREPARATION 52 [(2-Amino-1,3,4-thiadiazol-5-yl)amino]-1,3-benzodioxol-5-ylacetonitrile (W-100) (Refer to Chart W.)
According to GP I starting from thiadiazole W-95 (2.70g), aminonitrile W-99 (2.39 g) and DIPEA (2.70 mL) in DMF (60 mL), the product is purified by FC (AcOEt/hexanes 3:1→AcOEt). Nitrile W-100 is isolated as a brown powder (1.70 g).
Physical characteristics are as follows:
Rf=0.10 (AcOEt/hexanes 1:1). mp: 144° C. (dec). 1H-NMR (CD3OD, 300 MHz) δ 7.06, 7.02, 6.87, 5.99, 5.74. 13C-NMR (CD3OD, 75 MHz) δ 162.92, 158.60, 148.61, 148.39, 127.48, 120.91, 117.95, 108.07, 107.34, 101.66. HRMS (EI) 275.0461.
PREPARATION 53 N-(2-Amino-1,3,4-thiadiazol-5-yl)phenylalanine Methyl Ester (W-101) (Refer to Chart W.)
According to GP I starting from thiadiazole W-95 (1.50 g), phenylalanine methyl ester hydrochloride (1.80 g) and DIPEA (4.20 mL) in DMF (30 mL), the product is purified by FC (AcOEt/hexanes 3:1→AcOEt). Ester W-101 is obtained as a white powder (0.22 g).
Physical characteristics are as follows:
Rf=0.05 (AcOEt/hexanes 1:1). mp: 186-189° C.; 1H-NMR (CD3OD, 300 MHz) δ 7.27-7.09, 4.57, 3.67, 3.17, 3.01. 13C-NMR (CD3OD, 75 MHz) δ 172.74, 161.75, 160.65, 136.77, 128.85, 128.02, 126.45, 58.07, 51.16, 37.48. MS (EI) m/z: 278 (M+), 219, 187, 155, 127, 116. Anal. Found: C, 51.61; H, 4.98; N, 19.91.
PREPARATION 54 N-(2-Amino-1,3,4-thiadiazol-5-yl)-D-phenylalanine Methyl Ester (W-102) (Refer to Chart W.)
According to GP I starting from thiadiazole W-95 (1.50 g), D-phenylalanine methyl ester hydrochloride (1.80g) and DIPEA (4.20 mL) in DMF (30 mL), the product is purified by FC (AcOEt/hexanes 3:1→AcOEt). Ester W-102 is obtained as a white powder (0.19 g).
Physical characteristics are as follows:
Rf=0.05 (AcOEt/hexanes 1:1). mp: 186-189° C.; 1H-NMR (CD3OD, 300 MHz) δ 7.26-7.19, 4.57, 3.66, 3.17, 3.01. 13C-NMR (CD3OD, 75 MHz) δ 172.77, 161.75, 160.66, 136.76, 128.86, 128.03, 126.46, 58.07, 51.19, 37.48. MS (EI) m/z: 278 (M+), 219, 187, 155, 127, 116. Anal. Found: C, 51.57; H, 5.14; 19.86.
PREPARATION 55 2-(1,3-Benzodioxol-5-yl)glycine (W-103) (Refer to Chart W.)
Prepared according to literature procedure (E H W Boehm, R E Bambury, R J Baumann, R C Erickson, B L Harrison, P F Hoffman, F J McCarty, R A Schnettler, M J Vaal, D L Wenstrup, J. Med. Chem. 1980, 23, 405).
Physical characterstics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 6.22, 6.84, 5.97, 4.10. MS (EI) m/z 195 (M+), 150, 123, 93. HRMS (EI) 195.0530.
PREPARATION 56 2-(1,3-Benzodioxol-5-yl)glycine Tert-butyl Ester (W-104) (Refer to Chart W.)
2-(1,3-Benzodioxol-5-yl)glycine W-95 (5.00 g) is dissolved in a dioxane (50 mL) and conc. H2SO4 (3.90 mL) mixture. Liquid i-butylene (50 mL) is added, the flask rapidly tightly closed and shaken for 24 h. The mixture is poored into a mixtue of 1M NaOH/H2O, ice and AcOEt. After shaking, the phases are separated and the aq. phase is extracted with AcOEt (1×). The combined org. phases are dried over MgSO4. Removing the solvent under reduced pressure yields an oil containing 77% (1H-NMR) of ester W-104 (6.65 g, 5.10 g of product).
Physical characteristics are as follows:
1H-NMR (CDCl3, 300 MHz) δ 6.85-6.80, 6.74, 5.94, 4.42, 1.37.
PREPARATION 57 N-(2-Amino-1,3,4-thiadiazo-5-yl)-2-(1,3-benzodioxol-5-yl)glycine Tert-butyl Ester (W-105) (Refer to Chart W.)
According to GP I starting from thiadiazole W-95 (3.65 g), tert-butyl ester V-104 (5.10 g), DIPEA (6.8 mL) and DMF (150 mL). Crystallization of the crude from AcOEt/hexanes yieldsester W-105 as a white powder (6.15 g).
Physical characteristics are as follows:
Rf=0.05 (AcOEt/hexanes 1:1). 1H-NMR (d6-DMSO, 300 MHz), δ 7.42, 6.92-6.86, 6.26, 5.99, 5.05, 1.30. 13C-NMR (d6-DMSO, 75 MHz) δ 170.70, 160.60, 158.81, 147.73, 147.43, 131.33, 121.48, 108.67, 108.10, 101.61, 81.33, 61.03, 28.00. MS (EI) m/z 350 (M+), 249, 179, 148, 57. HRMS (EI) 350.1043.
PREPARATION 58 2-(1,3-Benzodioxol-4-yl)glycine (W-106) (Refer to Chart W.)
Prepared according to literature procedure (E H W Boehm, R E Bambury, R J Baumann, R C Erickson, B L Harrison, P F Hoffman, F J McCarty, R A Schnettler, M J Vaal, D L Wenstrup, J. Med. Chem. 1980, 23, 405).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 6.62, 6.00, 5.97, 4.23. MS (EI) m/z 195 (M+), 150, 123, 93, 75. HRMS (EI) 195.0527.
PREPARATION 59 2-(1,3-Benzodioxol-4-yl)glycine Tert-butyl Ester (W-107) (Refer to Chart W.)
2-(1,3-Benzodioxol-4-yl)glycine W-106 (1.72 g) is dissolved in a dioxane (20 mL) and conc. H2SO4 (1.35 mL) mixture. liquid i-butylene (20 mL) is added, the flask rapidly tightly closed and shaken for 24 h. The mixture is poored in a mixture of 1M NaOH/H2O, ice and AcOEt. After shaking, the phases are separated and the aq. phase is extracted with AcOEt (1×). The combined org. phases are dried over MgSO4. Removing the solvent under reduced pressure yields an oil containing 78% (1H-NMR) of ester W-107 (1.46 g, 1.14 g of product).
Physical characteristics are as follows:
1H-NMR (CDCl3, 300 MHz) δ 6.79-6.72, 5.97, 5.94, 4.57, 1.39.
PREPARATION 60 N-(2-Amino1,3,4-thiadiazo-5-yl)-2-(1,3-benzodioxol-4-yl)glycine Tert-butyl Ester (W-108) (Refer to Chart W.)
According to GP I starting from thiadiazole W-95 (0.83 g), 2-(1,3-benzodioxol-4-yl)glycine tert-butyl ester W-107 (1.14 g), DIPEA (1.5 mL) and DMF (30 mL). Crystallization of the crude from AcOEt/hexanes yields ester W-108 as a white powder (0.87 g).
Physical characteristics are as follows:
Rf=0.05 (AcOEt/hexanes 1:1). 1H-NMR (d6-DMSO, 300 MHz) δ 7.52, 6.90-6.78, 6.42, 6.03, 6.02, 5.30, 1.32. 13C-NMR (d6-DMSO, 75 MHz) δ 169.83, 160.87, 158.70, 147.55, 145.68, 122.18, 120.39, 119.02, 108.77, 101.50, 81.61, 55.41, 27.99. MS (EI) m/z 250 (M+), 249, 233, 148, 57. Anal. Found: C, 51.05; H, 5.35; N, 15.91.
PREPARATION 61 2-Amino-5-[N-(1,3-benzodioxol-5-ylmethyl)amino]-1,3,4-thiadiazole (X-109) (Refer to Chart XI)
According to GP I starting from thiadiazole W-95 (1.00 g), piperonylamine (0.83 mL), DIPEA (1.85 mL) and DMF (10 mL). Purification of the crude by FC (AcOEt→MeOH/AcOEt 1:19→MeOH/CH2Cl2 1:9) yields thiadiazole X-109 as a white powder (99 mg).
Physical characteristics are as follows:
Rf=0.02 (AcOEt/hexanes 1:1). mp: 164-187° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 7.18, 6.87, 6.83, 7.78, 6.24, 5.96, 4.20. 13C-NMR (d6-DMSO, 75 MHz) δ 160.32, 159.77, 147.62, 146.55, 133.78, 121.20, 108.56, 108.42, 101.25, 47.73. MS (EI) m/z 250 (M+), 208, 135, 105, 77,51. HRMS (EI) 250.0528.
PREPARATION 62 N-(2-Amino-1,3,4-thiadiazol-5-yl)tyrosine Tert-butyl Ester (X-110) (Refer to Chart X)
According to GP I starting from thiadiazole W-95 (760 mg), tyrosine tert-butyl ester hydrochloride (1.16 g), DIPEA (1.80 mL) and DMF (20 mL). Crystallization of the crude from AcOEt/hexanes yields ester X-110 as a white powder (0.98 g).
Physical characteristics are as follows:
Rf=0.25 (AcOEt). mp: 121-123° C.; 1H-NMR (CD3OD, 300 MHz) δ 8.20, 7.27, 6.93, 4.60, 3.08, 1.60. 13C-NMR (CD3OD, 75 MHz) δ 171.71, 161.65, 160.84, 155.95, 130.07, 127.47, 114.68, 81.37, 59.02, 36.85, 26.81. MS (EI) m/z 336 (M+), 263, 235, 173, 156, 116, 107, 57. HRMS (EI) 336.1259.
PREPARATION 63 N1-(2-Amino-1,3,4-thidiazol-5-yl)-N5-[(benzoy)carbonyl]lysine Tert-butyl Ester (X-111) (Refer to Chart X.)
According to GP I starting from thiadiazole W-95 (730 mg), N5-[(benzoxy)carbonyl]lysine tert-butyl ester hydrochloride (1.50 g), DIPEA (2.05 mL) and DMF (25 mL). Crystallization of the crude from AcOEt/hexanes yields ester X-111 as a white powder (0.96 g).
Physical characteristics are as follows:
Rf=0.25 (AcOEt). mp: 131-132° C.; 1H-NMR (CD3OD, 300 MHz) δ 7.33, 5.05, 4.13, 3.10, 1.95-1.45, 1.44. 13C-NMR (CD3OD, 75 MHz) δ 172.40, 161.58, 161.15, 157.53, 137.04, 128.06, 127.54, 127.36, 81.29, 65.92, 57.39, 40.09, 29.11, 26.89, 22.63, 19.24. Anal. Found: C, 55.08; H, 6.69; N, 16.22.
PREPARATION 64 N-(2-Amino-1,3,4-thiadiazol-5-yl)leucine Tert-butyl Ester (X-112) (Refer to Chart X)
According to GP I starting from thiadiazole W-95 (1.00 g), leucine tert-butyl ester hydrochloride (1.50 g), DIPEA (2.80 mL) and DMF (10 mL). Purification of the crude by FC (AcOEt/hexanes 1:1→AcOEt) yields ester X-112 as a white powder (1.06 g).
Physical characteristics are as follows:
Rf=0.20 (AcOEt). mp: 138-141° C.; 1H-NMR (CD3OD, 300 MHz) δ 4.38, 2.01, 1.82, 1.65, 1.18. 13C-NMR (CD3OD, 75 MHz); two rotamers visible δ 176.62, 172.89, 172.71, 163.47, 162.05, 160.64, 81.20, 72.76, 56.05, 42.83, 40.87, 35.58, 30.27, 26.86, 24.77, 21.87, 20.65. MS (EI) m/z 286 (M+), 269, 230, 213, 185, 156, 143, 129, 116, 57. HRMS (EI) 286.1461.
PREPARATION 65 N-(2-Amino-1,3,4-thiadiazol-5-yl)proline Tert-butyl Ester (X-113) (Refer to Chart X)
According to GP I starting from thiadiazole W-95 (1.00 g), proline tert-butyl ester hydrochloride (1.46 g), DIPEA (2.80 mL) and DMF (10 mL). Purification of the crude by FC (AcOEt/hexanes 1:1→AcOEt) yields ester X-113 as a white powder (0.55 g).
Physical characteristics are as follows:
Rf=0.25 (AcOEt). mp: 141-146° C.; 1H-NMR (CD3OD, 300 MHz) δ 4.20, 3.58-3.41, 2.37-2.31, 2.09-2.01, 1.45. 13C-NMR (CD3OD, 75 MHz) δ 171.91, 161.09, 160.95, 81.64, 63.13, 50.45, 30.29, 26.79, 23.45. MS (EI) m/z 270 (M+), 214, 197, 169, 142, 128, 100, 70, 57. HRMS (EI) 270.1154.
PREPARATION 66 N-(2-Amino-1,3,4-thiadiazol-5-yl)methionine Tert-butyl Ester (X-114) (Refer to Chart X.)
According to GP I sting from thiadiazole W-95 (750 mg), methionine tert-butyl ester hydrochloride (1.00 g), DIPEA (2.10 mL) and DMF (20 mL). Crystallization of the crude from AcOEt/hexanes yields ester X-114 as a white powder (0.60 g).
Physical characteristics are as follows:
Rf=0.25 (AcOEt). mp: 172-173° C.; 1H-NMR (CD3OD, 300 MHz) δ 4.31, 2.62-2.56, 2.16-1.92, 2.08, 1.45. 13C-NMR (CD3OD, 75 MHz) δ 172.04, 161.71, 161.09, 81.47, 56.52, 31.38, 29.75, 26.87, 13.85. MS (EI) m/z 304 (M+), 257, 258, 248, 231, 203, 185, 155, 141, 128, 100, 57. Anal. Found: C, 43.59; H, 6.59; N, 18.55.
PREPARATION 67 N-(2-Amino-1,3,4-thiadiazol-5-yl)tryptophane Tert-butyl Ester (X-115) (Refer to Chart X.)
According to GP I starting from thiadiazole W-95 (610 mg), tryptophane tert-butyl ester hydrochloride (1.00 g), DIPEA (1.70 mL) and DMF (20 mL). The crude ester X-115 is dried under high vacuum (0.86 g).
Physical characteristics are as follows:
Rf=0.25 (AcOEt). 1H-NMR (CD3OD, 300 MHz) δ 7.55, 7.31, 7.09-6.99, 4.54, 3.31-3.21, 1.29. 13C-NMR (CD3OD, 75 MHz) δ 173.95, 172.07, 163.45, 161.62, 160.98, 136.56, 127.54, 123.11, 120.95, 118.31, 110.78, 81.22, 58.40, 35.54, 30.23, 26.78. MS (EI) m/z 359 (M+), 243, 187, 130, 57. HRMS (EI) 359.1399.
PREPARATION 68 N-(2-Amino-1,3,4-thiadiazol-5-yl)-O7-tert-butyltyrosine Tert-butyl Ester (X-116) (Refer to Chart X)
According to GP I starting from thiadiazole W-95 (580 mg), O7-tert butyltyrosine tert-butyl ester hydrochloride (1.00 g), DIPEA (1.65 mL) and DMF (20 mL). Crystallization of the crude from AcOEt/hexanes yields ester X-116 as a white powder (0.89 g).
Physical characteristics are as follows:
Rf=0.35 (AcOEt). mp: 149-151° C.; 1H-NMR (CD3OD, 300 MHz) δ 7.15, 6.90, 4.42, 3.03, 2.89, 1.35, 1.30. 13C-NMR (CDCl3, 75 MHz) δ 171.58, 161.69, 160.74, 153.91, 132.01, 129.66, 123.79, 81.45, 78.13, 58.82, 37.10, 27.80, 26.85. MS (EI) m/z 392 (M+), 276, 235, 220, 173, 164, 116, 107, 57. HRMS EI) 392.1885. Anal. Found: C, 57.96; H, 7.25; N, 13.80.
PREPARATION 69 N-(2-Amino-1,3,4-thiadiazol-5-yl)aspartic Acid Di-tert-butyl Ester (X-117) (Refer to Chart X.)
According to GP I starting from thiadiazole W-95 (640 mg), aspartic acid di-tert-butyl ester hydrochloride (1.00 g), DIPEA (1.80 mL) and DMF (20 mL). Crystallization of the crude from AcOEt/hexanes yields ester X-117 as a white powder (0.84 g).
Physical characteristics are as follows:
Rf=0.30 (AcOEt). mp: 142-146° C.; 1H-NMR (CD3OD, 300 MHz) δ 4.50, 2.81, 2.71, 1.45, 1.44. 13C-NMR (CD3OD, 75 MHz) δ 170.46, 169.90, 161.85, 160.75, 81.75, 81.00, 54.20, 37.39, 26.94, 26.83. MS (EI) m/z 344 (M+), 288, 232, 215, 187, 143, 57. HRMS (EI) 344.1512.
EXAMPLE 243 8-Hydroxy-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-7-quinolinecarboxamide (Y-118) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (50 mg), pyridinium chloride (10.8 mg), 2-amino-5-(trifluoromethyl)-1,3,4-thiadiazole (15.7 mg) and CHCl3 (2 mL), amide Y-118 precipitates as a yellow powder without adding any aq. 1M HCl sol. (16.5 mg).
Physical characteristics are as follows:
mp: 300-302° C. (dec). 1H-NMR (d6-DMSO, 300 MHz) δ 8.88, 8.08, 7.96, 7.14. 13C-NMR (d6-DMSO, 75 MHz) δ 165.70, 163.15, 162.17, 144.83, 142.72, 5.49, 133.44, 130.08, 124.58, 112.61, 109.85. MS (EI) m/z 340 (M+), 172, 116, 89, 63. HRMS (E1) 340.0234. Anal. Found: C, 45.45; H, 2.25; N, 16.33.
EXAMPLE 244 N-(5-Bromo-1,3,4-thiadiazol-2-yl)-8-hydroxy-7-quinolinecarboxamide (Y-119) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (100 mg), pyridinium chloride (21.4 mg), 2-amino-5-bromo-1,3,4-thiadiazole W-95 (43 mg) and H2ClCH2HCl (2 mL), amide Y-119 precipitate as an orange powder without adding any aq. 1M HCl sol. (56 mg).
Physical characteristics are as follows:
mp: 250° C. (dec). 1H-NMR (d-TFA, 300 MHz) δ 9.35, 9.30, 8.67, 8.37, 8.03. MS (EI) m/z 350 and 352 (M+), 271, 172, 116, 89, 63. HRMS (EI) 349.9469. Anal. Found: C, 41.88; H, 2.31; N, 14.46.
EXAMPLE 245 8-Hydroxy-N-[5-(2-phenylethyl)amino-1,3,4-thiadiazol-2-yl]-7-quinolinecarboxamide Monohydrochloride (Y-120) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (50 mg), pyridinium chloride (10.8 mg), 2-amino-5-(2-phenylethyl)amino-1,3,4-thiadiazole W-96 (20.5 mg) and. CHCl3 (2 mL), amide Y-120 is obtained as a yellow powder (20 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.93, 8.84, 8.07, 7.90, 7.35-7.10, 3.58, 2.91. 13C-NMR (d6-DMSO, 75 MHz) δ 166.62, 163.52, 160.78, 144.45, 143.73, 138.88, 134.85, 132.99, 129.60, 129.31, 128.88, 126.92, 124.48, 113.69, 111.70, 46.39, 34.45. MS (EI) m/z 357 (M+), 186, 172, 116, 89. HRMS (EI) 392.1181.
EXAMPLE 246 N-[5(Butylamino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarbomide Monohydrochloride (Y-121) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (50 mg), pyridinium chloride (10.8 mg), 2-amino-5-(butylamino)-1,3,4-thiadiazole W-97 (16.0 mg) and CHC3 (2 mL), amide Y-121 is obtained as a yellow powder (22 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.90, 8.07, 7.97, 7.25, 3.35, 1.58, 1.36, 0.90. 13C-NMR (d6-DMSO, 75 MHz), δ 166.52, 163.64, 160.67, 145.13, 143.23, 134.55, 133.17, 129.81, 127.79, 124.57, 113.40, 111.07, 45.12, 30.37, 19.87, 14.00. HRMS (EI) 343.1084.
EXAMPLE 247 N-[5-({2-[(tert-Butoxy)amido]ethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (Y-122) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (50 mg), pyridinium chloride (10.8 mg), 2-amino-5-({2-[(tert-butoxy)amido]ethyl}amino)-1,3,4-thiadiazole W-98 (24 mg) and CHCl3 (2 mL), 1M HCl/H2O is not added, but the sol. diluted in some CHCl3, washed with an aq. buffer sol. at pH 4 (1×), dried over MgSO4, filtered and the solvent removed under reduced pressure. Purification of the residue by FC (AcOEt→MeOH/CH2Cl2 1:9) leads to amide Y-122 as a yellow powder (15 mg).
Physical characteristics are as follows:
1H-NMR (CD3OD, 300 MHz) δ 8.95, 8.83, 8.25, 7.95, 7.43, 3.49, 3.31, 1.43. 13C-NMR (d6-DMSO, 75 MHz), δ 168.49, 166, 163.84, 156.12, 146.36, 138.73, 135.28, 132.47, 130.75, 128.27, 123.60, 113.14, 111.63, 78.15, 44.09, 36.25, 28.70. MS (FAB) m/z 431 (MH+), 260, 204, 172, 57. HRMS (FAB) 431.1494.
EXAMPLE 248 N-{5-[(1,3-Benzodioxol-5-cyanomethyl)amino]-1,3,4-thiadiazol-2-yl}-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (Y-123) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (100 mg), pyridinium chloride (21.4 mg), 2-amino-1,3,4-thiadiazol-5-yl)anino]-1,3-benzodioxol-5-ylacetonitrile W-100 (51.0 mg), CHCl3 (4 mL) and THF (0.4 mL), amide Y-123 is obtained as a yellow powder (35 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 9.00, 8.89, 8.77, 8.14, 7.98, 7.43, 7.14, 7.11, 7.00, 6.07, 6.02. 13C-NMR (d6-DMSO, 75 MHz) δ 179.5, 160.81, 148.47, 148.22, 145.03, 144.09, 142.28, 134.05, 132.50, 129.37, 127.79, 124.43, 121.88, 118.98, 115.41, 114.28, 109.01, 108.42, 102.07, 60.87, 48.17. MS (FAB) m/z 447 (MH+), 276, 172. HRMS (FAB) 447.0866.
EXAMPLE 249 (S)-N-[5-({Benzyl[(methoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (Y-124) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), N(2-amino-1,3,4-thiadiazo-5yl)phenylalanine methyl ester W-101 (103 mg), and CHCl3 (8 mL), amide Y-124 is obtained as a yellow powder (100 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.98, 8.86, 7.50, 8.12, 7.94, 7.40, 7.27, 4.59, 3.14, 3.06. 13C-NMR (d6-DMSO, 75 MHz) δ 172.18, 167.06, 162.24, 145.07, 143.62, 137.14, 134.41, 132.52, 129.65, 129.27, 128.81, 127.23, 124.36, 115.11, 113.94, 58.44, 52.56, 37.4. MS (EI) m/z 449 (M+), 390, 372, 358, 287, 187, 172, 116. HRMS (FAB) 450.1233.
EXAMPLE 250 (R)-N-[5-({Benzyl[(methoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrochloride (Y-125) (Refer to Chart Y)
According to GP II, starting from anhydride U-1 (200 mg), pyridinium chloride (42 mg), N-(2-amino-1,3,4thiadiazo-5-yl)-D-phenylalanine methyl ester W-102 (103 mg), and CHCl3 (8 mL), amide Y-125 is obtained as a yellow powder (105 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.98, 8.86, 7.50, 8.12, 7.94, 7.40, 7.27, 4.59, 3.14, 3.06. 13C-NMR (d6-DMSO, 75 MHz) δ 172.18, 167.06, 162.24, 145.07, 143.62, 137.14, 134.41, 132.52, 129.65, 129.27, 128.81, 127.23, 124.36, 115.11, 113.94, 58.44, 52.56, 37.41. MS (EI) m/z 449 (M+), 390, 372, 358, 287, 187, 172, 116. HRMS (FAB) 450.1233.
EXAMPLE 251 N-[5-({1,3-Benzodioxol-5-yl-(tert-butoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Semihydrate (Y-126) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (131 mg), N-(2-amino-1,3,4-thiadiazo-5-yl)-2-(1,3-benzodioxol-5-yl)glycine tert-butyl ester W-105 (197 mg,), DIPEA (0.10 mL) and CH2Cl2 (6 mL). Stirred for 4 h, then overnight with MeOH. After adding MeOH, armide Y-126 precipitated as a yellow powder that is filtered and dried (120 mg).
Physical characteristics are as follows:
mp: 227-229° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 8.92, 8.63, 8.05, 7.77, 7.25, 6.97, 6.92, 6.02, 5.21, 1.33. 13C-NMR (d6-DMSO, 75 MHz), δ 169.80, 147.26, 147.04, 131.92, 130.28, 123.54, 121.02, 108.24, 107.65, 101.12, 81.04, 60.47, 27.43. MS (EI) m/z 521 (M+), 465, 447, 420, 249, 172, 56. HRMS (FAB) 522.1452. Anal. Found: 56.66; H, 4.49; N, 13.30.
EXAMPLE 252 N-[5-({1,3-Benzodioxol-4-yl-[(tert-butyloxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Semihydrate (Y-127) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (133 mg), N-(2-amino-1,3,4-thiadiazo-5-yl)-2-(1,3-benzodioxol4-yl)glycine tert-butyl ester W-108 (200 mg,), DIPEA (0.10 mL) and CH2Cl2 (6 mL), stirred for 4 h, then overnight with MeOH. The solution is diluted with some CH2Cl2, washed with sat. NaHCO3/H2O (1×) and an aq. buffer sol. at pH 4 (1×), an emulsion formed that separated slowly into two phases. The org. phase is dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue is triturated with AcOEt, filtered and dried. Amide Y-127 is obtained as a yellow powder (140 mg).
Physical characteristics are as follows:
1H-NME (d6-DMSO, 300 MHz) δ 8.88, 8.65, 8.20, 8.05, 7.83, 7.26, 7.00-6.30, 6.05, 5.42, 1.33. 13C-NMR (d6-DMSO, 75 MHz) δ 168.86, 159.12, 147.08, 145.22, 131.94, 128.37, 123.59, 121.77, 119.90, 117.96, 113.57, 108.53, 101.04, 81.36, 54.93, 27.41. MS (FAB) m/z 522 (MH+), 598, 466, 420, 249, 57. HRMS (FAB) 522.1447.
EXAMPLE 253 N-{5-[(1,3,-Benzodioxol-ylmethyl)amino]-1,3,4-thiadiazol-2-yl}-8-hydroxy-7-quinolinecarboxamide (Y-128) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (85 mg), 2-amino-5-[N-(1,3-benzodioxol-5-ylmethyl)amino]-1,3,4-thiadiazole X-109 (90 mg), DIPEA (70 μL) and CH2Cl2 (4 mL). Stirred for 20 h, then for 5 h with MeOH. After adding MeOH, a yellow precipitate appears, that is filtered and dried (40 mg); this precipitate proved to be the not quite pure amide Y-128 and was not further purified due to its low solubility.
Physical characteristics are as follows:
mp: 280-282° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 8.86, 8.53, 8.02, 7.85, 7.76, 7.22, 6.93, 6.85, 5.97, 4.34. 13C-NMR (d6-DMSO, 75 MHz), due to the low solubility of the product, an incomplete set of signals is obtained δ 147.72, 146.73, 133.15, 132.42, 123.95, 121.36, 121.23, 108.66, 108.54, 101.33. MS (EI) m/z 421 (M+), 270, 250, 208, 172, 150, 135, 116. HRMS (EI) 421.0827.
EXAMPLE 254 (S)-N-[5-({[(tert-Butoxy)carbonyl]-[4-hydroxybenzyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide (Y-129) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (500 mg), N-(2-amino-1,3,4-thiadiazol-5-yl)tyrosine tert-butyl ester X-110 (720 mg), DIPEA (0.36 mL) and CH2C2 (10 mL). Stirred for 7 h, then overnight with MeOH. The solvent is almost completely removed until a consistent precipitate appeared that is filtered, washed with AcOEt and MeOH and dried under high vacuum. The product obtained as a yellow powder (0.53 g) was a not unpurified mixture of amide Y-129 (80 mol % by 1H-NMR) and acetylated product (20 mol %).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.85, 8.54, 8.01, 7.90-7.70, 7.30-6.95, 4.60-4.30, 3.15-2.85, 1.31. MS (ES) m/z Neg. mode: 506 (MH+), 548 (acetylated product+H+).
EXAMPLE 255 (S)-N-[5-({5-Benzoxylamido-1-[(tert-butoxy)carbonyl]pentyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide (Y-130) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (500 mg)), N1-(2-amino-1,3,4-thiadiazol-5-yl)-N5-[(benzoxy)carbonyl]lysine tert-butyl ester X-111 (0.93 g), DIPEA (0.36 mL) and CH2Cl2 (10 mL). Stirred for 7 h, then overnight with MeOH. The solvent is almost completely removed until a consistent precipitate appears. It is filtered, washed with AcOEt and MeOH and dried. A yellow foam is obtained (0.50 g) that proved to contain about 90 mol % (1H-NMR) of amide Y-130.
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.76, 8.35, 7.95, 7.65-7.50, 7.35-7.20, 7.02, 4.98, 4.15-4.05, 2.97, 1.69, 1.38, 1.23. 13C-NMR (d6-DMSO, 75 MHz) δ 171.76, 162.63, 155.98, 145.51, 138.21, 137.14, 131.94, 128.22, 127.77, 127.61, 122.97, 122.41, 80.37, 64.99, 56.82, 53.39, 31.16, 28.96, 27.56, 22.57. MS (FAB) m/z 607 (MH+), 551, 288, 172. HRMS (FAB) 607.2345.
EXAMPLE 256 (S)-N-[5-({1-[(tert-Butoxy)carbonyl]-3-methylbutyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrate (Y-131) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (0.97 g)), N-(2-amino-1,3,4-thiadiazol-5-yl)leucine tert-butyl ester X-112 (1.18 g), DIPEA (0.70 mL) and CH2Cl2 (20 mL). Stirred for 7 h, then overnight with MeOH. Amide Y-131 appears as an orange precipitate that is filtered, washed with AcOEt and dried under high vacuum (440 mg).
Physical characteristics are as follows:
mp: 214-5° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 8.87, 8.61, 8.05, 7.83-7.65, 7.24, 4.14, 1.85-1.70, 1.65-1.50, 1.38, 0.92, 0.87. 13C-NMR (d6-DMSO, 75 MHz) δ 172.62, 165.76, 163.20, 159.98, 152.80, 145,62, 140.75, 137.60, 132.45, 128.73, 124.05, 113.91, 113.02, 80.99, 55.96, 40.96, 28.10, 24.95, 23.09, 19.01. MS (EI) m/z 457 (M+), 356, 345, 213, 172, 116, 89, 57. HRMS (EI) 457.1781. Kar-Fischer titration: 3.43% water (0.90 eq). Anal. Found: C, 55.53; H, 6.02; N, 14.59.
EXAMPLE 257 (S)-N-(5-{2-[(tert-Butoxy)carbonyl]pyrrolidin-N-yl}-1,3,4-thiadiazol-2-yl)-8-hydroxy-7-quinolinecarboxamide Semihydrate (Y-132) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (710 mg), N-(2-amino-1,3,4-thiadiazol-5-yl)proline tert-butyl ester X-113 (816 mg), DIPEA (0.51 mL) and CH2Cl2 (14 mL). Stirred for 7 h, then overnight with MeOH. Amide Y-132 is obtained as an orange precipitate that is filtered, washed with AcOEt and dried under high vacuum (955 mg).
Physical characteristics are as follows:
mp: Turned white between 220° C. and 250° C., then decomposed between 285° C. and 290° C. 1H-NMR (d6-DMSO, 300 MHz) δ 8.87, 8.65, 8.05, 7.82, 7.22, 4.28, 3.55-3.45, 2.40-2.20, 2.10-1.95, 1.39. 13C-NMR (d6-DMBO, 75 MHz) δ 171.57, 163, 160.42, 145.05, 141.5, 137, 132.56, 128.94, 124.10, 113.67, 112.29, 81.40, 62.74, 50.80, 30.66, 28.09, 24.04. MS (EI) m/z 441 (M+), 340, 172, 116, 57. HRMS (EI) 441.1472. Karl-Fischer titration: 2.09% water (0.55 eq). Anal. Found: C, 56.03; H, 5.32; N, 15.56.
EXAMPLE 258 (S)-N-[5-({1-[(tert-Butoxy)carbonyl]-3-[methylmercapto]propyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrate (Y-133) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (450 mg), N-(2-amino-1,3,4-thiadiazol-5yl)methionine tert-butyl ester X-114 (0.60 g), DIPEA (0.33 mL) and CH2Cl2 (10 mL). Stirred for 7 h, then overnight with MeOH. The orange-red amide Y-133 is filtered, washed with AcOEt and dried under high vacuum (0.60 g).
Physical characteristics are as follows:
mp: 204-205° C.; 1H-NMR (d6-DMSO, 300 MHz) δ 8.87, 8.61, 7.79, 7.23, 4.29, 2.57, 2.05, 2.05-1.90, 1.39. 13C-NMR (d6-DMSO, 75 MHz) δ 171.50, 162.89, 162.86, 159.75, 145.20, 140.35, 137.18, 137.14, 132.17, 128.47, 123.76, 113.55, 112.54, 80.98, 56.08, 31.19, 29.69, 27.70, 14.67. MS (EI) m/z 475 (M+), 401, 327, 270, 213, 172, 116, 61. HRMS (FAB) 476.1427. Karl-Fischer titration: 3.40% water (0.92 eq.). Anal. Found: C, 51.12; H, 5.46; N, 13.99.
EXAMPLE 259 (S)-N-[5-({1-[(tert-Butoxy)carbonyl]-2-indol-3-ylethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrate (Y-134) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (500 mg), N-(2-amino-1,3,4-thiadiazol-5-yl)tryptophane tert-butyl ester X-115 (770 mg), DIPEA (0.36 mL) and CH2Cl2 (10 mL). Stirred for 7 h, then overnight with MeOH. Amide Y-134 is obtained as a yellow precipitate that is filtered, washed with AcOEt and dried under high vacuum (0.52 g).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 10.90, 8.87, 8.58, 8.04, 7.84, 7.77, 7.53, 7.33, 7.23, 7.17, 7.06, 6.98, 4.48, 3.20-3.10, 1.27. 13C-NMR (d6-DMSO, 75 MHz) δ 171.77, 165.79, 162.99, 160.04, 152.93, 145.67, 140.62, 137.69, 136.57, 132.44, 128.70, 127.68, 124.34, 124.02, 121.44, 118.85, 118.77, 113.93, 113.04, 111.87, 109.91, 80.01, 58.39, 48.86, 27.98. MS (FAB) m/z 531 (MH+), 475, 288, 172. HRMS (FAB) 531.1841. Karl-Fischer titration: 2.61% water (0.79 eq.). Anal. Found: C, 59.24; H, 5.13; N, 15.13.
EXAMPLE 260 (S)-N-(5-{1-[(tert-Butoxy)carbonyl]-2-[4-(tert-butoxy)phenyl]ethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide monohydrate (Y-135) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (500 mg), N-(2-amino-1,3,4-thiadiazol-5-yl)-O7-tert-butyltyrosine tert-butyl ester X-116 (840 mg), DIPEA (0.36 mL) and CH2Cl2 (10 mL). Stirred for 7 h, then overnight with MeOH. The solvent is partially removed under reduced pressure until amide Y-135 appears as a consistent orange precipitate that is filtered and dried under high vacuum (0.80 g).
Physical characteristics are as follows:
mp: 124-125° C. (dec). 1H-NMR (d6-DMSO, 300 MHz) δ 8.84, 8.56, 8.02, 7.77, 7.75, 7.17, 6.87, 4.39, 2.97, 1.27, 1.23. 13C-NMR (d6-DMSO, 75 MHz) δ 170.95, 165.2, 162.29, 160.26, 153.53, 145.16, 139.66, 137.74, 131.91, 131.57, 129.74, 128.08, 123.45, 123.37, 113.19, 112.07, 80.57, 77.59, 58.36, 36.77, 28.39, 27.43. MS (FAB) m/z 564 (MH+), 508, 337, 281, 172, 57. HRMS (FAB) 564.2280. Karl-Fischer titration: 2.25% water (0.72 eq.); Anal. Found: C, 59.75; H, 6.01; N, 12.07.
EXAMPLE 261 (S)-N-[5-({1,2-Di-[(tert-butoxy)carbonyl]ethyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide Monohydrate, (Y-136) (Refer to Chart Y)
According to GP IV, starting from ester U-3 (500 mg), N-(2-amino-1,3,4-thiadiazol-5-yl)aspartic acid di-tert-butyl ester X-117 (740 mg), DIPEA (0.36 mL) and CH2Cl2 (10 mL). Stirred for 7 h, then overnight with MeOH. The solvent is removed under reduced pressure until amide Y-136 precipitates as a fine orange powder that is shortly triturated with MeOH, filtered and dried under high vacuum (0.73 g).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.87, 8.62, 8.04, 7.81, 7.22, 4.54, 2.77, 2.67, 1.38. 13C-NMR (d6-DMSO, 75 MHz) δ 169.80, 169.02, 164.80, 162.45, 159.55, 144.98, 140.43, 131.93, 128.22, 126.74, 123.52, 113.30, 112.28, 81.05, 80.44, 53.60, 37.24, 27.60, 27.48. MS (EI) m/z 515 (M+), 459, 358, 172, 116, 57. HRMS (EI) 535.1826. Karl-Fischer titration: 2.80% (0.82 eq.); Anal. Found: C, 53.75; H, 5.71; N, 13.23.
EXAMPLE 262 N-{2-[(8-Hydroxyquinolin-7-yl)amido]-1,3,4-thiadiazol-5-yl}-2-benzo-1,3-dioxol-5-ylglycine Monohydrotrifluoroacetate (Z137) (Refer to Chart Z.)
According to GP VI starting from N-[5-({1,3-benzodioxol-5-yl-[(tert-butoxy)carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide semihydrate Y-126 (72 mg) and TFPA (10 mL). Acid Z-137 is obtained as a yellow powder (68 mg).
Physical characteristics are as follows:
mp: 220-230° C. (dec). 1H-NMR (d6-DMSO, 300 MHz) δ 8.90, 8.67, 8.22, 8.07, 7.84, 7.29, 7.00, 6.93, 6.01, 5.24. 13C-NMR (d6-DMSO, 75 MHz) δ: 172.39, 166.26, 162.22, 159.24, 154.22, 147.86, 147.64, 145.37, 141.93, 136.35, 132.47, 131.10, 128.93, 124.17, 121.66, 114.40, 113.39, 108.78, 108.33, 101.69, 60.44. MS (FAB) m/z 466 (MH+), 288, 123. HRMS (FAB) 466.0826.
EXAMPLE 263 N-{2-[(8-Hydroxyquinolin-7-yl)amido]-1,3,4-thiadiazol-5-yl}-2-benzo-1,3-dioxol-4-ylglycine Monohydrotrifluoroacetate (Z-138) (Refer to Chart Z.)
According to GP VI starting from N-[5-({1,3-benzodioxol-4-yl-[(tert-butoxy)-carbonyl]methyl}amino)-1,3,4-thiadiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide semihydrate Y-127 (80 mg) and TFA (10 mL). Acid Z-138 is obtained as a yellow powder (50 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.90, 8.68, 8.26, 8.06, 7.83, 7.28, 6.86, 6.06, 6.05, 5.47. 13C-NMR (d6-DMSO, 75 MHz) δ 171.57, 166.24, 162.30, 159.21, 154.30, 147.67, 145.82, 145.32, 142.04, 136.25, 132.47, 128.97, 124.18, 122.33, 120.69, 118.81, 114.44, 113.37, 108.90, 101.62, 54.87. MS (FAB) m/z 466 (MH+), 542, 420. HRMS (FAB) 466.0830.
EXAMPLE 264 N-{2-[(8-Hydroxyquinlinolin-7-yl)amido]-1,3,4-thiadiazol-5-yl}-tryptophan Monohydrotrifluoroacetate (Z-139) (Refer to Chart Z.)
According to GP VI starting from (S)-N-[5-({1-[(tert-butoxy)carbonyl]-2-indol-3-ylethyl}amino)-1,3,4-thidiazol-2-yl]-8-hydroxy-7-quinolinecarboxamide monohydrate Y-134 (253 mg) and TFA (15 mL). Acid Z-139 is obtained as a yellow powder (270 mg).
Physical characteristics are as follows:
1H-NMR (d6-DMSO, 300 MHz) δ 8.91, 8.72, 8.15, 8.08, 7.77, 8.55, 7.30, 7.16, 7.02, 6.95, 4.54, 3.32, 3.14. 13C-NMR (d6-DMSO, 75 MHz) δ 173.29, 166.82, 162.67, 158.91, 154.52, 145.04, 143.04, 136.54, 135.27, 132.54, 129.13, 127.67, 124.48, 124.27, 121.44, 118.93, 118.69, 114.69, 113.54, 111.89, 109.63, 57.98. MS (FAB) m/z 475 (H), 551, 529, 305, 172. HRMS (FAB) 475.1198.
Following procedures analogous to those described above, the additional compounds of the present invention of Tables 13 and 14 are prepared.
Figure US06310211-20011030-C00124
TABLE 1
Compound of CMV pol Assay
Example No. Conc (M) pol type % Inhib IC50 μM
1 CMV 10.2
3.13E − 06 CMV −1.5
6.25E − 06 CMV 22.8
1.30E − 05 CMV 66.2
2.50E − 05 CMV 94.7
5.00E − 05 CMV 98.6
1.00E − 04 CMV 100
2 CMV 4.3
3.13E − 06 CMV 43.6
6.25E − 06 CMV 59.2
1.30E − 05 CMV 65.7
2.50E − 05 CMV 78
5.00E − 05 CMV 81.9
1.00E − 04 CMV 83
3 CMV 7.1
3.13E − 06 CMV 20.5
6.25E − 06 CMV 36.5
1.30E − 05 CMV 75.7
2.50E − 05 CMV 97.8
5.00E − 05 CMV 100.1
1.00E − 04 CMV 100.2
4 CMV 3.9
3.13E − 06 CMV 48.4
6.25E − 06 CMV 48
1.30E − 05 CMV 61.1
2.50E − 05 CMV 59.3
5.00E − 05 CMV 47.6
1.00E − 04 CMV 51.9
CMV 3.1
3.13E − 07 CMV 7.2
6.25E − 07 CMV 15.1
1.25E − 06 CMV 22.6
2.50E − 06 CMV 50.4
5.00E − 06 CMV 65.4
1.00E − 05 CMV 75.1
CMV 5.1
7.81E − 07 CMV 4.1
1.56E − 06 CMV 20.6
3.13E − 06 CMV 42.8
6.25E − 06 CMV 58.1
1.30E − 05 CMV 69.7
2.50E − 05 CMV 85.6
5 CMV 6.8
3.13E − 06 CMV 29.1
6.25E − 06 CMV 44
1.30E − 05 CMV 69.3
2.50E − 05 CMV 87.2
5.00E − 05 CMV 95.9
1.00E − 04 CMV 98.7
6 CMV 4.1
3.13E − 06 CMV 39.6
6.25E − 06 CMV 59
1.30E − 05 CMV 81.1
2.50E − 05 CMV 95.1
5.00E − 05 CMV 98.6
1.00E − 04 CMV 99.6
7 CMV 6.9
3.13E − 06 CMV 29.6
6.25E − 06 CMV 47.2
1.30E − 05 CMV 64.2
2.50E − 05 CMV 83.1
5.00E − 05 CMV 90.6
1.00E − 04 CMV 94.7
8 CMV 20.1
3.13E − 06 CMV 19.3
6.25E − 06 CMV 33.4
1.30E − 05 CMV 38.1
2.50E − 05 CMV 52
5.00E − 05 CMV 59.6
1.00E − 04 CMV 71
9 CMV 2.5
3.13E − 06 CMV 45.6
6.25E − 06 CMV 80.3
1.30E − 05 CMV 93.3
2.50E − 05 CMV 96.3
5.00E − 05 CMV 99.2
1.00E − 04 CMV 98.8
10 CMV 19
3.13E − 06 CMV −8.6
6.25E − 06 CMV 0.8
1.30E − 05 CMV 28.4
2.50E − 05 CMV 77.7
5.00E − 05 CMV 95.8
1.00E − 04 CMV 98.6
11 CMV 1.3
3.13E − 06 CMV 66
6.25E − 06 CMV 90.5
1.30E − 05 CMV 95.1
2.50E − 05 CMV 98.2
5.00E − 05 CMV 97.9
1.00E − 04 CMV 98.3
12 CMV 15.9
3.13E − 06 CMV −2.5
6.25E − 06 CMV 3.8
1.30E − 05 CMV 38.6
2.50E − 05 CMV 85
5.00E − 05 CMV 99.4
1.00E − 04 CMV 99.3
13 CMV >100
3.13E − 006 CMV −12.5
6.25E − 006 CMV 15.4
1.30E − 005 CMV 18.8
2.50E − 005 CMV 26.3
5.00E − 005 CMV 17.3
1.00E − 004 CMV 33.8
14 CMV 23.4
3.13E − 06 CMV −4.4
6.25E − 06 CMV 5.5
1.30E − 05 CMV 42.4
2.50E − 05 CMV 59.3
5.00E − 05 CMV 69.9
1.00E − 04 CMV 84.5
15 CMV 1.6
3.13E − 07 CMV 12.9
6.25E − 07 CMV 19.7
1.25E − 06 CMV 43
2.50E − 06 CMV 70.2
5.00E − 06 CMV 87.1
1.00E − 05 CMV 93.4
16 CMV 5.8
3.13E − 06 CMV 18.2
6.25E − 06 CMV 46.3
1.30E − 05 CMV 87.7
2.50E − 05 CMV 96.6
5.00E − 05 CMV 95.6
1.00E − 04 CMV 90.4
TABLE 2
Example No. Conc (M) pol type % Inhib IC50 μM
17 CMV 11.3
3.13e − 006 CMV 0.7
6.25e − 006 CMV 26.4
1.30e − 005 CMV 57.1
2.50e − 005 CMV 89
5.00e − 005 CMV 95.5
1.00e − 004 CMV 97.5
18 CMV 27.9
3.13e − 006 CMV 5.3
6.25e − 006 CMV 14.9
1.30e − 005 CMV 13.9
2.50e − 005 CMV 51.7
5.00e − 005 CMV 79.6
1.00e − 004 CMV 91.8
19 3.13e − 006 CMV 11.8
6.25e − 006 CMV 20
1.30e − 005 CMV 28.9
2.50e − 005 CMV 56.6
5.00e − 005 CMV 69.1
1.00e − 004 CMV 83.9
CMV 23.6
20 CMV 14.5
3.13e − 006 CMV 10.9
6.25e − 006 CMV 25.5
1.30e − 005 CMV 41.3
2.50e − 005 CMV 73.2
5.00e − 005 CMV 92
1.00e − 004 CMV 95.4
21 CMV 7.5
3.13e − 006 CMV 33.5
6.25e − 006 CMV 43.4
1.30e − 005 CMV 57.2
2.50e − 005 CMV 85.2
5.00e − 005 CMV 94.4
1.00e − 004 CMV 96.6
CMV 12.6
3.13e − 006 CMV 17.6
6.25e − 006 CMV 35.3
1.30e − 005 CMV 45.1
2.50e − 005 CMV 69.9
5.00e − 005 CMV 90.8
1.00e − 004 CMV 97.9
22 CMV 8.6
3.13e − 006 CMV 13.2
6.25e − 006 CMV 33.3
1.30e − 005 CMV 68.9
2.50e − 005 CMV 90.7
5.00e − 005 CMV 96.7
1.00e − 004 CMV 98.2
CMV 4.5
3.13e − 006 CMV 43.3
6.25e − 006 CMV 51.5
1.30e − 005 CMV 78.3
22 2.50e − 005 CMV 95.2
5.00e − 005 CMV 98.6
1.00e − 004 CMV 99.7
23 CMV 2
3.13e − 006 CMV 48
6.25e − 006 CMV 90.9
1.30e − 005 CMV 98.8
2.50e − 005 CMV 99.4
5.00e − 005 CMV 99.4
1.00e − 004 CMV 98.3
CMV 3.1
3.13e − 007 CMV 16.3
6.25e − 007 CMV 13
1.25e − 006 CMV 14.7
2.50e − 006 CMV 34.6
5.00e − 006 CMV 83.9
1.00e − 005 CMV 99.9
24 CMV >100
3.13e − 006 CMV 7.9
6.25e − 006 CMV 8
1.30e − 005 CMV 9.9
2.50e − 005 CMV 3.9
5.00e − 005 CMV −6.4
1.00e − 004 CMV −0.3
CMV 4.5
3.13e − 006 CMV 36.5
6.25e − 006 CMV 55.4
1.30e − 005 CMV 82.4
2.50e − 005 CMV 97.5
5.00e − 005 CMV 99.3
1.00e − 004 CMV 98.8
25 3.13e − 006 CMV 48.7
6.25e − 006 CMV 63.3
1.30e − 005 CMV 69.4
2.50e − 005 CMV 76.6
5.00e − 005 CMV 83.7
1.00e − 004 CMV 87.6
CMV 3.6
26 CMV 4.6
3.13e − 006 CMV 32.1
6.25e − 006 CMV 60.2
1.30e − 005 CMV 79.5
2.50e − 005 CMV 86.4
5.00e − 005 CMV 87.8
1.00e − 004 CMV 90.1
27 CMV 14.8
3.13e − 006 CMV 27.2
6.25e − 006 CMV 36.6
1.30e − 005 CMV 33.5
2.50e − 005 CMV 58.7
5.00e − 005 CMV 93.5
1.00e − 004 CMV 96.7
28 CMV 5.5
3.13e − 006 CMV 28.1
6.25e − 006 CMV 52
1.30e − 005 CMV 78.3
2.50e − 005 CMV 93
5.00e − 005 CMV 94.6
1.00e − 004 CMV 96.4
29 CMV 18.3
3.13e − 006 CMV 40.9
6.25e − 006 CMV 33.9
1.30e − 005 CMV 36.1
2.50e − 005 CMV 44.4
5.00e − 005 CMV 54.1
1.00e − 004 CMV 71.4
CMV 40.1
3.13e − 006 CMV 27.3
6.25e − 006 CMV 27.3
1.30e − 005 CMV 32.9
2.50e − 005 CMV 42
5.00e − 005 CMV 45.8
1.00e − 004 CMV 64
30 CMV 4.3
3.13e − 006 CMV 42.6
6.25e − 006 CMV 59.9
1.30e − 005 CMV 73.4
2.50e − 005 CMV 87.5
5.00e − 005 CMV 95.4
1.00e − 004 CMV 97
31 CMV <3.1
3.13e − 006 CMV 82.9
6.25e − 006 CMV 95
1.30e − 005 CMV 97.3
2.50e − 005 CMV 97.8
5.00e − 005 CMV 97.8
1.00e − 004 CMV 97.3
CMV 3.7
3.13e − 007 CMV −7.9
6.25e − 007 CMV 20
1.25e − 006 CMV 22.7
2.50e − 006 CMV 38.5
5.00e − 006 CMV 55
1.00e − 005 CMV 88.2
32 CMV <3.1
3.13e − 006 CMV 75.1
6.25e − 006 CMV 89.1
1.30e − 005 CMV 94.6
2.50e − 005 CMV 96.3
5.00e − 005 CMV 97.5
1.00e − 004 CMV 98.2
CMV 4.7
3.13e − 007 CMV −14.4
6.25e − 007 CMV 9.8
1.25e − 006 CMV 20.6
2.50e − 006 CMV 30.4
5.00e − 006 CMV 47.9
1.00e − 005 CMV 85.2
33 CMV 12.8
3.13e − 006 CMV −10.5
6.25e − 006 CMV 38.7
1.30e − 005 CMV 45.7
2.50e − 005 CMV 78
5.00e − 005 CMV 87.9
1.00e − 004 CMV 95.4
TABLE 3
Example No. Concentration (μM) % Inhibition IC50 (μM)
34 100 97 17.2
50 54
25 63
12.5 57
6.25 21
35 100 96 10.0
50 89
12.5 44
6.25 41
3.13 31
36 200 19 >200
100 3
50 15
25 0
12.5 6
6.25 −3
3.13 −1
37 100 55 72.3
50 50
25 21
12.5 12
6.25 3
38 100 97 10.5
50 96
25 62
12.5 58
6.25 36
39 200 90 21.6
100 71
50 79
25 41
12.5 43
6.25 28
3.13 16
40 100 94 13.7
50 80
25 53
12.5 47
6.25 36
3.13 22
TABLE 4
% Inh- IC50
Example No. Conc (μM) AV (AV)
41 2.00e + 000 56.0
1.00e + 001 92.0 0.5
5.00e + 001 78.0
4.00e + 001 76.0
2.00e + 001 76.0 1.4
4.00e + 000 70.0
8.00e − 001 39.0
4.00e + 001 99.0 3.8
2.00e + 001 86.0 3.8
8.00e + 000 78.0 3.8
4.00e + 000 65.0 3.8
8.00e − 001 0.0 3.8
42 8.00e − 001 0.0 5.2
4.00e + 000 51.0 5.2
2.00e + 001 88.0 5.2
4.00e + 001 92.0 5.2
4.00e + 001 99.0 <0.1
2.00e + 001 99.0 <0.1
4.00e + 000 89.0 <0.1
43 8.00e − 001 65.0 0.12
4.00e + 000 77.0 0.12
2.00e + 001 90.0 0.12
4.00e + 001 85.0 0.12
4.00e + 001 81.0 0.44
4.00e + 000 88.0 0.44
8.00e − 001 43.0 0.44
4.00e − 001 50.0 0.44
2.00e + 001 <0.5
1.00e + 001 99.0 <0.5
5.00e + 000 99.0 <0.5
2.50e + 000 99.0 <0.5
1.25e + 000 87.0 <0.5
44 8.00e − 001 23.0 2.7
4.00e + 000 65.0 2.7
2.00e + 001 88.0 2.7
4.00e + 001 93.0 2.7
4.00e + 001 44.0
2.00e + 001 43.0
4.00e + 000 59.0
8.00e − 001 58.0
45 8.00e − 001 39.0 1.2
4.00e + 000 75.0 1.2
2.00e + 001 83.0 1.2
4.00e + 001 89.0 1.2
TABLE 5
Example No. Conc (M) pol type % Inhib IC50 μM
46 5.00e − 005 CMV 67.1
1.00e − 004 CMV 83.2
2.50e − 005 CMV 54.2
CMV 23.3
3.13e − 006 CMV 13.9
6.25e − 006 CMV 23
1.30e − 005 CMV 30.7
47 3.13e − 006 CMV 76.5
6.25e − 006 CMV 61.3
1.30e − 005 CMV. 54.3
2.50e − 005 CMV 59.4
5.00e − 005 CMV 65.9
1.00e − 004 CMV 73.1
CMV 0.35
7.81e − 008 CMV 5.6
1.56e − 007 CMV 20.3
3.13e − 007 CMV 48.6
6.25e − 007 CMV 76.7
1.25e − 006 CMV 88.5
2.50e − 006 CMV 94.9
1.25e − 006 CMV 96.4
2.50e − 006 CMV 96.7
5.00e − 006 CMV 96.1
1.00e − 005 CMV 95.5
6.25e − 007 CMV 93.2
CMV <0.3
3.13e − 007 CMV 80.5
CMV 0.5
48 3.13e − 007 CMV 32.6
6.25e − 007 CMV 61.3
1.25e − 006 CMV 77.2
2.50e − 006 CMV 87.2
5.00e − 006 CMV 91.8
1.00e − 005 CMV 95.6
3.13e − 006 CMV 97.2
6.25e − 006 CMV 96.8
1.30e − 005 CMV 97.5
2.50e − 005 CMV 97.8
5.00e − 005 CMV 98.8
1.00e − 004 CMV 97.8
CMV <3.1
49 3.13e − 006 CMV 95.2
6.25e − 006 CMV 96
1.30e − 005 CMV 97
2.50e − 005 CMV 97.3
5.00e − 005 CMV 97.2
1.00e − 004 CMV 98.4
CMV <3.1
CMV 0.6
3.13e − 007 CMV 41.2
6.25e − 007 CMV 49.3
1.25e − 006 CMV 66.8
2.50e − 006 CMV 85.5
5.00e − 006 CMV 92.8
1.00e − 005 CMV 96.1
50 5.00e − 005 CMV 92.6
1.00e − 004 CMV 95.6
2.50e − 005 CMV 80.9
CMV <3.1
3.13e − 006 CMV 83.7
6.25e − 006 CMV 91.1
1.30e − 005 CMV 92.6
2.50e − 005 CMV 96
5.00e − 005 CMV 97.1
1.00e − 004 CMV 97.7
CMV 1.2
3.13e − 006 CMV 23.2
6.25e − 006 CMV 34.9
1.30e − 005 CMV 40.1
51 CMV <3.1
3.13e − 006 CMV 97.1
6.25e − 006 CMV 96.6
1.30e − 005 CMV 96.8
2.50e − 005 CMV 96.9
5.00e − 005 CMV 97.9
1.00e − 004 CMV 98.7
CMV 0.17
3.13e − 006 CMV 60.2
6.25e − 006 CMV 86.7
1.30e − 005 CMV 94.2
2.50e − 005 CMV 98.2
5.00e − 005 CMV 98.7
1.00e − 004 CMV 98.4
52 CMV <3.1
3.13e − 006 CMV 97.4
6.25e − 006 CMV 98.4
1.30e − 005 CMV 98.9
2.50e − 005 CMV 98.7
5.00e − 005 CMV 98.5
1.00e − 004 CMV 98.6
CMV 0.17
3.13e − 006 CMV 59.7
6.25e − 006 CMV 84.6
1.30e − 005 CMV 95.2
2.50e − 005 CMV 97.3
5.00e − 005 CMV 98.7
1.00e − 004 CMV 99
53 CMV <3.1
3.13e − 006 CMV 94.6
6.25e − 006 CMV 94.2
1.30e − 005 CMV 94.7
2.50e − 005 CMV 95.8
5.00e − 005 CMV 92.7
1.00e − 004 CMV 95.8
CMV 0.3
3.13e − 007 CMV 46
6.25e − 007 CMV 68.2
1.25e − 006 CMV 84.8
2.50e − 006 CMV 92.8
5.00e − 006 CMV 95.4
53 1.00e − 005 CMV 94.9
54 CMV <3.1
3.13e − 006 CMV 88.7
6.25e − 006 CMV 94.4
1.30e − 005 CMV 95.1
2.50e − 005 CMV 95.6
5.00e − 005 CMV 95.6
1.00e − 004 CMV 95.3
CMV 0.3
3.13e − 007 CMV 45.9
6.25e − 007 CMV 77.8
1.25e − 006 CMV 89.6
2.50e − 006 CMV 94.2
5.00e − 006 CMV 97.3
1.00e − 005 CMV 98.7
55 CMV 31.5
3.13e − 006 CMV 17.2
6.25e − 006 CMV 27.4
1.30e − 005 CMV 27.7
2.50e − 005 CMV 42.9
5.00e − 005 CMV 51.4
1.00e − 004 CMV 73.5
56 CMV 19.7
3.13e − 006 CMV 27.9
6.25e − 006 CMV 30
1.30e − 005 CMV 36.8
2.50e − 005 CMV 48.4
5.00e − 005 CMV 59.8
1.00e − 004 CMV 81.8
58 3.13e − 006 CMV −2.9
6.25e − 006 CMV 2.4
1.30e − 005 CMV 27.9
2.50e − 005 CMV 40.2
5.00e − 005 CMV 46.2
1.00e − 004 CMV 65
3.13e − 006 CMV −2.9
6.25e − 006 CMV 2.4
1.30e − 005 CMV 27.9
2.50e − 005 CMV 40.2
5.00e − 005 CMV 46.2
1.00e − 004 CMV 65
3.13e − 006 CMV −2.9
6.25e − 006 CMV 2.4
1.30e − 005 CMV 27.9
2.50e − 005 CMV 40.2
5.00e − 005 CMV 46.2
1.00e − 004 CMV 65
CMV 49.7
3.13e − 006 CMV −2.9
6.25e − 006 CMV 2.4
1.30e − 005 CMV 27.9
2.50e − 005 CMV 40.2
5.00e − 005 CMV 46.2
1.00e − 004 CMV 65
57 CMV 8.0
TABLE 6
Concentration
Example No. (μM) % Inhibition IC50 (μM)
Example 59 200 43 >200
100 31
50 14
25 0
12.5 −3
6.25 −6
3.13 −7
Example 60 200 70 57.4
100 55
50 51
25 32
12.5 31
6.25 19
3.13 30
Example 61 200 51 >200
100 38
50 30
25 30
12.5 23
6.25 15
3.13 13
Example 62 200 42 >200
100 33
50 14
25 10
12.5 6
6.25 3
3.13 1
Example 63 100 92 11.4
50 74
25 71
12.5 49
6.25 34
3.13 29
Example 64 200 84 29.8
100 58
50 75
25 46
12.5 25
6.25 25
3.13 16
Example 65 200 −8 >200
100 −23
50 −23
25 −21
12.5 −13
6.25 −8
3.13 −8
Example 66 200 89 11.0
100 86
50 64
25 57
12.5 60
6.25 41
3.13 32
200 88 17.9
100 91
50 71
25 77
12.5 37
6.25 30
3.13 13
Example 67 200 94 23.6
100 86
50 76
25 41
12.5 25
6.25 23
3.13 13
TABLE 7
Antiviral Selective
Polymerase IC50 Values
Example Number, Structure Polymerase IC50 (uM)
Figure US06310211-20011030-C00125
 		CMV 9.7 9.4
Figure US06310211-20011030-C00126
 		CMV 42.8 
Figure US06310211-20011030-C00127
 		CMV <3.1 
Figure US06310211-20011030-C00128
 		CMV 13.3 
CMV Antiviral Assay
% Inh — IC50
Example Number, Structure Conc (uM) AV (AV)
Figure US06310211-20011030-C00129
 		2.00e+001 4.00e+000 8.00e−001 90.0 41.0 34.0 3 3 3
Figure US06310211-20011030-C00130
 		4.00e+001 2.00e+001 4.00e+000 8.00e+001 4.00e+001 3.00e+001 2.00e+001 1.00e+001 8.00e+000 4.00e+000 99.0 96.0 12.0 21.0 66.0 52.0 54.0 50.0 35.0  8.0 3 3
# 3 3  14.1  14.1  14.1  14.1  14.1  14.1
TABLE 8
MS- MS-
ESI ESI
Compound (+) (−) NMR (d) (CDCl3) Elem. Anal.
 75 332 330 8.8, 8.2, 8.1, 7.9, 7.5, 7.4,
7.3, 7.2, 7.1, 3.9, 3.2
 76 309 307
 77 385 383
 78 347 345
 79 347 345
 80 329 327
 81 321 319
 82 301 299 8.8, 8.2, 7.8, 7.5, 7.4, 3.5,
1.7, 1.5-1.2, 0.9
 83 347 345
 84 347 345
 85 297 295
 86 361 359 8.8, 8.2, 7.9, 7.5, 7.4, 7.2,
3.8, 3.1
 87 325 323
 88 313 311
 89 293 291
 90 293 291
 91 313 311
 92 309 307 8.8, 8.3, 8.2, 7.6, 7.5, 7.4,
5.0, 4.0, 3.7
 93 369 367
 94 308 306
 95 301 299 8.8, 8.2, 7.8, 7.5, 7.4, 3.5,
1.6, 1.5-1.2, 1.0, 0.9
 96 343 341
 97 441 439
 98 371 369
 99 327 325
100 307 305
101 383 381
102 307 305
103 315 313 8.8, 8.2, 7.8, 7.5, 7.4, 3.5,
1.7, 1.5-1.2, 0.9
104 315 313
105 313 311
106 285 283
107 299 297
108 285 283
109 285 283
110 319 317
111 299 297
112 305 303
113 285 283
114 355 353
115 293 291
116 287 282
117 301 299
118 327 325
119 409 407
120 343 341
121 343 341
122 293 291
123 373 371
124 373 371
125 385 383
126 385 383
127 283 281
128 325 323
129 339 337
130 367 365 8.8, 8.2, 8.1, 7.5, 7.4-7.2,
5.3, 5.0, 4.2
131 367 355 8.8, 8.2, 8.1, 7.5, 7.4, 7.1,
6.8, 5.1, 3.8, 3.2
132 404 402
133 323 321
134 457 455
135 396 394
136 315 313
137 287 285
138 331 329
139 347 345
140 347 345
141 391 389
142 407 405
143 405 403
144 417 415
145 444 442
146 285 283 8.8, 8.2, 7.9, 7.5, 7.4, 3.4, C 71.57, H 7.08, N 9.87
1.9-1.6, 1.4-1.0
147 329 327 8.8, 8.2, 7.8, 7.6-7.4, 7.3, 5.2 C 76.52, H 5.19, N 8.59
148 327 325 10.0, 8.8, 8.2, 8.0, 7.5, 7.3, C 65.82, H 4.63, N 8.56
7.2, 7.1, 3.8, 3.0
149 347 345 9.6, 8.8, 8.4, 8.2, 7.7-7.3, 4.8 C 66.22, H 4.09, N 8.04
150 325 323 10.0, 8.8, 8.2, 8.1, 7.5, 7.4, C 66.48, H 5.06, N 8.55
7.3, 7.2, 7.1, 3.8, 3.2
151 287 285 10, 8.8, 8.1, 7.8, 7.5, 7.3,
3.5, 1.7, 1.5-1.2, 0.9
TABLE 9
CMV pol
Assay -
Example Number, Structure IC50 uM
Figure US06310211-20011030-C00131
 		0.9
Figure US06310211-20011030-C00132
 		<1.5
Figure US06310211-20011030-C00133
 		1.5
Figure US06310211-20011030-C00134
 		<3.1 1.6 20
Figure US06310211-20011030-C00135
 		1.7
Figure US06310211-20011030-C00136
 		2.2 4.7
Figure US06310211-20011030-C00137
 		2.2
Figure US06310211-20011030-C00138
 		2.3
Figure US06310211-20011030-C00139
 		<3.1 2.4 10.8
Figure US06310211-20011030-C00140
 		2.6
Figure US06310211-20011030-C00141
 		2.9 6.4
Figure US06310211-20011030-C00142
 		3
Figure US06310211-20011030-C00143
 		3.1
Figure US06310211-20011030-C00144
 		<3.1
Figure US06310211-20011030-C00145
 		<3.1 >10
Figure US06310211-20011030-C00146
 		3.1
Figure US06310211-20011030-C00147
 		3.2
Figure US06310211-20011030-C00148
 		3.7
Figure US06310211-20011030-C00149
 		4.5
Figure US06310211-20011030-C00150
 		4.6
Figure US06310211-20011030-C00151
 		4.9
Figure US06310211-20011030-C00152
 		5
Figure US06310211-20011030-C00153
 		5.2
Figure US06310211-20011030-C00154
 		5.2
Figure US06310211-20011030-C00155
 		5.6
Figure US06310211-20011030-C00156
 		5.6
Figure US06310211-20011030-C00157
 		6.6
Figure US06310211-20011030-C00158
 		6.7
Figure US06310211-20011030-C00159
 		6.9
Figure US06310211-20011030-C00160
 		7.1
Figure US06310211-20011030-C00161
 		7.1
Figure US06310211-20011030-C00162
 		7.4
Figure US06310211-20011030-C00163
 		7.6
Figure US06310211-20011030-C00164
 		7.6
Figure US06310211-20011030-C00165
 		7.8
Figure US06310211-20011030-C00166
 		7.9
Figure US06310211-20011030-C00167
 		8.1
Figure US06310211-20011030-C00168
 		8.1
Figure US06310211-20011030-C00169
 		8.4
Figure US06310211-20011030-C00170
 		8.4
Figure US06310211-20011030-C00171
 		8.5
Figure US06310211-20011030-C00172
 		8.7
Figure US06310211-20011030-C00173
 		9
Figure US06310211-20011030-C00174
 		11.3 9.2
Figure US06310211-20011030-C00175
 		9.2
Figure US06310211-20011030-C00176
 		9.3
Figure US06310211-20011030-C00177
 		9.4
Figure US06310211-20011030-C00178
 		9.6
Figure US06310211-20011030-C00179
 		10.8
Figure US06310211-20011030-C00180
 		11.1
Figure US06310211-20011030-C00181
 		12.1
Figure US06310211-20011030-C00182
 		12.6
Figure US06310211-20011030-C00183
 		13.2
Figure US06310211-20011030-C00184
 		13.7
Figure US06310211-20011030-C00185
 		14.6
Figure US06310211-20011030-C00186
 		14.8
Figure US06310211-20011030-C00187
 		15.7
Figure US06310211-20011030-C00188
 		16.8
Figure US06310211-20011030-C00189
 		17
Figure US06310211-20011030-C00190
 		17.5
Figure US06310211-20011030-C00191
 		19.2
Figure US06310211-20011030-C00192
 		19.3
Figure US06310211-20011030-C00193
 		19.7
Figure US06310211-20011030-C00194
 		20.1
Figure US06310211-20011030-C00195
 		20.6
Figure US06310211-20011030-C00196
 		20.7
Figure US06310211-20011030-C00197
 		21.1
Figure US06310211-20011030-C00198
 		22.2
Figure US06310211-20011030-C00199
 		22.3
Figure US06310211-20011030-C00200
 		22.6
Figure US06310211-20011030-C00201
 		23.2
Figure US06310211-20011030-C00202
 		23.3
Figure US06310211-20011030-C00203
 		23.8
Figure US06310211-20011030-C00204
 		24.2
Figure US06310211-20011030-C00205
 		24.3
Figure US06310211-20011030-C00206
 		24.5
Figure US06310211-20011030-C00207
 		24.6 29.4
TABLE 10
CMV pol Assay
Conc pol
Example Number, Structure (M) type % Inhib IC50 uM
Figure US06310211-20011030-C00208
 		1.00e-004 5.00e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  98.7  87.6    2.5  3.4  11.8  43.1  98.2        30.1
Figure US06310211-20011030-C00209
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  7  6.2  12.8  23.1  28.5  44  99.9 >100
Figure US06310211-20011030-C00210
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#    56.8  90.6  99.7  99.8 100.8 100.3  99.9    1.7
Figure US06310211-20011030-C00211
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#    2.6  9.8  13.6  28.9  40.7  60  63.8    68.2
Figure US06310211-20011030-C00212
 		  3.13e-007 6.25e-007 1.25e-006 2.50e-006 5.00e-006 1.00e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004
# CMW CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#    13.8  32.1  40.9  57.8  65.3  74.6    78.1  79.8  82.9  83.6  82.8  90.8
#    1.8                3.1
Figure US06310211-20011030-C00213
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    −3.9  3.3  6.6  15.8  20.5  57.2    90
Figure US06310211-20011030-C00214
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    −4.2  11.9  39.1  75.6  98.2 100    16.4
Figure US06310211-20011030-C00215
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    26.8  44.1  55.4  63.4  76.3  86.2    9.5
Figure US06310211-20011030-C00216
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#    3.1  4.8  30  82.9 100 100.3  98.7    16.9
Figure US06310211-20011030-C00217
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    0.4  7.1  8.4  26.2  26.5  59    82.9
Figure US06310211-20011030-C00218
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    1.1  6.6  32.7  58.1  68.8  80.6    26.3
Figure US06310211-20011030-C00219
 		1.25e-007 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004   CMV CMV CMV CMV CMV CMV CMV
#  −0.2  10.4  18.3  34.6  50.3  71.3                48.4
Figure US06310211-20011030-C00220
 		1.00e-004   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV
#  93.2    12  24.4  45.5  74.3  88.1      14
Figure US06310211-20011030-C00221
 		  3.13e-006 3.13e-006 6.25e-006 6.25e-006 1.30e-005 1.30e-005 2.50e-005 2.50e-005 5.00e-005 5.00e-005 1.00e-004 1.00e-004
# CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#    7.8  29.7 11.2  47.1  9.4  88.8  19.5 102.4  48.8 103  91.1 102.7    14.7
Figure US06310211-20011030-C00222
 		  3.13e-006 3.13e-006 6.25e-006 6.25e-006 1.30e-005 1.30e-005 2.50e-005 2.50e-005 5.00e-005 5.00e-005 1.00e-004 1.00e-004
# CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#    6  26.3  2.3  35.6  5.8  69.7  9.5 101.8  18.1 103.6  65.8 102.8    22.4
Figure US06310211-20011030-C00223
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV
#    17  18.6  41.9  91.9 102.8 102.9    12.2
Figure US06310211-20011030-C00224
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  73.7    13.2  21.2  29.7  77.9  98.6 100      15.5
Figure US06310211-20011030-C00225
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  90.8    26  58.1  87.3  97.6  99  99.4      2.4
Figure US06310211-20011030-C00226
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  90.6    10  15.6  26.7  68.5  96.3  99.8      9.2
Figure US06310211-20011030-C00227
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  71.5    9.8  15.5  19.9  59.5  69.9  51.4      32.7
Figure US06310211-20011030-C00228
 		250e-005 CMV  30.6
Figure US06310211-20011030-C00229
 		5.00e-005 2.50e-005 2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  99.6  98  95.4    13.9  23  47.4  87.7          5.9
Figure US06310211-20011030-C00230
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  85.3    17.4  49.8  85.1  97.2  98.3  99.1      2.9
Figure US06310211-20011030-C00231
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  91.9    7.7  15.2  11.9  19.5  57.3  91.1      25.5
Figure US06310211-20011030-C00232
 		6.25e-006 1.30e-005 2.50e-005 5.00e-005 3.13e-006 2.50e-005   1.56e-006 CMV CMV CMV CMV CMV CMV CMV CMV
#  13.1  23.1  75.4  99.1  11.1  84    5.9                19.2
Figure US06310211-20011030-C00233
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  79.6    10.7  16  14.4  37.1  85.3  99.7      29.7
Figure US06310211-20011030-C00234
 		1.00e-004 5.00e-005 2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 CMV CMV CMV CMV CMV CMV CMV CMV  99.2
#  98.3  68    17.2  39.8  78.5  95.3          6.9
Figure US06310211-20011030-C00235
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  67.1    8.9  15.2  19.5  38.9  77.2  98.8      30.5
Figure US06310211-20011030-C00236
 		2.50e-005 CMV  37.8
Figure US06310211-20011030-C00237
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 2.50e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#    24.7  26.3  30.5  43  41.3  52.7  41.8 >100
Figure US06310211-20011030-C00238
 		  3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 2.50e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#    30.8  63  88.9  97  97.8  98  42.7    4.1
Figure US06310211-20011030-C00239
 		2.50e-005 5.00e-005 1.00e-004   3.13e-006 6.25e-006 1.30e-005 2.50e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  87.3  77.3  71.8    31.3  65.7  82.9  37.5          3.9
Figure US06310211-20011030-C00240
 		2.50e-005 CMV  37.6
Figure US06310211-20011030-C00241
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  91.3    23.8  32.2  53  86.3  98.5  99.5      4.9
Figure US06310211-20011030-C00242
 		2.50e-005 CMV  30.5
Figure US06310211-20011030-C00243
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  81.8    −6  −5.4  −0.7  2.7  27.6  83.2      27.9
Figure US06310211-20011030-C00244
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  52    12.3  17  13.3  40.9  91.4 100.9      13.6
Figure US06310211-20011030-C00245
 		2.50e-005 CMV  30.8
Figure US06310211-20011030-C00246
 		2.50e-005 CMV  22.3
Figure US06310211-20011030-C00247
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  76.6    6.2  27.6  32.7  55.9  78.5  85.2      10.3
Figure US06310211-20011030-C00248
 		2.50e-005 CMV  39.3
Figure US06310211-20011030-C00249
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  52.2    10.8  17.6  16.8  33.2  51.1  75.5      22.4
Figure US06310211-20011030-C00250
 		2.50e-005 CMV  33.1
Figure US06310211-20011030-C00251
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  79.2    2.8  31.7  49.6  70.5  81.1  89.7      7.1
Figure US06310211-20011030-C00252
 		2.50e-005 CMV  35.9
Figure US06310211-20011030-C00253
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  46.7    5.4  4  4.1  10  7  45.7    >50
Figure US06310211-20011030-C00254
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  63.3    7.7  14  5.1  37  85.5 100      16
Figure US06310211-20011030-C00255
 		2.50e-005 CMV  35
Figure US06310211-20011030-C00256
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  47.7    7.9  15  19.8  65.4  96.9 100.8      10.1
Figure US06310211-20011030-C00257
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  57.5    7.6  8  10.4  17.8  36.2  95.5      27.3
Figure US06310211-20011030-C00258
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  63.9    12.3  15.9  9  30  72  99.6      18.5
Figure US06310211-20011030-C00259
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  73.9    2.1  13.6  14.3  20.6  35.7  93.9      26.8
Figure US06310211-20011030-C00260
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  61.4    5.3  8.3  7.9  13.4  31.2  98.4      27.4
Figure US06310211-20011030-C00261
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  94.6    26.5  27.1  32  48.7  92.7  99.4      9.4
Figure US06310211-20011030-C00262
 		2.50e-005 CMV  22.4
Figure US06310211-20011030-C00263
 		2.50e-005 CMV  29.3
Figure US06310211-20011030-C00264
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  91.7    30.1  50.5  64.1  80.2  89.5  95.7      3.3
Figure US06310211-20011030-C00265
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005
# CMW CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#  46.9    18.1  44.5  69.7  55  49.7  52.9    17.8  29.4  38.9  50  47.2  56.5      6.9                18.9
Figure US06310211-20011030-C00266
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  96.6    22.4  26.3  33.1  68.3  99  99.4      7.5
Figure US06310211-20011030-C00267
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  88.9    23.4  24.4  21.4  46  77.9  98.3      12.5
Figure US06310211-20011030-C00268
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  78.7    −1.3  9.7  3.3  3.7  1.2  −6.5   >100
Figure US06310211-20011030-C00269
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  29.4    24.8  33.6  30.4  35.6  53.8  78.4      13.8
Figure US06310211-20011030-C00270
 		2.50e-005 CMV  91.5
Figure US06310211-20011030-C00271
 		2.50e-005 CMV  37
Figure US06310211-20011030-C00272
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  97.5    23.3  30.1  61.5  92.8  98.4  99.5      4.3
Figure US06310211-20011030-C00273
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV  97.5
#    20.6  23.4  34.2  62.8  95.4  99.7      8.2
Figure US06310211-20011030-C00274
 		2.50e-005 CMV  24
Figure US06310211-20011030-C00275
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  83.8    17.7  20.3  21.9  37.8  84.5  98.7      13.4
Figure US06310211-20011030-C00276
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  88    21.9  30.4  44.9  85.5  99.3  99.3      5.5
Figure US06310211-20011030-C00277
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  96.9    28.8  27.3  31.9  54.6  94.7  99.4      8.6
Figure US06310211-20011030-C00278
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  97.6    19  20.7  32.4  67.9  98.9  99.8      8.1
Figure US06310211-20011030-C00279
 		2.50e-005 CMV  82.2
Figure US06310211-20011030-C00280
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  97.5    11.6  22.1  37.7  76.3  98.4  99.7      7.3
Figure US06310211-20011030-C00281
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  73.5    7.4  23.7  36.9  89.6 100.3 100.7      6.6
Figure US06310211-20011030-C00282
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  69.2    12.2  18.9  28.5  73.9  96.5 100      18.4
Figure US06310211-20011030-C00283
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  97    29.6  31.2  35.6  64.3  98.1  99.6      7
Figure US06310211-20011030-C00284
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  94.2    22.7  26.5  31  46.4  88.6  99.4      10.2
Figure US06310211-20011030-C00285
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  87    36.5  64  93.6  99.3  99.7  99.6      3.6
Figure US06310211-20011030-C00286
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  49    24.4  45  60.8  81.5  92.1  94      7.9
Figure US06310211-20011030-C00287
 		2.50e-005 CMV  39
Figure US06310211-20011030-C00288
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  95    33.5  77.7  97.6  99.8  99.7 100      3.1
Figure US06310211-20011030-C00289
 		2.50e-005 CMV  24
Figure US06310211-20011030-C00290
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  67    27.4  47.9  66.5  79.4  85.9  87.9      6.9
Figure US06310211-20011030-C00291
 		2.50e-005 CMV  25
Figure US06310211-20011030-C00292
 		2.50e-005 CMV  83
Figure US06310211-20011030-C00293
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  97    23.8  40.8  69.9  95.6  99.5  99.7      7
Figure US06310211-20011030-C00294
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004 CMV CMV CMV CMV CMV CMV CMV CMV
#  96    38.2  66  86.1  97.3  99.3  99.6      3.7
Figure US06310211-20011030-C00295
 		2.50e-005 CMV  35
Figure US06310211-20011030-C00296
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004   3.13e-007 6.25e-007 1.25e-006 2.50e-006 5.00e-006 1.00e-005
# CMW CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#  84    70.9  94.5  99  99.2  99.1  99.7    15.5  19.5  19.8  37.9  82.7  99.5
#    <3.1                2.8
Figure US06310211-20011030-C00297
 		2.50e-005 CMV  29
Figure US06310211-20011030-C00298
 		2.50e-005   3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 1.00e-004   3.13e-007 6.25e-007 1.25e-006 2.50e-006 5.00e-006 1.00e-005
# CMW CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV CMV
#  94    89.6  98.5  99.6  99.9  99.4  99.8    14.5  19.7  20.4  62.8  95.2  98.4
#    <3.1                2
Figure US06310211-20011030-C00299
 		2.50e-005 CMV  23
Figure US06310211-20011030-C00300
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  43.2    18  24.7  28.6  37.5  54.9  58.1      21.6
Figure US06310211-20011030-C00301
 		2.50e-005   1.56e-006 3.13e-006 6.25e-006 1.30e-005 2.50e-005 5.00e-005 CMV CMV CMV CMV CMV CMV CMV CMV
#  82.3    16.8  14.1  16.6  43.6  78.5  96.3      14.5
TABLE 11
CMV pol
Assay
Example Number, Structure IC50 uM
Figure US06310211-20011030-C00302
 		71
Figure US06310211-20011030-C00303
 		93.2
Figure US06310211-20011030-C00304
 		2.4
Figure US06310211-20011030-C00305
 		2.5
Figure US06310211-20011030-C00306
 		14.3
Figure US06310211-20011030-C00307
 		3.1
Figure US06310211-20011030-C00308
 		15.4
Figure US06310211-20011030-C00309
 		9.4
Figure US06310211-20011030-C00310
 		4.3
Figure US06310211-20011030-C00311
 		4.7
Figure US06310211-20011030-C00312
 		7.1
Figure US06310211-20011030-C00313
 		<3.1
Figure US06310211-20011030-C00314
 		<3.1
Figure US06310211-20011030-C00315
 		11.4
Figure US06310211-20011030-C00316
 		13.9
Figure US06310211-20011030-C00317
 		26.6
Figure US06310211-20011030-C00318
 		<3.1
Figure US06310211-20011030-C00319
 		4.5
Figure US06310211-20011030-C00320
 		24.2
Figure US06310211-20011030-C00321
 		22.6
Figure US06310211-20011030-C00322
 		18.9
Figure US06310211-20011030-C00323
 		8.5
TABLE 12
CMV Antiviral Assay
% Inh — IC50
Example Number, Structure Conc (uM) AV (AV)
Figure US06310211-20011030-C00324
 		4.00e+001 2.00e+001 4.00e+000 8.00e−001 33.0 50.0 34.0 28.0 25.5 25.5 25.5 25.5
Figure US06310211-20011030-C00325
 		4.00e+001 2.00e+001 4.00e+000 8.00e−001 2.00e+001 8.00e+000 4.00e+000 1.00e+000 90.0 74.0 66.0 29.0 78.0 12.0 62.0 20.0  2.5  2.5  2.5  2.5  3.6  3.6  3.6  3.6
Figure US06310211-20011030-C00326
 		4.00e+001 2.00e+001 1.00e+001 4.00e+000 8.00e−001 2.00e+001 1.50e+001 1.00e+001 5.00e+000 94.0 69.0  8.0  1.0  4.0 78.0 60.0 45.0 36.0 14.4 14.4 14.4 14.4
# 14.4  9.4  9.4  9.4  9.4
Figure US06310211-20011030-C00327
 		2.00e+001 1.00e+001 4.00e+000 8.00e−001 93.0 97.0 54.0  0.0  3.5  3.5  3.5  3.5
Figure US06310211-20011030-C00328
 		2.00e+001 1.00e+001 4.00e+000 8.00e−001 79.0 26.0 17.0 35.0 14.6 14.6 14.6 14.6
Figure US06310211-20011030-C00329
Figure US06310211-20011030-C00330
 		8.00e+000 4.00e+000 2.00e+000 1.00e+000 63.0 53.0 48.0  0.0  3.9  3.9  3.9  3.9
TABLE 13
Structure and Name MP (° C.) Mass Spec IC50 (μM)
Figure US06310211-20011030-C00331
 		55-58 (EI) 394, M+ 35% inhibition @ 100 uM
N-[(4-Chlorophenyl)methyl]-8-hydroxy-
4-methyl-2-(trifluoromethyl)-7-
quinolinecarboxamide
Figure US06310211-20011030-C00332
 		163-165 (EI) 312, M+ 7.6
N-(4-Chlorophenyl)-8-hydroxy-2-
methyl-7-quinolinecarboxamide
Figure US06310211-20011030-C00333
 		218-220 (dec) (EI) 357, M+ 2.6
N-[(4-Chlorophenyl)methyl]-8-hydroxy-
5-nitro-7-quinolinecarboxamide
Figure US06310211-20011030-C00334
 		289-290 (dec) (EI) 408, M+ 5.2
N-[4,5-dihydro-[5-(3-nitrophenyl)]-4-
oxo-2-thiazolyl]-8-hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00335
 		249-250 (dec) (EI) 411, M+ 1.7
N-[5-[3-(4-Chlorophenyl)methyl]-4,5-
dihydro-4-oxo-2-thiazolyl]-8-hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00336
 		127-129 (ESI) 393, M + H 41.6
8-Hydroxy-N-[2-(phenylthio)ethyl]-2-
(trifluoromethyl)-7-
quinolinecarboxamide
Figure US06310211-20011030-C00337
 		274-276 (EI) 342, M+ 102
N-[(4-Chlorophenyl)methyl]-4,8-
dihydroxy-2-methyl-7-
quinolinecarboxamide
Figure US06310211-20011030-C00338
 		110-111 (ESI) 393, M + H 5.1
(E)-8-Hydroxy-2-(2-phenylethenyl)-N-
(3-phenylpropyl)-7-
quinolinecarboxamide
TABLE 14
Structure and Name Mass Spec IC50 (μM)
Figure US06310211-20011030-C00339
 		ESI -MS: M + H = 287 ESI-MS: M − H = 285 21 % inhibition at 25 uM
8-Hydroxy-quinoline-7-
carboxylic acid trans-4-
hydroxy-cyclohexylamide
Figure US06310211-20011030-C00340
 		ESI -MS: M + H = 402 ESI-MS: M − H = 400 14
[4-(3,4-Dichlorophenyl)-
piperazin-yl]-(8-hydroxy-
quinolin-7-yl)-methanone
Figure US06310211-20011030-C00341
 		ESI -MS: M + H = 323 ESI-MS: M − H = 321 26
8-Hydroxy-quinoline-7-
carboxylic acid
bezo[1,3]dioxol-5-
ylmethylamide
Figure US06310211-20011030-C00342
 		ESI -MS: M + H = 273 ESI-MS: M − H = 271 27
N-Hexyl-8-hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00343
 		ESI -MS: M + H = 354 ESI-MS: M − H = 352 42
8-Hydroxy-quinoline-7-
carboxylic acid 2-(5-nitro-
pyridin-2-ylamino)-
ethylamide
Figure US06310211-20011030-C00344
 		ESI -MS: M + H = 309 ESI-MS: M − H = 307 29
8-Hydroxy-N-[2-
(phenyloxy)ethyl]-7-
quinolinecarboxamide
Figure US06310211-20011030-C00345
 		ESI -MS: M + H = 323 ESI-MS: M − H = 321 41
8-Hydroxy-quinoline-7-
carboxylic acid 2-(R)-
hydroxy-1-(S)-methyl-2-
phenyl-ethylamide
Figure US06310211-20011030-C00346
 		ESI -MS: M + H = 365 ESI-MS: M − H = 363 41
(S)-2-[(8-Hydroxy-
quinoline-7-carbonyl)-
amino]-3-phenyl-
propionic acid ethyl ester
Figure US06310211-20011030-C00347
 		ESI -MS: M + H = 304 ESI-MS: M − H = 302 54
8-Hydroxy-quinoline-7-
carboxylic acid cyano-
phenylylamide
Figure US06310211-20011030-C00348
 		ESI -MS: M + H = 359 ESI-MS: M − H = 357 51
(S)-2-[(8-Hydroxy-
quinoline-7-carbonyl)-
amino]-4-methyl-
penatnoic acid tert-butyl
Figure US06310211-20011030-C00349
 		ESI -MS: M + H = 339 ESI-MS: M − H = 337 14
(S,S)-8-Hydroxy-
quinoline-7-carboxylic
acid 2-hydroxy-1-
(hydroxy-phenyl-methyl)-
ethylamide
Figure US06310211-20011030-C00350
 		ESI -MS: M + H = 289 ESI-MS: M − H = 287 26
(S,S)-8-Hydroxy-
quinoline-7-carboxylic
acid 1-hydroxymethyl-2-
methyl-butylamide
Figure US06310211-20011030-C00351
 		ESI -MS: M + H = 323 ESI-MS: M − H = 321 93% inhibition at 25 uM
(S)-8-Hydroxy-quinoline-
7-carboxylic acid 1-
benzyl-2-hydroxy-
ethylamide
Figure US06310211-20011030-C00352
 		ESI -MS: M + H = 285 ESI-MS: M − H = 283 34
8-Hydroxy-quinoline-7-
carboxylic acid thiophen-
2-ylmethylamide
Figure US06310211-20011030-C00353
 		ESI -MS: M + H = 309 ESI-MS: M − H = 307 19
(R)-8-Hydroxy-quinoline-
7-carboxylic acid 2-
hydroxy-1-phenyl-
ethylamide
Figure US06310211-20011030-C00354
 		ESI -MS: M + H = 327 ESI-MS: M − H = 325 26
N-[2-(2-
chlorophenyl)ethyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00355
 		ESI -MS: M + H = 315 ESI-MS: M − H = 313 42
N-[3,4-
Difluorophenyl)methyl]-
8-hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00356
 		ESI -MS: M + H = 331 ESI-MS: M − H = 329 30
N-[(2-Chloro-6-fluoro-
phenyl)methyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00357
 		ESI -MS: M + H = 331 ESI-MS: M − H = 329 28
N-[(2-Chloro-4-fluoro-
phenyl)methyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00358
 		ESI -MS: M + H = 347 ESI-MS: M − H = 345 27
N-[(3,5-Dichloro-
phenyl)methyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00359
 		ESI -MS: M + H = 309 ESI-MS: M − H = 307 39% inhibition at 25 uM
(S)-8-Hydroxy-quinoline-
7-carboxylic acid 2-
hydroxy-1-phenyl-
ethylamide
Figure US06310211-20011030-C00360
 		ESI -MS: M + H = 311 ESI-MS: M − H = 309 39% inhibition at 25 uM
N-[2-(2-
fluorophenyl)ethyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00361
 		ESI -MS: M + H = 311 ESI-MS: M − H = 309 42% inhibition at 25 uM
N-[2-(4-
fluorophenyl)ethyl]-8-
hydroxy-7-
quinolinecarboxamide
Figure US06310211-20011030-C00362
 		ESI -MS: M + H = 458 ESI-MS: M − H = 456 4
trans-8-Hydroxy-
quinoline-7-carboxylic
acid 4-[(8-hydroxy-
quinoline-7-carbonyl)-
amino]-cyclohexyl ester

Claims (9)

What is claimed is:
1. A compound of formula IA
Figure US06310211-20011030-C00363
wherein R0 is
a) —CH2)n-phenyl substituted with Cl, Br, —O-phenyl, CF3, or —S-phenyl substituted with ethoxy; provided that when R0 is a), R1 is H, F, Cl, or Br; R2 is H, —CH═CH-furanyl, or —CH═CH-phenyl, optionally substituted with methoxy, and R3 is H;
b) —(CH2)n-phenyl substituted with two Cl atoms or two F atoms provided that the F atom is at 2-, or 6-position of the phenyl ring;
c) —(CH2)n-indolyl,
d) —(CH2)n-benzothiazolyl,
e) —(CH2)n-naphthyl,
f) —(CH2)n-biphenyl,
g) —(CH2)n-tetrahydro-naphthyl,
h) —(CH2)n-fluorenyl;
i) —(CH2)n-Y,
j) —(CH2)pW1X2,
k) —(CH2)pW1CH2X1, or
l) —(CH2)n—CHR9—(CH2)n—X1,
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl,
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
i) —NHV1,
j) —CH2NHV1, or
k) —CH2Z1;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein R4 is
a) —H
b) —F,
c) —Cl,
d) —Br,
e) —NO2,
f) —CF3,
g) —W1—R10,
h) —C1-C6 alkyl,
i) —C3-C8 cycloalkyl,
j) —(CH2)n-aryl,
k) —CH2—C3-C8 cycloalkyl,
l) —SO2NH-indazoyl
m) —CN,
n) —I, or
o) —CH2—OH;
wherein R8 is
a) —C1-C4 alkyl,
b) —W1—H, or
c) —CH2W1H;
wherein R9 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11,
e) —CH(OH)R11,
f) —CH2OH,
g) —CO2R11, or
h) -aryl;
wherein R10 is
a) —H,
b) —C1-C6 alkyl,
c) —C3-C8 cycloalkyl,
d) —(CH2)n-aryl optionally substituted with F, Cl, CH2OH or —NO2,
e) —CH2—C3-C8 cycloalkyl,
wherein R11 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —(CH2)nX1, or
d) —CH2—C3-C8 cycloalkyl;
wherein Y is
a) —CH(OH)-phenyl,
b) —S-phenyl,
c) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4,
d) —CN,
e) —C3-C8 cycloalkyl substituted by ethoxy, t-butyl or two (2) R8, or
f) -4-cyano-2,3,5,6-tetrafluoro-phenyl;
wherein X1 is
a) -aryl substituted by zero (0), one (1), two (2), or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R5,
c) —C7-C8 alkyl, provided that when X1 is alkyl, R9 is not alkyl;
d) —CH(OH)-phenyl,
e) —S-phenyl,
f) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4,
g) —CN,
h) —C3-C8 cycloalkyl substituted by ethoxy, t-butyl or two (2) R8, or
i) -4-cyano-2,3,5,6-tetrafluorophenyl;
wherein X2 is
a) -aryl substituted by zero (0), one (1), two (2) or three (3) R4,
b) —C1-C8 alkyl,
c) —CH(OH)-phenyl, or
d) —C3-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8;
wherein W1 is
a) oxygen, provided that when X1 or X2 is phenyl, W1 is not oxygen,
b) —NH, or
b) -sulfur,
wherein V1 is
a) —R11,
b) —C(O)R11,
c) —SO2R11, or
d) —C(O)NHR11;
wherein Z1 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11, or
e) —CO2R11;
wherein -aryl is
a) -phenyl,
b) -naphthyl,
c) -biphenyl,
d) -tetrahydro-naphthyl, or
e) fluorenyl;
wherein -het is a 5-membered saturated or unsaturated ring having from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur,
wherein -cycloalkyl is a saturated or unsaturated hydrocarbon ring, optionally fused to a benzene ring;
n is zero (0) to six (6), inclusive, provided that where R0 is a)-h), n is at least one; and p is one (1), two (2) or three (3);
or a pharmaceutically acceptable salt or N-oxide thereof.
2. A compoun d of formula IA as shown in claim 1 which is
Figure US06310211-20011030-C00364
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl, or
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein X1 is
a) phenyl substituted with Cl, Br, —O-phenyl, CF3, or —S-phenyl substituted with ethoxy; provided that when X1 is a), R1 is H, F, Cl, or Br; R2 is H, —CH═CH-furanyl, or —CH═C-phenyl, optionally substituted with methoxy, and R3 is H;
b) phenyl substituted with two Cl atoms or two F atoms provided that the F atom is at 2-, or 6-position of the phenyl ring;
c) indoyl,
d) benzothiazolyl,
e) —C7-C12 alkyl,
f) —CH(OH)-phenyl,
g) —S-phenyl,
h) -naphthyl,
i) —NHSO2-phenyl substituted by one (1) R4, or
j) —CN;
wherein R4 is
a) —H
b) —F,
c) —Cl,
d) —Br,
e) —NO2,
f) —OCH3,
g) —CF3, or
h) —C1-C4 alkyl;
n is zero (0) to three (3) inclusive, provided that where X1 is a)-d), n is at least one; and p is one (1), two (2) or three (3);
or a pharmaceutically acceptable salt or a N-oxide thereof.
3. A compoun d of formula IA as shown in claim 1 which is
Figure US06310211-20011030-C00365
wherein R1 is
a) —H,
b) —Cl,
c) —Br, or
d) —NO2;
wherein R2 is
a) —H,
b) —CH3,
c) —CF3,
d) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
e) —CH═CH-furanyl, or
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4;
wherein X1 is
a) phenyl substituted with Cl, Br, —O-phenyl, or CF3, provided that when X1 is a), R1 is H, Cl, or Br; R2 is H, —CH═CH-furanyl, or —CH═CH-phenyl, optionally substituted with methoxy, and R3 is H;
b) phenyl substituted with two Cl atoms or two F atoms provided that the F atom is at 2-, or 6-position of the phenyl ring;
c) indoyl,
d) benzothiazolyl,
e) —CH(OH)-phenyl,
f) —S-phenyl,
g) -naphthyl,
h) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4, or
i) —CN;
wherein R4 is
a) —H,
b) —Cl,
c) —Br, or
d) —NO2;
n is zero (0) to six (3) inclusive, provided that where X1 is a)-d), n is at least one; and p is one (1), two (2) or three (3).
4. A compound of claim 1 which is:
1) 5-Bromo-N-[(4-chloropbenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
2) 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
3) 5-Fluoro-N-[[4-chlorophenyl]methyl]-8-hydroxy-7-quinolinecarboxamide;
4) N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide;
5) 8-Hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
6) 8-Hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
7) N-[(4-Chlorophenyl)methyl]-2-[2-(2-furyl)ethenyl]-8-hydroxy-7-quinolinecarboxamide;
8) 5-chloro-8-hydroxy-2-methyl-N-[(2-phenylthio)ethyl]-7-quinolinecarboxamide;
9) 8-hydroxy-N-[5-[4-[(1-methylethyl)phenylsulfonyl]amino]pentyl]-7-quinolinecarboxamide;
10) 8-Hydroxy-N-[2-(3-indolyl)ethyl)-7-quinolinecarboxamide;
11) N-[2-(2,4-Dichlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
12) N-[(2-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
13) 8-Hydroxy-N-[(3-methylphenyl)methyl]-7-quinolinecarboxamide;
14) N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
15) N-(2,2-Diphenylethyl)-8-hydroxy-7-quinolinecarboxamide;
16) N-[2-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
17) N-[2-(4-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
18) N-(3,3-Diphenylpropyl)-8-hydroxy-7-quinolinecarboxamide;
19) N-[(2,6-Difluorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
20) N-[(3-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
21) N-(2,3-Dimethylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
22) 8-Hydroxy-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-7-quinolinecarboxamide;
23) N-(4-tert-Butylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
24) R-8-Hydroxy-N-[1-(1-naphthyl)ethyl]-7-quinolinecarboxamide;
25) N-[2-((1S,2R)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
26) N-[2-((1R,2S)-1,2-Diphenyl-1-hydroxy)ethyl]-8-hydroxy-7-quinolinecarboxamide;
27) 8-Hydroxy-N-[1-(1-hydroxyethyl)cyclopentyl]-7-quinolinecarboxamide;
28) N-[(2,3-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
29) N-[(2,5-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
30) N-[2-([(2,6-Dichlorophenyl)methyl]thio)ethyl]-8-hydroxy-7-quinolinecarboxamide;
31) 8-Hydroxy-N-(2-[(4-[2-trifluoromethyl]quinolyl)thio]ethyl)-7-quinolinecarboxamide;
32) 8-Hydroxy-N-(1-naphthalenylmethyl)-7-quinolinecarboxamide;
33) N-[2-(3-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide; or
34) 8-Hydroxy-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide.
5. A compound of claim 1 which is:
1) N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
2) 5-Bromo-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
3) N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-methyl-7-quinolinecarboxamide;
4) 5-Chloro-N-[(4-chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
5) 8-Hydroxy-N-[(4-nitrophenyl)methyl]-7-quinolinecarboxamide;
6) N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide;
7) 8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-(2-phenylethenyl)-7-quinolinecarboxamide;
8) N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(2-phenylethenyl)-7-quinolinecarboxamide;
9) 8-Hydroxy-2-(2-phenylethenyl)-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
10) 8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethenyl]-7-quinolinecarboxamide;
11) 8-Hydroxy-2-[2-(4-methoxyphenyl)ethenyl]-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide;
12) N-[(4-Chlorophenyl)methyl]-8-hydroxy-2-(trifluoromethyl)-7-quinolinecarboxamide;
13) N[(4-Chlorophenyl)methyl]-2-[2-(2-furyl)ethenyl]-8-hydroxy-7-quinolinecarboxamide;
14) N-[(4-Chlorophenyl)methyl]-8-hydroxy-7-quinoline-N-oxide carboxamide;
15) 5-chloro-8-hydroxy-2-methyl-N-(3-phenylpropyl)-7-quinolinecarboxamide;
16) 5-chloro-8-hydroxy-2-methyl-N-[(2-phenylthio)ethyl]-7-quinolinecarboxamide;
17) 8-hydroxy-N-[5-[4-[(1-methylethyl)phenylsulfonyl]amino]pentyl]-7-quinolinecarboxamide;
18) 8-hydroxy-N-(2-hydroxy-2-phenylethyl)-2-[2-(4-methoxyphenyl)ethyl]-7-quinolinecarboxamide;
19) N-[2-(3-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
20) 8-Hydroxy-N-[2-(3-indolyl)ethyl)-7-quinolinecarboxamide;
21) N-[(2,4-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
22) N-[(3,4-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
24) 8-Hydroxy-N-(4-phenylbutyl)-7-quinolinecarboxamide;
25) N-[2-(2,4-Dichlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
26) N-[(2-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
27) 8-Hydroxy-N-(2-hydroxy-2-phenylethyl)-7-quinolinecarboxamide;
28) N-[2-(4-Bromophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
29) N-[2-(4-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide;
30) 8-Hydroxy-N-[2-(4-methylphenyl)ethyl]-7-quinolinecarboxamide;
31) N-[(3-Chlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
32) N-(2,3-Dimethylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
33) 8-Hydroxy-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-7-quinolinecarboxamide;
34) N-(4-tert-Butylcyclohexyl)-8-hydroxy-7-quinolinecarboxamide;
35) N-[(2,3-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
36) N-[(2,5-Dichlorophenyl)methyl]-8-hydroxy-7-quinolinecarboxamide;
37) N-[2-([(2,6-Dichlorophenyl)methyl]thio)ethyl]-8-hydroxy-7-quinolinecarboxamide;
38) 8-Hydroxy-N-(1-naphthalenylmethyl)-7-quinolinecarboxamide;
39) N-[2-(3-Chlorophenyl)ethyl]-8-hydroxy-7-quinolinecarboxamide; or
40) 8-Hydroxy-N-[2-(phenylthio)ethyl]-7-quinolinecarboxamide.
6. A compound of formula V
Figure US06310211-20011030-C00366
wherein
R1, R2, and R3 are independently hydrogen;
X1 is
a) phenyl substituted by one Cl, I, —CH2OH, ethyl, propyl, ethoxy, —O-benzyl, —O-phenyl, —SO2NH-indazoyl, or NO2;
b) 2-methylphenyl,
c) 2-bromophenyl,
d) phenyl substituted by two substituents wherein one substituent is (Cl, Br, I, methyl or NO2, the other substituent is F, Cl, methyl, NO2, or methoxy;
e) phenyl substituted by Cl, methyl, and methoxy,
f) naphthyl substituted by F, Br, Cl, or OH;
g) fluorenyl
h) het, or
i) 4-cyano-2,3,5,6-tetrafluorophenyl;
and het is
a) coumarinyl,
b) indazoyl,
c) indolyl,
d) benzothiazolyl,
e) benzothiadiazolyl, or
f) quinolinyl.
7. A compound of claim 6 which is
1) N-(3-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
2) 8-hydroxy-N-(4-nitrophenyl)-7-quinolinecarboxamide;
3) N-(5-Fluoro-2-methylphenyl)-8-hydroxy-7-quinolinecarboxamide;
4) N-(2,4-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide;
5) 8-Hydroxy-N-(3-methylphenyl)-7-quinolinecarboxamide;
6) N-(2-Chloro-5-methoxyphenyl)-8-hydroxy-7-quinolinecarboxamide;
7) N-(3,4-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
8) N-(3,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
9) 8-Hydroxy-N-(3-benzyloxyphenyl)-7-quinolinecarboxamide;
10) N-(3,5-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide;
11) 8-hydroxy-N-(4-phenoxyphenyl)-7-quinolinecarboxamide;
12) 8-Hydroxy-N-(4-benzoxyphenyl)-7-quinolinecarboxamide;
13) 8-Hydroxy-N-indol-5-yl-7-quinolinecarboxamide;
14) N-Benzo-2,1,3-thiadiazol-4-yl-8-hydroxy-7-quinolinecarboxamide;
15) 8-Hydroxy-N-quinolin-5-yl-7-quinolinecarboxamide;
16) 8-Hydroxy-N-quinolin-8-yl-7-quinolinecarboxamide;
17) 8-Hydroxy-N-isoquinolin-5-yl-7-quinolinecarboxamide;
18) 8-Hydroxy-N-(4-methoxy-2-nitrophenyl)-7-quinolinecarboxamide;
19) N-(3,5-Dinitrophenyl)-8-hydroxy-7-quinolinecarboxamide;
20) N-(2-Bromophenyl)-8-hydroxy-7-quinolinecarboxamide;
21) N-(2-Chlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
22) N-(4-Bromo-2-chlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
23) N-(2,4-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
24) N-(2-Chloro-4-nitrophenyl)-8-hydroxy-7-quinolinecarboxamide;
25) N-(2,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide;
26) N-(2-Chloro-5-methylphenyl)-8-hydroxy-7-quinolinecarboxamide;
27) 8-hydroxy-N-(2-nitrophenyl)-7-quinolinecarboxamide;
28) 8-Hydroxy-N-(2-methylphenyl)-7-quinolinecarboxamide;
29) 8-Hydroxy-N-(2-methyl-3-nitrophenyl)-7-quinolinecarboxamide;
30) N-(2,3-Dimethylphenyl)-8-hydroxy-7-quinolinecarboxamide;
31) N-(2-Ethylphenyl)-8-hydroxy-7-quinolinecarboxamide;
32) 8-Hydroxy-N-(2-methyl-4-fluorophenyl)-7-quinolinecarboxamide;
33) N-(4-Chloro-2-methoxy-5-methylphenyl)-8-hydroxy-7-quinolinecarboxamide;
34) 8-Hydroxy-N-(4-propylphenyl)-7-quinolinecarboxamide;
35) N-(4-Bromo-2-fluorophenyl)-8-hydroxy-7-quinolinecarboxamide;
36) N-Benzo-1 ,3-thiazol-6-yl-8-hydroxy-7-quinolinecarboxamide;
37) 8-Hydroxy-N-indazol-5-yl-7-quinolinecarboxamide;
38) 8-hydroxy-N-(5-iodo-2-methylphenyl)-7-quinolinecarboxamide;
39) 8-hydroxy-N-(2-fluoro-4-iodophenyl)-7-quinolinecarboxamide;
40) 8-hydroxy-N-(2-iodophenyl)-7-quinolinecarboxamide; or
41) 8-hydroxy-N-(3-iodophenyl)-7-quinolinecarboxamide.
8. A compound of formula IA
Figure US06310211-20011030-C00367
wherein R0 is
a) —(CH2)pW1X2,
b) —(CH2)pW1CH2X1, or
c) —(CH2)n—CH9—(CH2)nX1;
wherein R1 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —CF3, or
f) —NO2;
wherein R2 is
a) —H,
b) —C1-C3alkyl,
c) —OH,
d) —CF3,
e) —CH═CH-furanyl,
f) —CH═CH-phenyl substituted by zero (0) or one (1) R4,
g) —CH═CH-pyridinyl,
h) —(CH2)p-phenyl substituted by zero (0) or one (1) R4,
i) —NHV1,
j) —CH2NHV1, or
k) —CH2Z1;
wherein R3 is
a) —H,
b) —OH,
c) —CF3, or
d) —C1-C3alkyl;
wherein R4 is
a) —H
b) —F,
c) —C1,
d) —Br,
e) —NO2,
f) —CF3,
g) —W1—R10,
h) —C1-C6 alkyl,
i) —C3—C8 cycloalkyl,
j) —(CH2)n-aryl,
k) —CH2—C3-C8 cycloalkyl,
l) —SO2NH-indazoyl,
m) —CN,
n) —I, or
o) —CH2—OH;
wherein R5 is
a) —H,
b) —F,
c) —Cl,
d) —Br,
e) —W1—R10,
f) —CF3,
g) —C1-C6 alkyl,
h) —C3-C8 cycloalkyl,
i) —(CH2)n-aryl substituted by R6, or
j) —CH2—C3-C8 cycloalkyl;
wherein R6 is
a) —H,
b) —F,
c) —Cl, or
d) —Br;
wherein R8 is
a) —C1-C4 alkyl,
b) —W1—H, or
c) —CH2W1H;
wherein R9 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
C) —C(O)R11,
d) —C(O)NHR11,
e) —CH(OH)R11,
f) —CH2OH,
g) —CO2R11, or
h) -aryl;
wherein R10 is
a) —H,
b) —C1-C6 alkyl,
c) —C3-C8 cycloalkyl,
d) —(CH2)n-aryl optionally substituted with F, Cl, CH2OH or —NO2,
e) —CH2—C3-C8 cycloalkyl;
wherein R11 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —(CH2)nX1, or
d) —CH2—C3-C8 cycloalkyl;
wherein X1 is
a) -aryl substituted by zero (0), one (1), two (2), or three (3) R4,
b) -het substituted by zero (0), one (1) or two (2) R5,
c) —C7-C8 alkyl, provided that when X1 is alkyl, R9 is not alkyl;
d) —CH(OH)-phenyl,
e) —S-phenyl,
f) —NHSO2-phenyl substituted by one (1), two (2) or three (3) R4,
g) —CN,
h) —C3-C8 cycloalkyl substituted by ethoxy, t-butyl or two (2) R8, or
i) -4-cyano-2,3,5,6-tetrafluoro-phenyl;
wherein X2 is
a) -aryl substituted by zero (0), one (1), two (2) or three (3) R4,
b) —C1-C8 alkyl,
c) —CH(OH)-phenyl, or
d) —C3-C8 cycloalkyl substituted by zero (0), one (1) or two (2) R8;
wherein W1 is
a) oxygen, provided that when X1 or X2 is phenyl, W1 is not oxygen,
b) —NH, or
c) -sulfur,
wherein V1 is
a) —R11,
b) —C(O)R11,
c) —SO2R11, or
d) —C(O)NHR11;
wherein Z1 is
a) —C1-C7 alkyl,
b) —C3-C8 cycloalkyl,
c) —C(O)R11,
d) —C(O)NHR11, or
e) —CO2R11;
wherein -aryl is
a) -phenyl,
b) -naphthyl,
c) -biphenyl,
d) -tetrahydro-naphthyl, or
e) fluorenyl;
wherein -het is a 5-membered saturated or unsaturated ring having from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur,
wherein -cycloalkyl is a saturated or unsaturated hydrocarbon ring, optionally fused to a benzene ring; wherein n is zero (0) to six (6), inclusive, provided that where X1 is a) or b), n is at least one; p is one (1), two (2) or three (3);
or a pharmaceutically acceptable salt or N-oxide thereof.
9. A compound which is
8-Hydroxy-N-(cis-myrtanyl)-7-quinolinecarboxamide; or
N-(2-Adamantyl)-8-hydroxy-7-quinolinecarboxamide.
US08/924,683 1996-09-10 1997-09-05 8-hydroxy-7-substituted quinolines as anti-viral agents Expired - Fee Related US6310211B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/924,683 US6310211B1 (en) 1996-09-10 1997-09-05 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,564 US6252080B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,789 US6211376B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US10/014,780 US6500842B1 (en) 1996-09-10 2001-10-23 8-hydroxy-7-substituted quinolines as anti-viral agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2587096P 1996-09-10 1996-09-10
US5072097P 1997-06-25 1997-06-25
US08/924,683 US6310211B1 (en) 1996-09-10 1997-09-05 8-hydroxy-7-substituted quinolines as anti-viral agents

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/425,789 Division US6211376B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,564 Division US6252080B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US10/014,780 Division US6500842B1 (en) 1996-09-10 2001-10-23 8-hydroxy-7-substituted quinolines as anti-viral agents

Publications (1)

Publication Number Publication Date
US6310211B1 true US6310211B1 (en) 2001-10-30

Family

ID=26700264

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/924,683 Expired - Fee Related US6310211B1 (en) 1996-09-10 1997-09-05 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,564 Expired - Fee Related US6252080B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,789 Expired - Fee Related US6211376B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US10/014,780 Expired - Fee Related US6500842B1 (en) 1996-09-10 2001-10-23 8-hydroxy-7-substituted quinolines as anti-viral agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
US09/425,564 Expired - Fee Related US6252080B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US09/425,789 Expired - Fee Related US6211376B1 (en) 1996-09-10 1999-10-22 8-hydroxy-7-substituted quinolines as anti-viral agents
US10/014,780 Expired - Fee Related US6500842B1 (en) 1996-09-10 2001-10-23 8-hydroxy-7-substituted quinolines as anti-viral agents

Country Status (6)

Country Link
US (4) US6310211B1 (en)
EP (1) EP0927164A1 (en)
JP (1) JP2002505660A (en)
AU (1) AU4172197A (en)
CA (1) CA2262786A1 (en)
WO (1) WO1998011073A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410558B1 (en) * 1991-10-18 2002-06-25 Monsanto Technology Llc Fungicides for the control of take-all disease of plants
US20040167124A1 (en) * 2002-10-16 2004-08-26 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20060116356A1 (en) * 2004-04-14 2006-06-01 Cai Zhenhong R Phosphonate analogs of HIV integrase inhibitor compounds
US20080050761A1 (en) * 2006-08-28 2008-02-28 Massachusetts Institute Of Technology Sox-based kinase sensor
US20080085529A1 (en) * 2003-10-08 2008-04-10 Massachusetts Institute Of Technology Fluorescence assay for kinase activity
US20090227621A1 (en) * 2004-02-04 2009-09-10 Teruhiko Taishi Naphthyridine derivatives having inhibitory activity against hiv integrase
US20100168428A1 (en) * 2007-02-26 2010-07-01 Massachusetts Institute Of Technology Environmentally sensitive fluorophores
US20110053180A1 (en) * 2009-08-31 2011-03-03 Massachusetts Institute Of Technology Kinase sensors
WO2011080264A1 (en) 2009-12-29 2011-07-07 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
WO2011080265A1 (en) 2009-12-29 2011-07-07 Polichem S.A. Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
WO2011080266A1 (en) 2009-12-29 2011-07-07 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives.
US20110184028A1 (en) * 2010-01-22 2011-07-28 Brent Richard Stranix Derivatives of pyridoxine for inhibiting hiv integrase
WO2016057518A1 (en) * 2014-10-06 2016-04-14 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP2456759B1 (en) * 2009-07-24 2017-04-19 Bayer CropScience AG Pesticidal carboxamides
CN114195736A (en) * 2021-12-30 2022-03-18 浙江闰土染料有限公司 Preparation method of 2-amino-5-bromo-1, 3, 4-thiadiazole

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761687B1 (en) * 1997-04-08 2000-09-15 Centre Nat Rech Scient QUINOLEIN DERIVATIVES, ESPECIALLY HAVING ANTIVIRAL PROPERTIES, THEIR PREPARATIONS AND THEIR BIOLOGICAL APPLICATIONS
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
TW500724B (en) * 1999-10-05 2002-09-01 Pharmacia & Amp Upjohn Company Oxazinoquinolones useful for the treatment of viral infections
JP2003529601A (en) * 2000-03-21 2003-10-07 ファルマシア・アンド・アップジョン・カンパニー 4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxamide as antiviral agent
WO2001070742A1 (en) * 2000-03-21 2001-09-27 Pharmacia & Upjohn Company 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
WO2002017969A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Reagents and methods for the diagnosis of cmv dissemination
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
AU1152702A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
ES2274913T3 (en) 2000-10-12 2007-06-01 MERCK &amp; CO., INC. AZA AND POLIAZA-NAFTALENIL CARBOXAMIDS USEFUL AS INTEGRATED HIV INHIBITORS.
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
ATE411292T1 (en) 2001-03-01 2008-10-15 Shionogi & Co NITROGEN-CONTAINING HETEROARYL COMPOUNDS WITH HIV INTEGRASE INHIBITING EFFECT
AR036256A1 (en) * 2001-08-17 2004-08-25 Merck & Co Inc SODIUM SALT OF AN HIV INTEGRAS INHIBITOR, PROCESSES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
US6821998B2 (en) 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
MXPA04001797A (en) 2001-08-30 2004-07-08 Pharmacia & Upjhon Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS.
AR038118A1 (en) 2002-01-14 2004-12-29 Upjohn Co COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
AR038117A1 (en) 2002-01-14 2004-12-29 Upjohn Co ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
AR038294A1 (en) 2002-01-14 2005-01-12 Upjohn Co OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
DE60315796T2 (en) * 2002-01-17 2008-06-05 Merck & Co., Inc. HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
EP1539141B1 (en) * 2002-08-29 2010-07-14 Boehringer Ingelheim Pharmaceuticals Inc. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
CA2537325A1 (en) * 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
JP5014983B2 (en) 2004-05-07 2012-08-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
UA87328C2 (en) 2004-08-30 2009-07-10 Янссен Фармацевтика Н.В. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1786774B1 (en) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (en) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv OXYSTEROID DEHYDROGENASE INHIBITORS
WO2006043153A2 (en) * 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
JPWO2006077901A1 (en) * 2005-01-20 2008-06-19 塩野義製薬株式会社 CTGF expression inhibitor
WO2007038865A1 (en) * 2005-10-05 2007-04-12 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
EP2079699A1 (en) * 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
US8188314B2 (en) * 2008-06-24 2012-05-29 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US9555106B2 (en) * 2011-09-30 2017-01-31 Kineta, Inc. Anti-viral compounds
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
BR112014029016A8 (en) * 2012-05-23 2018-01-09 European Molecular Biology Laboratory 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN103709162B (en) * 2012-09-29 2016-12-07 中国科学院上海药物研究所 Tri-substituted imidazole benzodiazine ketonic compound and its production and use
KR102439852B1 (en) * 2015-04-17 2022-09-05 가천대학교 산학협력단 2-Aminoquinolin-8-ol derivatives and use thereof
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
TW202126649A (en) 2019-09-26 2021-07-16 瑞士商諾華公司 Antiviral pyrazolopyridinone compounds
CN111689944B (en) * 2020-06-10 2021-11-16 中山大学 Quinoline tryptamine heterozygote and application thereof in preparation of medicine for treating Alzheimer disease
WO2023041657A1 (en) 2021-09-15 2023-03-23 Katholieke Universiteit Leuven Alkylated haloquinolines for use in epilepsy
EP4166560A1 (en) 2021-10-13 2023-04-19 Consejo Superior de Investigaciones Cientificas Tri-substituted tetrahydrofurans and use thereof
WO2024162814A1 (en) * 2023-02-01 2024-08-08 프라비바이오 주식회사 Novel bicyclic compound and use thereof

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1908548A1 (en) 1968-02-29 1970-11-05 Warner Lambert Co Quinoline derivatives
EP0206751A2 (en) 1985-06-18 1986-12-30 Merck Frosst Canada Inc. 2-Substituted quinolines, their preparation and use
JPS63307451A (en) 1987-06-09 1988-12-15 Konica Corp Silver halide color photographic sensitive material with improved graininess
JPH01136152A (en) 1987-11-21 1989-05-29 Konica Corp Silver halide color photographic sensitive material
EP0326328A2 (en) 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline derivatives
EP0326330A2 (en) 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline fungicides
US4881969A (en) 1988-02-18 1989-11-21 Basf Aktiengesellschaft Sulfonamides
JPH02152966A (en) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd 4-hydroxycarbostyril derivative
US4959363A (en) 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
EP0399818A1 (en) 1989-05-24 1990-11-28 Merck Frosst Canada Inc. Diarylstyrylquinoline diacids
JPH0373949A (en) 1989-05-13 1991-03-28 Konica Corp Heat developable color photosensitive material and image forming method
US5378694A (en) 1990-09-07 1995-01-03 Schering Corporation Acyl and alkoxy substituted quinolines
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
US5412104A (en) 1990-09-07 1995-05-02 Schering Corporation Ester and alkoxy substituted benzopyrans
WO1995011592A1 (en) 1993-10-29 1995-05-04 J.C. Hempel's Skibsfarve-Fabrik A/S Marine structure
JPH07165748A (en) 1993-12-13 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk Derivative having heterocyclic ketone skeleton and antiviral agent
US5459146A (en) 1993-12-09 1995-10-17 Schering Corporation 4-substituted pyrazoloquinoline derivatives
US5463072A (en) 1992-06-03 1995-10-31 Agfa Gevart Ag, D-51368 Process for the preparation of naphtholic 2-equivalent cyan couplers
DE4425647A1 (en) 1994-07-20 1996-01-25 Bayer Ag Heterocyclyl-1-phenyl substituted quinolonecarboxylic acids
DE4425659A1 (en) 1994-07-20 1996-01-25 Bayer Ag New N1-diverse 6-fluoro-8-difluoromethoxy substituted quinolonecarboxylic acids
DE4425650A1 (en) 1994-07-20 1996-01-25 Bayer Ag Substituted triazolylmethylphenylnaphthyridones
DE4425648A1 (en) 1994-07-20 1996-01-25 Bayer Ag Novel 6 and 6,8-substituted 1- [4- (1H-1,2,4-triazol-1-ylmethyl) phenyl] quinolonecarboxylic acids
WO1996006084A1 (en) 1994-08-19 1996-02-29 C & C Research Labs. Novel quinolylamine derivative, process for production thereof, and use thereof as antiarrhythmic agent
US5506236A (en) 1994-04-28 1996-04-09 Schering Corporation 4-substituted pyrazoloquinoline derivatives
JPH0899957A (en) 1994-09-30 1996-04-16 Toyama Chem Co Ltd New quinolone or naphthylidone compound or salt thereof, and antiherpes viral agent consisting thereof
WO1996025399A1 (en) 1995-02-17 1996-08-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
WO1996032015A1 (en) 1995-04-08 1996-10-17 Basf Aktiengesellschaft Synergistic fungicide compositions made of quinoline derivatives and cytochrom b/c inhibitors
WO1997003069A1 (en) 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them
JPH1136152A (en) 1997-07-11 1999-02-09 Toray Ind Inc Combined processed filament yarn

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1908548A1 (en) 1968-02-29 1970-11-05 Warner Lambert Co Quinoline derivatives
EP0206751A2 (en) 1985-06-18 1986-12-30 Merck Frosst Canada Inc. 2-Substituted quinolines, their preparation and use
JPS63307451A (en) 1987-06-09 1988-12-15 Konica Corp Silver halide color photographic sensitive material with improved graininess
JPH01136152A (en) 1987-11-21 1989-05-29 Konica Corp Silver halide color photographic sensitive material
EP0326328A2 (en) 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline derivatives
EP0326330A2 (en) 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline fungicides
US5240940A (en) 1988-01-29 1993-08-31 Dowelanco Quinoline and cinnoline fungicide compositions
US4881969A (en) 1988-02-18 1989-11-21 Basf Aktiengesellschaft Sulfonamides
JPH02152966A (en) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd 4-hydroxycarbostyril derivative
JPH0373949A (en) 1989-05-13 1991-03-28 Konica Corp Heat developable color photosensitive material and image forming method
EP0399818A1 (en) 1989-05-24 1990-11-28 Merck Frosst Canada Inc. Diarylstyrylquinoline diacids
US4959363A (en) 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5412104A (en) 1990-09-07 1995-05-02 Schering Corporation Ester and alkoxy substituted benzopyrans
US5378694A (en) 1990-09-07 1995-01-03 Schering Corporation Acyl and alkoxy substituted quinolines
US5463072A (en) 1992-06-03 1995-10-31 Agfa Gevart Ag, D-51368 Process for the preparation of naphtholic 2-equivalent cyan couplers
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
WO1995011592A1 (en) 1993-10-29 1995-05-04 J.C. Hempel's Skibsfarve-Fabrik A/S Marine structure
US5459146A (en) 1993-12-09 1995-10-17 Schering Corporation 4-substituted pyrazoloquinoline derivatives
JPH07165748A (en) 1993-12-13 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk Derivative having heterocyclic ketone skeleton and antiviral agent
US5506236A (en) 1994-04-28 1996-04-09 Schering Corporation 4-substituted pyrazoloquinoline derivatives
DE4425650A1 (en) 1994-07-20 1996-01-25 Bayer Ag Substituted triazolylmethylphenylnaphthyridones
DE4425659A1 (en) 1994-07-20 1996-01-25 Bayer Ag New N1-diverse 6-fluoro-8-difluoromethoxy substituted quinolonecarboxylic acids
DE4425648A1 (en) 1994-07-20 1996-01-25 Bayer Ag Novel 6 and 6,8-substituted 1- [4- (1H-1,2,4-triazol-1-ylmethyl) phenyl] quinolonecarboxylic acids
DE4425647A1 (en) 1994-07-20 1996-01-25 Bayer Ag Heterocyclyl-1-phenyl substituted quinolonecarboxylic acids
WO1996006084A1 (en) 1994-08-19 1996-02-29 C & C Research Labs. Novel quinolylamine derivative, process for production thereof, and use thereof as antiarrhythmic agent
JPH0899957A (en) 1994-09-30 1996-04-16 Toyama Chem Co Ltd New quinolone or naphthylidone compound or salt thereof, and antiherpes viral agent consisting thereof
WO1996025399A1 (en) 1995-02-17 1996-08-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
WO1996032015A1 (en) 1995-04-08 1996-10-17 Basf Aktiengesellschaft Synergistic fungicide compositions made of quinoline derivatives and cytochrom b/c inhibitors
WO1997003069A1 (en) 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them
JPH1136152A (en) 1997-07-11 1999-02-09 Toray Ind Inc Combined processed filament yarn

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Derwent Abstract No. 22,706.
Derwent Abstract No. 85-063337/11.
Derwent Abstract No. 90-264471/35.
Derwent Abstract No. 90-290145/38.
Derwent Abstract No. 90-343755/46.
Derwent Abstract No. 91-232424/32.
Kemp et al., "Peptide Synthesis with Benzisoxazolium Salts," Tetrahedron, vol. 30, pp. 3677-3688, 1974.*
Urbanski et al., "Research on New Antituberculous Drugs," Chemical Abstract, vol. 53, No. 5, 4567, Mar. 10, 1959. *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521603B2 (en) 1991-10-18 2003-02-18 Monsanto Technology Llc Fungicides for the control of take-all disease of plants
US6410558B1 (en) * 1991-10-18 2002-06-25 Monsanto Technology Llc Fungicides for the control of take-all disease of plants
US20040167124A1 (en) * 2002-10-16 2004-08-26 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US7253180B2 (en) 2002-10-16 2007-08-07 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20080085529A1 (en) * 2003-10-08 2008-04-10 Massachusetts Institute Of Technology Fluorescence assay for kinase activity
US7892775B2 (en) 2003-10-08 2011-02-22 Massachusetts Institute Of Technology Fluorescence assay for kinase activity
US20090227621A1 (en) * 2004-02-04 2009-09-10 Teruhiko Taishi Naphthyridine derivatives having inhibitory activity against hiv integrase
US7919623B2 (en) 2004-02-04 2011-04-05 Shionogi & Co., Ltd. Naphthyridine derivatives having inhibitory activity against HIV integrase
US20060116356A1 (en) * 2004-04-14 2006-06-01 Cai Zhenhong R Phosphonate analogs of HIV integrase inhibitor compounds
US8586570B2 (en) 2006-08-28 2013-11-19 Massachusetts Institute Of Technology Sox-based kinase sensor
WO2008082715A3 (en) * 2006-08-28 2008-12-24 Massachusetts Inst Technology Sox-based kinase sensor
US20080050761A1 (en) * 2006-08-28 2008-02-28 Massachusetts Institute Of Technology Sox-based kinase sensor
US7964729B2 (en) 2006-08-28 2011-06-21 Massachusetts Institute Of Technology Sox-based kinase sensor
US8440835B2 (en) 2007-02-26 2013-05-14 Massachusetts Institute Of Technology Environmentally sensitive fluorophores
US20100168428A1 (en) * 2007-02-26 2010-07-01 Massachusetts Institute Of Technology Environmentally sensitive fluorophores
EP2456759B1 (en) * 2009-07-24 2017-04-19 Bayer CropScience AG Pesticidal carboxamides
US8409820B2 (en) 2009-08-31 2013-04-02 Massachusetts Institute Of Technology Kinase sensors
US20110053180A1 (en) * 2009-08-31 2011-03-03 Massachusetts Institute Of Technology Kinase sensors
US20120316167A1 (en) * 2009-12-29 2012-12-13 Polichem Sa Secondary 8-hydroxyquinoline-7-carboxamide derivatives
WO2011080266A1 (en) 2009-12-29 2011-07-07 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives.
WO2011080265A1 (en) 2009-12-29 2011-07-07 Polichem S.A. Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
US8729076B2 (en) * 2009-12-29 2014-05-20 Polichem Sa Secondary 8-hydroxyquinoline-7-carboxamide derivatives
WO2011080264A1 (en) 2009-12-29 2011-07-07 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2345641A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives
EP2345642A1 (en) 2009-12-29 2011-07-20 Polichem S.A. Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
EP2345643A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
AU2010338269B2 (en) * 2009-12-29 2014-03-06 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives.
US8664248B2 (en) 2010-01-22 2014-03-04 Taimed Biologics, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US20110184028A1 (en) * 2010-01-22 2011-07-28 Brent Richard Stranix Derivatives of pyridoxine for inhibiting hiv integrase
WO2016057518A1 (en) * 2014-10-06 2016-04-14 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CN114195736A (en) * 2021-12-30 2022-03-18 浙江闰土染料有限公司 Preparation method of 2-amino-5-bromo-1, 3, 4-thiadiazole

Also Published As

Publication number Publication date
US6211376B1 (en) 2001-04-03
EP0927164A1 (en) 1999-07-07
JP2002505660A (en) 2002-02-19
WO1998011073A1 (en) 1998-03-19
CA2262786A1 (en) 1998-03-19
AU4172197A (en) 1998-04-02
US6252080B1 (en) 2001-06-26
US6500842B1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
US6310211B1 (en) 8-hydroxy-7-substituted quinolines as anti-viral agents
EP1064273B1 (en) 1,3,4-thiadiazoles useful for the treatment of cmv infections
EP0596406B1 (en) Imidazo (1,2-a) Pyridines as bradykinin antagonists
EP0874827B1 (en) Quinoline derivatives as nk3 antagonists
US20050004134A1 (en) Thiazole derivative and pharmaceutical use thereof
US20040171881A1 (en) N,N&#39;-substituted-1,3-diamino-2-hydroxypropane derivatives
US20040072818A1 (en) Substituted quinoline CCR5 receptor antagonists
SK10802003A3 (en) Fused heterocyclic compounds
JP2000159749A (en) Benzimidazole derivative
WO2002098424A1 (en) Novel anti-infectives
AU1031897A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists.
WO2001030757A1 (en) Drug discharge pump inhibitors
AU2007359392A1 (en) Benzothiazole compounds
SK2242004A3 (en) Quinoline compound
NZ323387A (en) Quinoline derivatives having neurokinin antagonist activity, preparation and use thereof
JP2005510508A6 (en) Thiazolepyridazinones as adenosine antagonists
KR20120054568A (en) Compounds useful as medicaments
TW201738217A (en) Novel antiviral compounds
JP2016128465A (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
US6194396B1 (en) Benzimidazole compounds as bradykinin antagonists
US7009053B2 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
CZ20023141A3 (en) 4-Oxo-1,4-dihydro-3-cinnoline carboxamides functioning as antiviral compounds
WO2005003140A1 (en) 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
AU2002345636A1 (en) Novel anti-infectives

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA & UPJOHN COMPANY, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAILLANCOURT, VALERIE A.;ROMINES, KAREN R.;ROMERO, ARTHUR G.;AND OTHERS;REEL/FRAME:010649/0929

Effective date: 19971001

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20091030